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“Quis credat tantas operum sine numine moles ex minimis caecoque creatum
foedere mundum? Si fors ista dedi nobis, fors ipsa gubernet. At cur dispositis
vicibus consurgere signa et velut imperio praescriptos reddere cursus cernimus ac
nullis properantibus ulla relinqui? Cur eadem aestivas exornant sidera noctes sem-
per et hibernas eadem, certamque figuram quisque dies reddit mundo certamque
relinquit?”
“ Who could believe that such massive structures have been created from tiny
atoms without the operation of a divine will, and that the universe is the creature of
a blind compact? If chance gave such a world to us, chance itself would govern it.
Then why do we see the stars arise in regular succession and duly perform as at the
word of command their appointed courses, none hurrying ahead, none left behind?
Why are the summer nights and the nights of winter ever made beautiful with the
selfsame stars? Why does each day of the year bring back to the sky a fixed pattern
and a fixed pattern leave at its departure?”
(from the book Astronomica of the Roman poet Manilius, ˜ 20 Antum Domini)
“.. and why has a week 7 days and 7 nights, why are there 7 deadly sins and
7 wonders of the world, 7 oceans and 7 continents, why is Rome build on 7 hills,
and “hast ein Buch 7 Siegel”, why has Little Tumb 7-mileboats, and Snow White 7
dwarfs and why has an GPCR 7 transmembrane helices ?
Just by chance ?”
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Chapter 1
Scope of the Thesis
"I may disagree with what you have to say, but I shall defend, to the death, your
right to say it."
• Voltaire
(1694-1778), writer and philosopher)
CHAPTER 1. SCOPE OF THE THESIS
Nearly every aspect of life on earth is controlled by processes that, from a biochemical point
of view, rely on molecular recognition phenomena [1, 2]. The ability of individual molecules
to bind selectively to structurally and functionally related target systems is a key principle for
understanding biochemical reactivity, which affects processes such as enzyme catalysis, gene
regulation, immunological defense, transmembrane signal transduction and numerous other im-
portant physiological events. The determination of molecular recognition phenomena in struc-
tural terms, especially those phenomena which encompass the interaction of small molecules
(substrates, ligands) with highly complex biopolymers (enzymes, receptors), has been the aim
of numerous research projects in medicinal, pharmaceutical and biophysical research. The
attempt to rationalize the binding mode of, e.g., a low-molecular weight compound and a pro-
teinogenic receptor system at an atomic resolution has developed into a vital component within
the realm of structure-based drug design. More than 17000 experimentally determined high-
resolution structures of proteins are currently known to the scientific community, numerous
potential targets for drug discovery projects are among these. This situation is due to progress
made over the last decade in, e.g., the development of high-technology instrumentation, such as
synchrotrons and area detectors for X-ray crystallography, computer graphic systems connected
to multi-processor supercomputer, and methodological developments in the area of high-field
NMR spectroscopy. Despite this tremendous progress we have witnessed over the last decade,
membrane-bound receptor systems are still underrepresented in the database of structurally
characterized proteins, due to the problems associated with protein preparation, purification, and
crystallisation or solubilization, respectively. Apart from the structures of an ion-channel [3],
the αvβ3-integrin [4], and bovine rhodopsin [5], as a member of the GPCR family, not very
many only a very small number of membrane-bound proteins relevant for drug discovery are
currently determined at atomic resolution.
Consequently, the application of knowledge-based techniques from the realm of molecular mod-
elling aimed at generating structural models for those proteins emerged as useful approaches
towards a deeper understanding of the structural requirements underlying the corresponding
molecular recognition events comprising experimentally non-amenable targets.
The research project presented in this study aims to introduce a novel approach towards the
modelling receptor proteins from the target superfamily of G protein-coupled receptors (GP-
CR’s), based on all principally available structure-relevant information originating from hetero-
geneous sources, such as site-directed mutagenesis, bioinformatics studies, structure-activity
relationships of a series of low-molecular weight antagonists, protein modelling and molecular
dynamics simulations. The relevance of those data for a model building approach is extensively
evaluated throughout the different chapters of this thesis. The viability of the newly developed
procedure is demonstrated with the generation, evaluation and validation of a complex between
a model of the human CCK-B receptor and a series of experimentally characterized antagonists.
The entire study is presented in five chapters. First is presented in chapter 2 an introduction on
the basic principles underlying the signal transduction system of a GPCR. Thereby is empha-
sis laid on the current available information about GPCR structures. After this introduction an
extensive study in terms of protein sequence analyses is presented in chapter 3 with the aim
to unambiguously identify the transmembrane portions in the sequence of a GPCR, in other
words, to generate the so-called 1D topology of the receptor. Chapter 4 describes the model
building procedure exemplified with the human CCK-B receptor that, after molecular dynamics
simulation under explicit treatment of the non-isotropic environment for energetic relaxation,
revealed a receptor protein model that was pursued further to molecular docking studies. Prior
13
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to a detailed description of the applied methodology for molecular docking and all associated
comparative studies described in chapter 6, an overview is given on the various different chemo-
types that qualified as promising lead series for CCK-A, as well as CCK-B antagonists (Chapter
5). Based on this overview, the entire study is designed along a path of increasing complexity,
starting with protein sequence studies, followed by receptor protein modelling and subsequent
simulations, finally yielding 3D models of molecular complexes comprising the target receptor
and a series of low-molecular weight compounds. It is the intention of the author to emphasis
that the entire modelling approach bears the potential to allow the experienced user to generate
3D models of any GPCR, provided a sufficient amount of structurally relevant input data is
available.
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Chapter 2
General Background
"GPCRs, such as the histamine H2-receptor, can be regarded as proton pumps,
which lack one piece in their proton shuttle to be able to pump continuously."
• P.H.J. Nederkoorn
Thesis (1996)
CHAPTER 2. GENERAL BACKGROUND
2.1 G protein-coupled receptors
Among transmembrane proteins of current biomedical interest, the G protein-coupled receptors
(GPCRs) constitute a superfamily of transmembrane receptor proteins that establish a func-
tional and unidirectional link between the exterior of a cell and its cytoplasm [6, 7, 8, 9, 10]. A
cascade of signal transduction events is induced by an extracellular occurring receptor-ligand
recognition event and is transferred through the receptor by a yet unknown mechanism to the
intracellular compartment involving binding to a heterotrimeric guanine nucleotide-binding reg-
ulatory protein: the so-called G protein.
The general idea is that the GPCR mediate the ligand action through a conformational change
of the receptor, which is detected by the G protein [11, 8]. The conformation of the Gα subunit
of the ternary complex changes its conformation so that the bound GDP molecule is displaced
by an GTP molecule (the exchange mechanism). The Gα subunit dissociates subsequently
from the Gβγ-dimer. Both free subunits associate with effector enzymes, such as adenylate cy-
clase, guanylate cyclase, phospholipase A2 or C, stimulating or inhibiting production of second
messengers including cAMP, cGMP, diacyl glycerol and IP3, which in turn cause downstream
effects including the opening of Ca2+ or K+ channels and the generation of other messengers
such as arachidonic and phosphatidic acid [8, 10] (Figure 2.1).
Figure 2.1: General signal transduction pathway for G protein-coupled receptors.
Several experiments [12, 13] published some years ago are not in accordance with the GDP-
GTP-exchange mechanism. One would expect an increase in GDP concentration and an equal
drop in GTP concentration upon activation. However, in one of those studies [12] it is re-
ported that in rod outer segments, where rhodopsin and G proteins are abundant, GDP con-
centrations drop dramatically whereas GTP concentrations remain almost constant in the first
4 seconds after activation. Furthermore, it is reported that phosphate transfer occurs via Gβ
subunits yielding GTP from GDP and Pi [14]. Such a phosphorylation reaction is ignored in the
GDP-GTP-exchange mechanism, but this and aforementioned GDP concentration drop would
17
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excellently agree with a GTP synthesis mechanism driven by a proton transport via the activated
receptor. In a theoretical study of Nederkoorn et al. [7, 15] it was demonstrated that this ligand-
mediated proton transfer is feasible for a series of GPCRs. The ligand-activation ends up with
one or more protons per agonist bound, thus explaining why sometimes more than one G pro-
tein is activated by one bound agonist (signal amplification). In combination with the theory of
Topiol [16], the deletion model for the origin of receptors, a GPCR can be regarded as a proton
pump which lacks in the inactivated state one part of its proton pumping mechanism. An addi-
tional aspect is the similarity with the F1F0-ATP synthase [17, 18] and that the mechanisms of
GTP synthesis and GDP hydrolysis (of the Gα subunit at the effector protein) resemble that of
the phosphorylation and dephosphorylation reactions in nucleoside diphosphate kinases. Also
other experiments (e.g. instability of uncomplexed Gα subunits [19], the double proton trans-
fer of the tautomeric histamine molecule in the activation of the H2-receptor [20], existence
of constitutively activated mutant receptors [21], receptors with two different agonistic bind-
ing sites [22, 23]) are in agreement with this model and, in addition, this new model does not
exclude some kind of conformational change of the GPCR [7, 15, and the references therein].
The proton-translocation-GTP-synthesis mechanism is not the only proposed “pumping” mech-
anism in GPCR signal transduction. Luca Turin [24] proposed that inelastic electron tunnelling
would be the signal transduction mechanism for olfactory receptors, because not the molecu-
lar shape of the ligands but their vibrational properties are important for the activation of the
receptor.
The multi-step cascade of signal transduction events is highly depending on the very nature
of the distinct member of the GPCR family recognising its ligand with high specificity [25]
(Figure 2.1). A broad spectrum of chemically diverse endogenous, as well as exogenous ligands,
ranging from cations, biogenic monoamines, fragrances and taste molecules, lipidic mediators,
oligopeptides of different size, up to large globular proteins elicit their biological activity by
targeting their specific GPCR. Obviously, nature has designed a highly efficient transmembrane
signal transduction system in that the great variety of receptor agonists converges towards the
same type of target receptors, while the diversity is retained, since ligand-specific signalling
cascades are triggered upon GPCR activation (Figure 2.2).
From a pharmaceutical research point of view, GPCRs represent one of the most prominent
classes of validated drug targets. According to a survey from 1997, 25% of the one hundred
world-wide top-selling drugs exert their therapeutic effect by targeting distinct receptors from
the GPCR family [26], while the ratio referenced to all approved drugs is even 50 - 60% [27].
In terms of sales, GPCR-targeted drugs created a market potential that was estimated to approx-
imately 16 000 million US $ during 1997 when referring to the top 100-selling drugs world-
wide [26]!
A more detailed analysis of GPCRs, in terms of marketed drugs, reveals a strong bias in favour
of the classical neurotransmitter receptors, such as the 5-HT, histamine, muscarinic acetyl-
choline, dopamine, or the noradrenaline receptor. Comparing the target-receptor distribution
profile of released GPCR-targeted drugs with the number of identified receptors that can be
attributed as therapeutically relevant target systems, a significant imbalance becomes immedi-
ately apparent, thus demanding future pharmaceutical research to focus on, e.g., peptide-binding
GPCRs [28, 29].
Referring to the pharmacodynamic and -kinetic problems, generally associated with the chemi-
cal nature of peptides, modern medicinal chemistry will make extensive use of established
peptidomimetic concepts to approach this goal following a ligand-guided strategy. A com-
18
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Figure 2.2: Diversity of ligands, sequences, G proteins and effectors versus functional conver-
gence of G protein-coupled receptors.
plementary approach, relying on screening of random, diverse or targeted compound libraries,
discovered already numerous non-peptide leads for peptide-binding GPCRs, interestingly most
of them act as antagonists [30].
2.1.1 Binding Site Ambiguity
For the biogenic monoamines, a consensus binding mode within the transmembrane portion
of the receptor protein was deduced. The putative binding site within the protein was mapped
by mutational studies, while the key interactions, driving the corresponding molecular recog-
nition event, were determined following classical comparative analyses on series of congeneric
low-molecular weight compounds. These studies succeeded to correctly predict site-directed
mutaganeses of the receptor protein or corresponding tailor-made modification of the ligand
molecule, thereby supporting the structural hypothesis underlying an interaction model as shown
in Figure 2.3 [31, 32]. Consequently, the numerous biogenic monoamine agonists and antag-
onists are accommodated in the same or highly overlapping binding pocket of in the target
protein. They can thus be interpreted as classical competitive modulators.
As mentioned above, the comprehensive screening programs conducted over the last years
mostly in pharmaceutical industry uncovered for almost any peptide-binding GPCR non-peptidic,
low-molecular weight ligands, however the majority being antagonists [30].
From mutational mapping increasing evidence emerged that almost all peptide agonists inter-
act with sequentially discontinuous epitopes on the extracellular surface of the transmembrane
protein, while the non-peptide antagonists seem to address receptor residues further to the in-
terior along the normal of the membrane surface [28]. The antagonists obviously penetrate the
seven-helix bundle that all GPCRs are believed to be composed of, and they probably populate
a common biogenic monoamine-related binding site (Figure 2.3).
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Figure 2.3: Schematic presentation of the consensus binding mode, identified for the biogenic
monoamine-GPCR interaction. Transmembrane helices are depicted as vertical rods, aromatic
rings of Phe and Trp sidechains are shown as squares. The ammonium ion of the ligands binds
to an highly conserved Asp in helix 3 by an electrostatically driven interaction.
Consequently agonists and antagonists of peptide-binding GPCRs do not address the same
"lock", even though some antagonists turned out to competitively displace the native ligand.
The hypothesis of two spatially separated, not even overlapping binding sites for agonists and
antagonists is further corroborated by the results of numerous diverse research projects on both
molecular interaction partners, the receptor protein and the ligands, respectively. By construct-
ing chimeric receptors it could be shown that the exchange of extracellular portions of the
receptor protein allowed a directed shift of agonist-specificity, while non-peptide antagonist-
binding was retained [28]. Even the complete deletion of a huge extracellular domain of, e.g.,
metabotropic glutamate receptors (mGluRs), proven to be responsible for agonist (glutamate)
binding [33], yielded a receptor construct that could functionally be activated by non-peptide
compounds [34]. In an elegant protein-engineering approach, a Zn2+ binding site was intro-
duced into the neurokinin-1 receptor by replacing selected transmembrane residues against
metal ion-coordinating histidines [28, 35]. These mutations did not affect native ligand binding,
but spatially interferred with a non-peptide antagonist (CP-96,345) binding site, thus completely
abolishing antagonist binding [28, 35]. Also a study of Ji et al. [36] on the angiotensin II recep-
tor from Xenopus laevis underlined the spatially separated binding pockets of peptide agonist
and non-peptide antagonist. The angiotensin II receptor from Xenopus laevis turned out to bind
the native ligand with unaltered affinity, while the binding of the biphenyl-tetrazole drug Loser-
tan could not be detected. Mutation of the 13 different transmembrane residues of the Xenopus
laevis receptor with the human residues yielded a receptor capable of binding Losertan. This
study and other available data clearly defeats the hypothesis of a common overlapping pharma-
cophore arrangement as is claimed for, e.g., biphenyl-tetrazole drugs and angiotensin II [37],
whereby structural resemblance of the non-peptide antagonist and the corresponding peptide
agonist was an important working hypothesis.
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It should further be noted that, although a remarkable diversity is covered by the non-peptide
antagonists of peptide-binding GPCRs, inherently reflecting the different origins of these com-
pounds (in-house stocks, combinatorial chemistry-derived libraries, natural products), highly
redundant structural elements can be identified among antagonists targeting different recep-
tors [38]. These frequently recurring privileged substructures support a further idea, namely the
existence of a binding pocket within the transmembrane domain, obviously highly conserved
throughout the entire family of GPCRs that might correspond to the delineated binding site
within the biogenic monoamine receptors [31, 32, 11] (Figure 2.3). This conserved binding site
can be explained by the proton-translocation-GTP-synthesis mechanism [7, 15].
The hypotheses on binding sites and binding modes of GPCR ligands discussed above clearly
demand further biochemical experiments and computer simulations that provide more detailed
insights into the binding event of agonists and antagonists to their corresponding receptors.
An improved 3D structural model could serve as a common working platform for "asking new
questions" and assist in designing new experiments.
2.1.2 Structural Investigations on 7TM Proteins
Rhodopsins constitute a family of integral membrane proteins covalently binding a retinal
molecule (vitamin A aldehyde) through a Schiff-base linkage to the -NH2 group of a lysine
residue that is located approximately in the middle between the cytoplasmic and extracellular
surfaces of the protein. Members of these photoactive pigments fall into two distinct subfa-
milies, the prokaryotic and eukaryotic rhodopsins, respectively [39, 40]. Prokaryotic rhodopsins
function as light-driven primary proton pumps (bacteriorhodopsin, archaerhodopsins), light-
driven chloride ion pumps (halorhodopsin), and photosensors, mediating photoattractant as well
as photophobic responses. In contrast, eukaryotic rhodopsins are G protein-coupled receptors
acting as visual pigments in initiating the visual excitation cascade upon absorption of light
(possibly via secondary proton-pump mechanism). The structurally unifying feature among all
rhodopsins is a widely conserved protein topology characterised by seven sequentially conse-
cutive transmembrane stretches that adopt α-helical conformations, linked by extracellular and
intracellular loop regions with an extracellular N- and an intracellular C-terminus [9]. Despite
of these common structural principles, the prokaryotic rhodopsins definitely do not belong to the
family of GPCRs, as indicated by a low sequence homology between, e.g., bacteriorhodopsin
and the visual pigments or other GPCRs of approximately 10% to 15% [9]. Thus, the 3D struc-
ture of prokaryotic rhodopsins such as bacteriorhodopsin or halorhodopsin cannot simply be
accepted as a structural framework for molecular modelling attempts aiming at GPCR struc-
tural models.
2.1.2.1 Prokaryotic Rhodopsins
Undoubtedly, bacteriorhodopsin is by far the best characterised 7TM protein not only in terms
of function, but also from a structural point of view. The fundamental observation that bacte-
riorhodopsin can be induced to form large and stable 2D crystals set the stage for all following
structure determination efforts on 7TM proteins for many years. The first milestone was a 7
Å resolution map of the purple membrane obtained by Henderson and Unwin via electron mi-
croscopy and electron diffraction techniques in 1975 [41]. Even though this pioneering work
dates back 27 years, the first 3D structure of bacteriorhodopsin with a resolution comparable to
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that usually obtained for soluble proteins was described just in 1997 [42]. This breakthrough be-
came possible through a novel crystallisation strategy yielding 3D crystals of sufficient diffrac-
tion quality for synchrotron studies [43].
2.1.2.2 2D Crystals of Bacteriorhodopsin
Since 3D crystallisation followed by crystal structure determination were not successful until
1999, the vast majority of structural studies on 7TM proteins applied electron microscopy in
combination with computational image processing of 2D crystals. A 2D crystal is a highly
ordered, single-layered crystalline specimen of very limited thickness (with vertical unit-cell
dimension), obtained by detergent-mediated reconstitution of solubilised and purified protein
into bilayers, closely resembling a native, membrane-like environment [44, 45, 46, 47]. Within
these planar lattices that occur as vesicles, sheets, or tubes, repetitive subunits of identical com-
position appear in equivalent positions with a high degree of symmetry, being the precondition
for extracting information about structural details by electron microscopy and diffraction tech-
niques [44, 45, 46, 47]. Although the information on structural details is not visible on the
primary image, computational processing in combination with electron diffraction patterns help
to elucidate structural details close to atomic resolution. In practise, a series of projections ob-
tained at different tilt angles are combined to reproduce a 3D image of the investigated object
that shows high resolution in the in-plane dimensions and decreased resolution in the vertical
direction. Compared to single crystal diffraction techniques, electron microscopy-based imag-
ing and diffraction collects deviating information. In X-ray crystallography the intensity of the
diffracted beam can be related to the atomic scattering factors. In electron diffraction the rela-
tionship to atomic scattering factors is more complex. The electrons interact with the Coulombic
potential that arises from the negatively charged electron cloud, as well as from the positively
charged nuclei. Therefore, electron form factors (atomic electron scattering cross-sections)
are more sensitive to the physicochemistry of atoms, such as the nature of chemical bonding,
ionised functionalities, or polarised, partially charged groups. One advantage of electron crys-
tallographic structure determination over X-ray crystallography is that phase information, often
a major obstacle in X-ray-based structure determination, is available from images taken with
the electron microscope [44, 45, 46, 47].
The 3D map of Bacteriorhodopsin was described as dominated by numerous "rod-shaped fea-
tures" aligned perpendicular to the membrane surface [41]. Within each asymmetric unit seven
rods form a molecule with overall dimensions of 25 Å x 35 Å x 40 Å (X x Y x Z, Z being
perpendicular to the membrane plane). All rods span a distance of 35 Å to 40 Å along their
main axis, perfectly corresponding to the thickness of the 2D crystal. Each protein molecule
contributes to a trimeric bundle with a threefold symmetry axis [41]. As first established in
1975, the rods were assumed to represent the seven transmembrane α-helices forming the 7TM
domain of retinal proteins.
The structure model, released as 1BRD to the Brookhaven Protein Data Bank was based on
the potential map derived from 72 images of tilted specimen recorded at the temperature of
liquid helium [48]. Combining electron cryo-microscopically derived micrographs and electron
diffraction patterns allowed to drive the resolution of the resulting projection map up to 3.5 Å
in the membrane plane and 7.8 Å perpendicular to the membrane surface [48].
It is noteworthy that in this study the retinal molecule was clearly visible. The chromophore is
covalently bound to the -NH2 group of Lys-216 and governs the gating of the proton pump by
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A
B
Figure 2.4: (A) Projection of the map of electron scattering density of bacteriorhodopsin onto
the plane of the membrane at 7 Å resolution [41]. The individual molecules are arranged about
a 3-fold rotational axes of symmetry normal to the plane of the membrane (triangles) to form
trimers in the membrane. The projection of one molecule with designed helix-numbering is
depicted in inset. (B) A 3D-reconstruction of bacteriorhodopsin made of sections through the
3D map of electron scattering density at 2 Å interval and traced onto balsa wood [41].
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its isomerisational switch. The Schiff-base forms a kind of bottom of two half-channels pro-
truding from the centre of the helix bundle towards the extracellular and intracellular surface,
respectively. The residues delineating both half-channels could clearly be identified from the
experimental data and were further assumed to contribute specifically to the molecular mecha-
nism of the ion transport process [48].
By expanding the available experimental data set by 30 additional images of tilted specimen,
thus contributing phase information to the density map, the resolution could further be enhanced
from 7.8 Å (1BRD) to 4.3 Å (2BRD) in the vertical dimension [49] (Figure 2.4). Apart from
the first extracellular and the first and third intracellular loops which show no interpretable
density, the entire protein is visible. Interesting structural details became obvious with this
refined structure which were undetected or even misinterpreted in the precursor structure. In
this context, transmembrane helix 4 had to be altered with respect to the initially released model
by a 4 Å shift towards the cytoplasm. Further it turned out that transmembrane helices 2, 3, and
6 show an overall kinked shape due to proline residues near the centre of the helical stretches
(Pro-50, Pro-91, Pro-186) [49].
A further high-resolution electron crystallography study on bacteriorhodopsin appeared in 1997
[50]. The derived data even allowed to improve the in-plane resolution further up to 3.0 Å
(1AT9), thereby revealing new structural details, especially an improved surface structure of
the transmembrane protein. While in 2BRD three loops were assigned as disordered, in the
latest study of a Japanese group all loops are shown to be highly structured [50]. With the
refinement of the water-accessible surface area of the transmembrane protein, new features,
probably driving the transport mechanism, became apparent.
Apart from studies on bacteriorhodopsin, much effort has been spent on the structure elucida-
tion of the light-driven chloride-ion pump halorhodopsin from Halobium salinarium. As net
result from a series of investigations, the projected structure of halorhodopsin seems to be al-
most identical to that derived for bacteriorhodopsin, thus reflecting the close sequential relation
between these proteins [51, 52].
2.1.2.3 X-ray Structure of Bacteriorhodopsin
At the end of 1996, Landau and Rosenbusch published their promising results on obtaining
3D mircrocrystals of bacteriorhodopsin [53, 42] utilising a new concept of membrane protein
crystallisation from 3D membrane-mimetic matrices, afforded by a distinct morphological state
of lipid membranes, notably the lipidic cubic phases [54, 55]. The major refinement of the
bacteriorhodopsin structure achieved by the X-ray study clearly refers to the enhanced spatial
resolution along the main helix axis of the seven α-helices constituting the 7TM domain. The
2.5 Å structure closely resembles the structural details elaborated over two decades by elec-
tron microscopy, image reconstruction, and electron crystallography on 2D crystals. However,
distinct differences can be found in loop conformations and in the orientation of sidechains
from selected residues. Due to the well resolved positions of functionally important amino acid
sidechains, together with the precise position of interacting water molecules presumably par-
ticipating in the proton transport, a high resolution picture of a likely proton pathway emerged
from that study [53, 42].
Only 9 months later the X-ray structure of bacteriorhodopsin was published [42], a further struc-
ture with slightly improved resolution (2.3 Å) was solved by taking advantage of the very same
crystallisation technology employing cubic phases [56]. In this study, the authors observed an
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unexpected C2 symmetry, presumably due to twinned crystals, which was explicitly accounted
for within the refinement strategy. Apart from a different number of localised water molecules
aligning the proton-conducting pathway, the overall structure reproduces the findings derived
previously. As in 1AP9 [42], the newly released structure 1BRX [56] does not show any inter-
pretable density for the N- (1-5) and C-termini (229-248), respectively. Also parts of the third
cytoplasmic loop (154-166) are obviously disordered.
2.1.2.4 Eukaryotic Rhodopsins
Unlike the rhodopsins from bacterial sources, the eukaryotic rhodopsins belong to the protein
superfamily of GPCRs, thus qualifying them as ideal candidates to derive experimental struc-
tural data indicative for this target family, since these proteins also tend to form 2D crystals
amenable to electron microscopy and crystallography methods. In contrast to the bacterial
rhodopsins that function as primary ion pumps, eukaryotic rhodopsins are visual pigments.
They trigger the aforementioned GPCR-G protein signal transduction cascade upon light ab-
sorption, thereby inducing membrane hyperpolarization and nerve excitation [39, 40]. Compar-
ative protein sequence analyses reveal amino acid sequence homology of eukaryotic rhodopsins
with several members of the GPCR family, supporting not only the functional relation between
rhodopsins and GPCRs, but also suggesting that the numerous members of this pharmacologi-
cally interesting target family are structurally related to the rhodopsins.
A huge body of structurally relevant data were derived over the last few years based on elec-
tron cryo-microscopy, image processing, and electron crystallographic studies of 2D crystals
with steadily increasing spatial resolution. Projection structures of bovine rhodopsin [57], frog
rhodopsin [58], and squid rhodopsin [59] were calculated at resolutions that clearly allow to de-
fine the topological differences between GPCRs on one hand and bacterio- and halorhodopsin
on the other hand. This was confirmed in 2000 by the X-ray structure of bovine rhodopsin [5].
The history of structural elucidation of eukaryotic rhodopsins is different from that of bacte-
riorhodopsin in that it is characterised by a steady interplay between experimental structural
studies on receptor proteins from different vertebrate and invertebrate sources. Even though no
high resolution structure was available until the year 2000 [5], a prototype 3D structure model
for the 7TM domain of the rhodopsin family of GPCRs could be deduced from an iterative
structure refinement procedure, permanently interfacing structural bioinformatics studies con-
ducted by Joyce Baldwin [60, 6] into the structure reconstruction attempts. With respect to
the X-ray structure determined in the year 2000 [61], the model generated by Baldwin can be
ranked as “very reasonable”.
The first projection structure of bovine rhodopsin with an in-plane resolution of 9Å was pub-
lished in 1993 [57]. The resulting projection density map revealed interesting details about the
arrangement of the transmembrane helices. The density map displays an arc-shaped feature
in proximity to four resolved peaks of density (see first picture of Figure 2.8). While the arc-
shaped density was assigned to three tilted or kinked helices with overlapping termini in the
projection plane, the four resolved peaks were interpreted as four helices oriented perpendicu-
larly in the membrane. Since no structural data were collected from tilted specimen, only 2D
structural information in terms of the projection map emerged from this investigation [57].
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2.1.3 Structural Data Meet Sequence Data
Two weeks after the manuscript on the projection structure of bovine rhodopsin was submitted
for publication, Joyce Baldwin submitted a paper on the tentative structure of the transmem-
brane domain of GPCRs [60]. Structural implications for the 7TM domain are extracted from a
thorough comparative sequence analysis study and combined in an elegant way with the exper-
imentally derived structural data on bovine rhodopsin discussed above [57]. Distinct features in
the amino acid sequence of GPCRs were analysed from alignments of approximately 200 GPCR
sequences [60]. From this multiple alignment strategy, a "fingerprint" was deduced identifying
highly conserved patterns in the primary structure of the 7TM domain (Figure 2.5). Based on
Figure 2.5: The fingerprint derived by Baldwin for the 7TM domains of approximately 200
GPCR sequences
this sequence pattern, the putative transmembrane sequence stretches spanning the hydrophobic
core of the bilayer membrane were assigned under the following assumptions:
• the 7TM domain is formed by ideal α-helices, each consisting of 26 residues;
• 18 residues are required to span the hydrophobic core of the membrane, no polar or
charged residues are expected to face the lipophilic environment in this part of the se-
quence;
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• four residues flank the 18 core residues on the extracellular and the cytoplasmic surface,
respectively.
These qualitative, 1D structural data were expanded by 2D structure information by imposing
the fingerprint onto helical wheels. This approach revealed helices 1, 4, 5, and 6 to display large
surfaces with nonpolar residues, assigning them to be significantly exposed to the lipophilic en-
vironment. Helices 2, 3, and 7 seem to be more buried, since their hydrophobic radial segments
are definitely smaller [60].
A more detailed consideration of sequence characteristics allowed for a clear discrimination of
lipid-facing surface patches from helix contact areas and from the interior of the helix bundle.
The assignment of residues oriented inwards into the helix bundle was corroborated by the con-
sideration of residues, identified to be involved in ligand binding from numerous mutagenesis
studies. Finally, the distinct helical wheels were assembled to a 7TM helix bundle, thus rep-
resenting cross-sections of the receptor protein taken at different heights along the normal of
the membrane. Helices 1, 4, and 5 were found to be exposed to the lipophilic exterior, while
helix 3 turned out to be well protected from the membrane environment. Additionally, the an-
ticlockwise arrangement when viewed from the extracellular side (outside-in view) emerged
as the most likely circular topology for GPCRs, since only this arrangement accounted for the
majority of available mutagenesis and ligand binding data on GPCRs [60].
Thus, valuable structural information could be deduced from a sequence analysis on approxi-
mately 200 GPCR sequences that yielded not only a rough assignment of the transmembrane
sequence stretches, but also resulted in a 3D model, the characteristics of which turned out to
be compatible with the low-resolution projection map of bovine rhodopsin [57].
2.1.4 Enhanced Resolution of Rhodopsin
In 1995 Schertler et al. succeeded in improving the structural details of GPCRs, by combining
micrographs taken from 2D crystals with different tilt angles [62]. After image processing a
3D structure could be obtained, still with poor vertical resolution. However, from the cryo-
microscopically derived 3D structure, four clearly resolved helices together with three remark-
ably tilted helices could be identified, clearly resembling the 3D model obtained from the GPCR
sequence analysis discussed above [62].
In the year 1998 crystals from bovine rhodopsin were obtained that were sufficient in size and
order for structure elucidation by means of electron crystallography [64]. The horizontal re-
solution could be improved to 5 Å. Helices 4, 6, and 7 are visible as isolated density peaks and
seem to be inserted almost perpendicular into the membrane, while helices 1,2, and 3 are tilted
and overlap in the projection. In contrast to the previously described low resolution structure
[62, 57], helix 5 significantly deviates from a perpendicular orientation [64].
Not only structural data on bovine rhodopsin [64, 62, 57] were accumulated, but also data on
other vertebrate and invertebrate rhodopsins [58, 59, 62, 65]. The results obtained from mi-
croscopical and diffraction techniques on frog rhodopsin [58, 62] complement the work on the
bovine receptor protein [64, 62, 57]. Given a sequence identity of 85% between both proteins,
bovine and frog rhodopsin are assumed to share very similar, if not identical 3D structural fea-
tures in the transmembrane domain. From the enhanced resolution structure of frog rhodopsin
it became obvious that helix 5 was more tilted than anticipated from the very first study on the
bovine protein. The density map at a resolution of 6 Å shows three resolved and isolated peaks
27
CHAPTER 2. GENERAL BACKGROUND
Figure 2.6: Schematic presentation of the reconstructed frog rhodopsin topology (left), derived
from a stack of density maps taken from different heights along the membrane normal. The
density maps (right) are shown in an inside-out view, revealing the clockwise arrangement of the
seven transmembrane helices. The pictures and a detailed description of the biophysical studies
on rhodopsins can be found on the internet pages from the Schertler group at the MRC (http://-
www2.mrc-lmb.cam.ac.uk/groups/GS/rhodopsin.html) or in the article of Unger and Schertler
[63].
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in a triangular arrangement, accounting for helices 4, 6, and 7 and a contiguous band of density
extending through the centre of the molecule. This density feature arises from a series of tilted
helices that are not sequentially arranged in a consecutive manner. For the final helix assign-
ment, the authors interfaced the results from the exhaustive structural bioinformatics study from
J. Baldwin [60, 6]. The most interesting finding from this study refers to the orientation of helix
5, which turns out to be in contact with helix 3 due to the pronounced inclination angle of the
helix axis [58]).
In 1997, a further improved 3D structure of frog rhodopsin was reported [62] (Figure 2.6). The
achieved resolution allowed to compute approximate tilt angles for all seven helices. The tilt
angles for the three perpendicular helices 4, 6, and 7 range from 3.8◦ to 13.4◦, while helices
1, 2, 3, and 5 display values between 22.7◦ and 30.0◦, respectively. Due to the significant
tilted insertion mode of four helices, the specific helix-helix interactions are not restricted to
sequentially adjacent transmembrane sequence stretches. Also the degree of lipid exposure of
distinct helices changes significantly along their pathways through the lipid bilayer.
The most tilted helix 3 is deeply buried in the protein, its cytoplasmic end being surrounded by
helices 2, 4, 5, and 7. On its way to the extracellular surface the helix axis drifts away from
helix 5. In the centre of the membrane, helix 3 is in close proximity to helix 7 establishing a
"through-bundle" contact. Helix 4 seems to be the shortest and least tilted helix.
The overall helix packing is more dense on the cytoplasmic surface and the helix bundle opens
up ascending towards the extracellular side, thereby forming a cavity delineated by surface
patches from helices 3, 4, 5, 6, and 7 accessible from the extracellular compartment. This is
undoubtedly interesting for the entire family of GPCRs in terms of ligand binding capabilities
[62].
2.1.5 3D Structure Template for GPCRs
Baldwin expanded her study to approximately 500 GPCR sequences and included further indi-
rect structural data obtained from a series of biochemical studies on numerous GPCRs elabo-
rated by different research groups [6]. It was the frog rhodopsin density map with considerably
high resolution vertical to the membrane plane [58] which Baldwin et al. [66] used to gener-
ate a 3D model for a prototype GPCR (Figure 2.7). Based on the density maxima observable
for all seven helices of frog rhodopsin in the corresponding projection map over a 20 Å axis
perpendicular to the membrane plane, the trace of each helix across the lipid bilayer could be
reconstructed and so a first atomic model with Cα-positions of each transmembrane amino acid
adopting a helical conformation could be constructed including helix kinks induced by proline
residues [66]. For helices 5 and 6 the occurrence of prolines in the transmembrane sequence
stretches produces significant changes of the inclination angle relative to the normal of the
membrane plane.
According to the rules for transmembrane helix bundles referring to amphiphilicity, as well as
conserved and variable sequence positions [67, 68], the lipid-facing surface patches could be
unambiguously identified. Together with the cross sections of the frog rhodopsin density map,
the orientation of each helix with respect to the centre of the bundle was clearly deducible.
Helices 1, 4, and 5 exhibit large lipid-facing surface areas displaying large sections of variable
sequence positions. A high degree of conservation, being an indicator for structural or func-
tional important residues, was identified for large surface areas of helices 2, 3, and 7. From the
model building procedure it became obvious that the membrane-water boundary not necessarily
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Figure 2.7: In-plane cross sections (right column) of the Cα-template (coordinates were kindly
provided by Joyce Baldwin) taken over a transmembrane range of 32 Å. The 0 Å plane defines
the central core section of the membrane, while the upper and lower picture represent the cy-
toplasmic and extracellular interface region, respectively. The corresponding density maps are
shown in the center.
disrupts the helical conformation of the transmembrane sequences. Although an uncertainty re-
mains for the assignment of the exact helix termini, some of them clearly protrude from the
membrane surface into the flanking aqueous compartments [66]. The final structural model
was extensively verified against results from various protein engineering studies on different
peptide-binding GPCRs [66, and references therein].
The differences between GPCRs and bacteriorhodopsins described in the next section will
demonstrate that any modelling attempt of GPCR structures employing the bacterial receptor
protein structure remain highly questionable.
2.1.6 Structure Scaffolds for GPCR-models:
Bacteriorhodopsin versus Rhodopsin
The majority of GPCR modelling attempts described in literature aimed to obtain 3D struc-
tural models of the 7TM domain for rationalising, e.g., structure-activity relationships of low-
molecular weight agonists and/or antagonists within the putative ligand binding pocket of the
target receptor employed the coordinates of bacteriorhodopsin 1BRD as underlying structural
scaffold [32]. This is certainly due to the availability of this coordinate set to the scientific
community via the Brookhaven Protein Data Bank since 1990 [48]. In light of the structural
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and functional knowledge on rhodopsins derived over the last years, rhodopsin structures from
bacterial sources can no longer serve as templates to built GPCR structure models on.
On the level of primary structure, no significant homology can be detected between bacteri-
orhodopsin and, e.g., human rhodopsin. A sequence similarity search over protein sequence
databases with vertebrate rhodopsins as queries unravels numerous sequences of GPCRs to be
homologous with significant sequence identity to the query. Using bacteriorhodopsin as query,
almost no GPCR sequences are found with high similarity or identity scores.
Although no structure of a vertebrate rhodopsin was determined at a comparably high reso-
lution as for bacteriorhodopsin (until 2000 1), several structural features were identified to be
entirely different in both protein classes. In contrast to bacteriorhodopsin, which has no cys-
teine residues, almost all eukaryotic GPCRs form a highly conserved disulphide bond between
the extracellular terminus of helix 3 and the second extracellular loop connecting helices 4 and
5 [9]. A comparable structural constraint is totally absent in bacteriorhodopsin. In general,
membrane cross sections of the vertebrate rhodopsin structures are described to appear as com-
pact entities, while the bacterial receptors exhibit an elongated helix bundle when projected into
the membrane plane [63, 65] (Figure 2.8). Also the pattern of tilt angles is significantly different
Figure 2.8: Left: Experimentally derived electron scattering projection maps of bovine
rhodopsin (above) and bacteriorhodopsin (below). Right: Side-by-side stereo picture of the
Cα-trace-model of vertebrate rhodopsins compared to the X-ray-derived structure of bacteri-
orhodopsin (PDB entry code: 1AP9). The density maps, as well as the helix bundles are shown
in an inside-out view.
when the projection map of bacteriorhodopsin is compared to either frog [62, 58], squid [59],
or bovine [57, 63, 64] rhodopsin. In the bacterial helix bundle, helices 2, 3, and 4 show an
almost perpendicular arrangement, while the remaining helices overlap to form an extended
arc-shaped density trace [49]. In contrast, helices 4, 6, and 7 are oriented along the membrane
1 In 2000 the X-ray crystal structure of bovine rhodopsin was published. This was after all the modelling studies
in this thesis were prerformed. Therefore this structure could regrettable not be taken as scaffold structure in the
modelling studies, but in the final notes a comparison between this high resolution X-ray structure of rhodopsin
and our modelled structure of the human CCK-B receptor has be made (see Chapter 4).
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normal in the eukaryotic receptor proteins, while helices 1, 2, 3, and 5 partially overlap in an
in-plane projection (Figure 2.8). Also the distribution of helix-distorting proline residues in the
transmembrane helices shows an entirely unique pattern. Prolines are found in helices 2, 3,
and 6 in the bacterial receptor, and in helices 4, 5, 6, and 7 in the vertebrate rhodopsins. The
combination of the different membrane insertion modes and a different pattern of helix kinks
clearly reveal the substantial differences of both receptor proteins.
Functionally, the bacterial proteins act as light-driven primary ion pumps [42], facilitating trans-
port of matter through the transmembrane helix bundle against a proton gradient (up-hill), while
eukaryotic rhodopsins work as switching moieties, possibly by a down-hill proton translocation
mechanism, transmitting a signal across the membrane [7, 15]. This functional difference is
further reflected by the different ground states of the covalently bound cofactor, retinal. In
bacteriorhodopsin the absorption of light triggers isomerisation of all-trans retinal to the 11-cis
isomer, while in vertebrate rhodopsin the 11-cis isomer represents the ground state.
In the light of these pronounced structural differences between the ion-pump bacteriorhodopsin
and the vertebrate rhodopsin GPCRs, one should refrain from employing any bacteriorhodopsin
structure as underlying framework for GPCR modelling purposes.
Structural models of GPCRs based on the current state of available experimental input data can
by no means be compared to classical homology models of soluble proteins. They clearly lack
the degree of spatial resolution and structural refinement necessary for giving an approximately
correct picture of the atomic details that would be mandatory for, e.g., structure-based drug de-
sign or the derivation of quantitative estimates of ligand-receptor interactions. However, GPCR
models have to be seen as a very useful working platform to discuss findings from molecular
biology and medicinal chemistry and to create new ideas about possible experiments.
2.1.7 Crystal Structure of Rhodopsin
In August 2000, after the modelling study described in this thesis was accomplished, the very
first crystal structure at 2.8 Å resolution of bovine rhodopsin was published by Palczewski et
al. [5]. It shows the seven transmembrane domains, the 70 residues of the cytoplasmic domain
- the three intercellular loops and the carboxyl terminus - and the 74 residues of the extracel-
lular region (Figure 2.9). In the same issue of Science, Bourne and Meng [61] described the
superposition between the crystal structure of rhodopsin and three recent model structures and
found that the Cα-trace of the transmembrane helices fitted reasonably well (RMS-deviations
of 3.1 - 3.2 Å). Of course from now on, it is preferable to use this structure of rhodopsin [5] as
template for any modelling study of a GPCR, but also former models based on the mentioned
assumptions together with structurally relevant data resulted in reasonable models.
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Figure 2.9: Ribbon drawings of rhodopsin of Palczewski et al. [5] (A) Parallel to the plane of the
membrane (stereoview). (B) View from the cytoplasmic side and (C) view from the extracellular
side orthogonal to the membrane plane.
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2.2 CCK-receptors
Cholecystokinin (CCK) is a peptidic prehormone formed by 115 amino acids. It is expressed
in neurons throughout the central and peripheral autonomic nervous systems and in intestinal
endocrine cells and neurons, where it is released in response to a meal with proteins and lipids.
The major forms are the 58- and 8-amino acid C-terminal amidated peptides. The last seven
amino acids from the C-terminus are fully responsible for the biological activity. The tyrosine
at the seventh position from the C-terminus has to be sulfated for biological activity and it is
also essential that the C-terminus is α-amidated [69, 29, 70, 71].
Comparable to CCK, Gastrin also occurs in multiple forms composed by 101 amino acids. The
major forms are the 34- and 17-amino acid C-terminal amidated peptides. Although also for
Gastrin the α-amidation is essential for biological activity, only the last five amino acids from
the C-terminus are necessary. The crucial tyrosine, here located on the sixth position from the
C-terminus, has not necessarily to be sulfated (only∼50% are sulfated) [70, 71]. In Figure 2.10
the endogenous ligands for the two type CCK-receptors are depicted and their activity for both
receptors are listed.
Figure 2.10: Endogenous Ligands of the CCK-A and CCK-B receptors.
The first CCK-receptors were characterised on pancreatic acinar cells and are called CCK type
A receptors. In the same year, a second receptor with a different pharmacology was discovered
in the brain, the CCK type B receptor. These two receptor types can be pharmacological distin-
guished on their basis of their affinity to the different CCK and gastrin peptides. The CCK-A re-
ceptors are highly selective for sulfated CCK-peptides, whereas the CCK-B receptors have simi-
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larly high affinity for both, the sulfated and non-sulfated CCK- and gastrin-peptides [70, 71, and
references therein].
CCK is expressed in the central nervous system and the gastrointestinal tract. Endogenous CCK
is a primary hormonal regulator of gall bladder contraction in response to a meal and has further
great influence on the gastrointestinal physiology as, e.g., pancreatic exocrine secretions of
amylases, lipases and proteases, insulin release, and basal acid secretion. At the central nervous
system level, CCK is presented as an important neurotransmitter and neuromodulator, involved
in the aetiology of anxiety and panic disorders, affecting cognitive functions and release of other
neurotransmitters as dopamine [70, 71, and references therein].
Gastrin causes many of the changes mediated by CCK in various tissues and also regulates
the release of acid by directly activating CCK-B receptors on parietal cells and on nearby
enterochromaffin-like (ECL) cells that release histamine to stimulate acid secretion via H2-
histamine receptors on parietal cells [70, 71, and references therein].
2.3 Molecular Dynamics
Molecular Dynamics (MD) is a simulation technique that allows to investigate the dynamics of
molecules. Knowledge of the motions of a complex system of particles, as, e.g., a protein solved
in water, provides valuable insights into its functional details. The application of the concept of
kinetic energy (velocity) allows the system to overcome energy barriers between nearby local
minima and to search considerable areas of the corresponding molecular hypersurface.
From the interaction potentials that operates between the different particles of the system the
interaction forces can be computed by calculating the first derivative of the potentials with
respect to the positions of the particles. The numerical integration of the Newton’s equations
of motion yields the new molecular coordinates after the (usually) empirically derived force
has been applied for a predefined time period. The leapfrog algorithm is the most common
method to accomplish this integration. Iteration of the integration until a specified time period
has passed provides the trajectory of the configuration of the system as a function of time. The
time step of integration for macromolecules is in the order of a femtosecond (1 fs = 10−15s) to
ensure the numerical stability of the integration.
The trajectory can be analysed and different ensemble averages can be determined as, e.g.,
the average total, potential and kinetic energy, or the average position of an atom. Also ra-
dial distribution functions, which give the probability of finding a particle at distance r from
another particle, or system properties as, e.g., the temperature or root mean square deviation
with reference to the starting structure or atom positions as a function of time can be evaluated.
With these statistical mechanics calculation the macroscopic behaviour is analysed by calcu-
lating microscopic interactions. Thereby, the assumption is made that the set of configurations
is statistically representative for the whole configuration space experienced by the investigated
molecular system.
The general process of a molecular dynamic simulation is depicted in the flow chart in Figure
2.11.
The available computer hardware resources (memory and disk space) limit the number of parti-
cles of the system and the time regime covered by a MD-simulation. By using periodic boundary
conditions (PBC) a simulation can be performed by eliminating unreasonable effects resulting
from arbitrary boundary settings. A defined assembly is centred in a periodic box and has iden-
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Figure 2.11: A flow-chart of a Molecular Dynamics simulation.
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tical neighbouring images on each face of the box. These box images experience the same
forces and thus perform the same particle movements as the central box. If a particle moves
out of the central periodic box during the simulation, an identical particle enters the box from
the opposite face. To avoid the anisotropy of interaction due to the shape of the nearest image
box, a spherical cut-off radius is applied. Interactions between pairs of atoms that are further
separated than the cutoff radius are set to zero. The cut-off radius should be smaller than one
half of one length of the smallest face of the periodic box.
We have applied molecular dynamic simulations for the refinement of structural models which
were generated by model-building. Furthermore molecular dynamic simulations are applied
to study the flexibility and motion of molecules as, e.g., the lateral diffusion of lipids within
a membrane, or the conformational sampling of molecular arrangements of a molecule as a
function of the environment (water, non-polar solution etc.).
The methodology, the computational procedures, the simplifications, the assumptions and the
approximations of molecular dynamic simulations are reviewed in great detail by van Gunsteren
& Berendsen [72] and by Karplus & Petsko [73].
2.4 3Phasic-Box
MD simulations are performed to characterise the dynamics of biologically relevant molecules,
in our case the 3D model of the human CCK-B receptor. However, if in such MD simulations
an explicit membrane model with explicit lipid molecules and water molecules is used, the
size of the system easily exceed the available computational resources. Therefore, a membrane
mimetic has been applied in the calculations described in this thesis. This membrane mimetic is
described as Lennard-Jones particles corresponding to the physicochemical properties of CCl4-
molecules [74, 75]. They represent a phospholipid bilayer membrane in the liquid-crystalline
Lα-phase. This lipid phase is flanked by two water compartments, thus representing different
solvent phases of opposing polarity, viscosity, and hydrogen-bond donor/acceptor capabilities.
Since the CCl4-molecules are treated as united atoms, the number of atoms of the simulation
cell, in comparison to an explicit membrane model, is reduced by at least one order of magnitude
[74, 75]. However, the system should be envisioned as just a crude representation of the complex
membrane system of water molecules and phospholipid molecules with their zwitterionic head
groups and alkyl chains.
All MD simulations in this thesis were carried out in a rectangular cell with standard three
dimensional periodic boundary conditions (PBC) with temperature and pressure bath coupling
[72]. After positioning of the modelled protein in the simulation cell, the remaining space
in the cell was soaked from previously equilibrated solvent boxes, first with water up to the
required height and the rest with CCl4. The interface plane corresponds to the XZ plane, while
the Y-direction is orthogonal to the interface plane of the cell (“the membrane plane”). In
case of the receptor simulations, a so-called three-phasic box (Figure 2.12) was generated. In
general, the probability distribution of atoms shows an average occupancy along the Y-direction,
whereas the time course of the individual Y-coordinates of the atoms illustrates the transition
dynamics across the membrane plane. The density profiles of water and CCl4 can be calculated
from the trajectory by counting the number of oxygen and carbon atoms, respectively, in cross-
sections at certain heights in the Y-direction and normalised with respect to the idealised atomic
densities of water (density 0.0333 number of water-molecules / Å3) and CCl4 (density 0.0062
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Figure 2.12: The three-phasic box with two water phases and one CCl4 phase. On the left of
the box are the probabilities displayed.
number of CCl4-molecules / Å3) [74, 75]. These density profiles are overlapping, because of
the lower particle density of the CCl4-molecules in comparison to the particle density of water,
and because of a small amount of phase intermixing (Figure 2.12).
Further details about the simulation set-up are given separately within the corresponding sec-
tions of this thesis.
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3.1 Introduction
Extensive biophysical, biochemical and immunological studies have revealed an enormous
amount of structural data on GPCRs. These data support that the GPCRs share a common
protein topology consisting of a membrane-spanning seven-helix bundle which is believed to
accommodate the ligand-binding site, at least for the low-molecular weight compounds. The
amino terminus of the membrane protein is located on the extracellular side of the membrane,
while the carboxy terminus is situated intracellularly. The transmembrane helices are intercon-
nected by three extra- and three intracellular loops. The intracellular parts of the receptor are
involved in binding the G protein, thus giving rise to the name to the receptor family. Despite
of all this knowledge, a high-resolution structure of any member of this superfamily was not
available when the studies described in this thesis were initiated. In August 2000, researchers
found a way to circumvent the difficulties associated with purification and crystallisation of
these proteins. Consequently, the high resolution 3D structure of bovine rhodopsin in complex
with retinal was solved [5]. However, these results did not serve as experimental structure basis
for the sequence analyses described in the following.
At the beginning of this thesis, a low-resolution two-dimensional (2D) map of the electron
density of bovine rhodopsin, a GPCR accommodating the visual pigment retinal, provided first
experimentally derived structural evidence for the seven transmembrane helix topology for a
GPCR [57]. A low-resolution three-dimensional (3D) structure of bovine rhodopsin [63, 64]
together with projection structures of other rhodopsins [58, 62, 59] confirmed the arrangement
of the seven transmembrane helices. The low-resolution structures also show that, although the
membrane topology of bacteriorhodopsin (at that time the only membrane protein with a seven
transmembrane helix bundle and a high resolution 3D structure) and the GPCRs are similar, the
3D structures are significantly different. The facts that bacteriorhodopsin is not a GPCR (light
driven ion-pump) and displays only a low sequence homology to any of the GPCRs, renders
it hard to rationalise that bacteriorhodopsin could be used as template structure for generating
3D models of GPCRs by molecular modelling, even though this has be the usual practise for
several years. Only in a few studies the projection maps and low resolution 3D structure of
rhodopsin were used, or alternatively, the 3D models were constructed de novo. However,
all studies are based on mutually different experimental and theoretical data sets employing
different methodologies for receptor reconstruction, thus rendering a comparative judgement of
the models impossible.
The first and most critical step in the modelling procedure of every GPCR is the assignment
of the transmembrane sequence stretches (TMSS) from multiple protein sequence alignments.
Therefore, in this study a comparative evaluation of protein sequence analyses tools was car-
ried out. Several of these tools are tailor-made for the modelling of the seven transmembrane
domains (TMDs) of GPCRs. Protein sequence analysis tools such as periodicity analyses of
amino acid properties, multiple sequence alignments, distribution analyses of amino acids or
directional helix descriptors of, e.g., hydrophobicity or conservation moments were especially
developed for GPCR modelling. In this context, we demonstrate that, with respect to the ap-
plication of different methods, contradictory results can be obtained for the identification of the
putative TMSS of GPCRs, as exemplified by a comprehensive protein sequence analysis study
based on the most prominent members of peptide-binding GPCRs.
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3.2 Methods
3.2.1 Amino Acid Sequences
All amino acid sequences used in this study were retrieved from the protein sequence database
SWISSPROT using the computer programs from the University of Wisconsin Genetics Com-
puter Group (GCG 1). The available sequences of ten different families of peptide-binding
GPCRs were retrieved from the database:
family # of sequences # of subtypes
1. angiotensin II 16 3
2. bradykinin 5 2
3. cholecystokinin/gastrin 9 2
4. endothelin 10 3
5. interleukin-8 13 2
6. neuropeptide Y 12 5
7. somatostatin 17 5
8. tachykinin 3
9. substance P and K 11 2
10. neuromedin 5 2
total sequences 101
For each family, a multiple sequence alignment was generated using the pam250 comparison
table [76, 77]. First, the potential transmembrane sequence stretches (TMSS) could be roughly
identified from these 10 multiple sequence alignments by the use of the fingerprint of Bald-
win [60, 6, 66]. This fingerprint was initially based on 204 sequences of GPCRs [60], including
76 cationic amine receptors, 32 visual pigments, 9 glycoprotein hormone receptors, 66 recep-
tors for peptides and 21 receptors for other small ligands. Baldwin [66] extended this database
to 493 sequences leading to an extension of the transmembrane segments by 7 amino acids on
both sides to a total length of 40 amino acids. This fingerprint is considered as a relevant indi-
cator for conserved patterns in transmembrane sequences over the entire rhodopsin-like GPCR
superfamily. Therefore, is it not surprising that it is found in all 10 multiple sequence align-
ments. The potential transmembrane sequence stretches (TMSSs) of the 10 different families
are further aligned using the fingerprint suggested by Baldwin to generate 7 multiple sequence
alignments of 101 sequences, each representing a distinct transmembrane helix.
The lengths for the potential TMSS in these seven multiple sequence alignments were set to
36 amino acids, corresponding to 10 helical turns, which is sufficient to span the hydrophobic
core of the membrane. Further, 10 helical turns accounts for a certain margin of error in the
fingerprint, i.e., depending on the angle between the helical axis and the membrane plane, only
16 to 18 residues are needed for spanning the hydrophobic core of the membrane.
3.2.2 Amino Acid Property Scales
The seven multiple sequence alignments of 101 sequences, each comprising 36 amino acids,
are used to determine the transmembrane domain boundaries (TMDBs) employing different
bioinformatic tools and protein modelling techniques. The most common method for the deter-
mination of the TMDBs is the hydrophobicity profile of one sequence based on the hydropho-
1 GCG R© Wisconsin Package, Copyright c©1982-2002 Accelrys Inc., http://www.accelrys.com.
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bicity scale of, e.g., Kyte-Doolittle [78]. However, many additional amino acid property scales
and other useful approaches exist that address the problem of determination of the TMDBs
solely from the primary structure. A comparison of the profiles has been described by several
authors [79, 80, 81, 82, 83, 84].
In general, an amino acid property scale can be described as assigning distinct weights to each
type of amino acid based on its physiochemical character. For a hydrophobicity scale, this
weight represent the tendency of the amino acid to dissolve in water and in nonpolar solvents,
respectively. The 20 commonly occurring residues are classified with respect to their side chains
as polar, nonpolar, or amphiphilic (partly polar and partly nonpolar). However, even residues
with a nonpolar side chain can be reviewed as amphiphilic, because the backbone N-H and
C=O groups are themselves highly polar. The method of such a classification of the amino
acids can be of theoretical nature, e.g., based on the calculation of the partition coefficients
and free energies of transfer, but can also be of more empirical character, e.g., based on the
statistical analysis of the observed distributions of the amino acid residues between the water-
accessible surface and the buried interior in globular proteins with known 3D structure. The
third group of scales, including the scale of Kyte-Doolittle [78], is a combination of different
scales. As a matter of fact, these scales of different origin can disagree substantially, depending
on the calculated method, the criteria used and the investigators involved. These differences
are not minor disagreements in the relative ordering of hydrophobicity of the amino acids, but
they extend to the classification whether an amino acid has to be considered as hydrophilic or
hydrophobic. The choice of the amino acid property scale will have severe influence on the
results for the determination of the TMDBs.
Since only a small number of high resolution 3D structures of membrane proteins is known
(bacteriorhodopsin, photosynthetic reaction centre, porin, potassium channel and in some ex-
tent: the light-harvesting complex, the acetyl choline receptor and rhodopsin) the accuracy of
the different amino acid property scales used in the different determination methods of the
TMDBs cannot be evaluated by using a large test-database. Consequently, it can hardly be
assessed whether the prediction error of the TMDBs depends on the choice of the amino acid
property scale, the selected determination method or whether it is simply a consequence of the
nature of the proteins of this small set itself. Therefore, an evaluation of different bioinformatic
tools that use these amino acid property scales for the determination of the TMDBs of GPCRs,
has to complemented by as much experimental information as possible.
3.2.3 Amino Acid Property Profiles
The amino acid property scales used in this study are listed in Table 3.1. The chosen amino acid
property scales are used in different bioinformatic tools, e.g., in the calculation of a property
profile of an amino acid sequence. With the selected amino acid property scale, an average
property is calculated for a sequence window. The plot of this average property of the sequence
window against the sequence number of the central amino acid results in the property profile.
The choice of the length of the sequence window is related to the thickness of the membrane
bilayer. Depending on the angle between the main helix axis and the membrane plane, the
transmembrane helix needs to be composed of minimally 16 to 18 residues in order to span the
hydrophobic core of a general lipid bilayer at the level of the carbon chains of the phosphatidyl
lipids. However, this thickness of the membrane bilayer can vary considerable, therefore in
many studies the optimal window was set to 19. Also smaller windows (for example 7) have
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Method Scale Refs.
variability/conservation of - fingerprint analysis of Baldwin [60, 6, 66]
amino acids in high homologue
sequence groups
- conserved polar residues of Zhang
and Weinstein
[85]
amino acid property scales - hydrophilicity of Kyte-Doolittle [78]
for property profiles - hydrophilicity of Wolfenden [86]
- hydrophilicity of Eisenberg [87]
- hydropathy by Hopp and Woods [88]
- hydrophobicity by Abraham [89]
- hydrophobicity of Roseman [90]
- hydrophobicity of Sweet [91]
- polarity index of Zimmerman [92]
- bulkiness index of Zimmerman [92]
- mutability index of Dayhoff [76]
- burriness index of Janin [93]
- helical index of Chou/Fasman [94]
amino acid occurrence - positive inside rule by von Heijne [95]
within the transmembrane - proline residues in transmembrane [96, 97, 98]
regions helices
- aromatic residues in membrane
boundary regions
[98]
α-helical periodicity - helical wheel representation [99]
of amino acid properties - sequence property moments [100, 101, 87]
- helical net representation [102]
- Fourier Transform analysis [103]
Table 3.1: Amino acid property scales and approaches for the determination of the Transmem-
brane Domain Boundaries.
been used, since they give a better resolution to separate TMDs and a better prediction of the
TMD-termini. In this study, we employed several sequence window sizes; 3, 4, 5, 6, 7, 9, 11,
17 and 19, in the calculation of property profiles.
Given the fact that a mutation of a single amino acid residue can significantly influence the
property profile of a single sequence, we have not calculated the property profiles of single
sequences, but calculated property profiles for the different multiple alignments of the seven
TMSS. These property profiles are thus average profiles over multiple sequences and have the
advantage to compensate for small, irrelevant deviations of single amino acid sequences. For
each TMSS, each property scale and each sequence window 11 different property profiles were
calculated; 10 of the multiple alignments of the 10 different families and one of the multiple
alignment of all 101 sequences. This results in 11 (alignments) * 12 (scales) * 9 (windows)
= 1188 profiles per transmembrane sequence, from which the TMDBs were determined. To
reliably identify a TMDB, the property profile must exhibit a clear break at this point. A TMDB
is clearly identified whenever a distinct discontinuity occurs in a property profile.
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3.2.4 Amino Acid Distribution Profiles
Furthermore, also profiles for the distribution of the 20 common amino acids occurring in
the different multiple alignments of the TMSSs were determined. This parallels the study of
Landolt-Marticorena [98] on the distribution of amino acids in the transmembrane segments and
flanking regions of human type I single span plasma membrane protein. In agreement with the
positive inside rule of von Heijne [95, 104], Landolt-Marticorena [98] reported that the amino
acids are non-randomly distributed over the transmembrane sequence and their occurrence de-
pends on the topology of the TMD. In agreement with these findings, it can be expected, that
these non-random-distribution of amino acids will also be found in the multiple alignments of
the TMSSs of GPCRs. By depicting the distribution profiles as the observed percent occurrence
of each amino acid at a position in the TMSS, these profiles can also be a tool for the deter-
mination of the TMDBs. These distribution profiles were determined for the seven multiple
alignments of the TMSSs with all the 101 sequences. For comparison and validation, distribu-
tion profiles were also constructed for seven multiple alignments of the TMSSs of 50 sequences
of the family of opsine receptors, another important member of the superfamily of GPCRs.
3.2.5 Helical Property Moments
The different amino acid property scales can be further used in the determination of the so-called
property moments of the TMDs [100]. A property moment is a quantitative description of the
asymmetry of the used property over a particular molecular structure, for example, a sequence of
amino acid residues with a defined secundary structure. Using a scale of atomic charges over a
certain molecular conformation will determine the electric dipole moment as property moment.
For the calculation, an ideal α helical conformation is assumed for the TMSSs. Already in 1967,
Schiffer and Edmundson represented an ideal α helix as a two-dimensional helical wheel [99].
The property moment for an ideal α helix of amino acids can be calculated by representing the
hydrophobicity of an amino acid as a vector directed radial from the projected helix centre to
the projected idealised Cα-atom position, with the length of the vector being the property value
of this amino acid. The sequence helical property moment is then given by:
µHP =


[∑
n
Pn sin (δn)
]
2
+
[∑
n
Pn cos (δn)
]
2


1
2
(3.1)
The sum, µHP accounts for all amino acid residues of the sequence segment, Pn is the property
of the nth residue, and δ is the angle (for an ideal α helix 100◦), measured in radians, between
consecutive Cα-atoms.
In this study, the helical property moments have been calculated with different property scales
for the TMDs of the 11 different multiple alignments of each of the seven TMSSs. Again,
the consensus approach will rule out the influence of an irrelevant deviation by a single amino
acid mutation in a sequence. In contrast to the polarity moments determined by Zhang and
Weinstein [85], these property moments are based on the property character of the total TMD
and not on single, highly conserved residues.
For comparison and better validation, also the sequence property moments were calculated for
the multiple alignments of the seven TMDs of 50 opsine receptors and additionally for the
multiple alignments of the seven TMDs of 623 sequences of rhodopsin-like GPCRs. These
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seven multiple alignments of 623 sequences were subtracted from the alignments given on the
web-pages of the GPCRDB-server at EMBL-Heidelberg 2.
By molecular modelling, a 3D model of a GPCR can be build using the detected TMDs. We
used the Cα trace model of Baldwin [66] to transfer the sequentially derived information into
a rough 3D model. From that, structural property moments can be calculated for the trans-
membrane helices. The atomic co-ordinates of the amino acids are used and not just an ideal
projection of them on a helical wheel representation. The structural helical property moment is
given by:
µSP =
∑
n
Pnvn (3.2)
The sum, µHP , accounts for all amino acid residues of the sequence segment, Pn is the value
of the property of the nth residue, and vn is the unit vector pointing from the Cα-atom of the
nth residue to its Cβ-atom. This moment has the advantage that it refers to a realistic α helix
structure with bends and kinks and not an ideal α helix.
In order to get detailed insights into the comparability of sequence helical property moments
and structural helical property moments, we determined these property moments for two pro-
teins with known high resolution 3D structure comprising a helical topology, notably bacteri-
orhodopsin (PDB: 2brd) and the four helix bundle protein Felix (PDB: 1FLX and 3FLX). The
later is a designed globular protein, which should have an ideal distribution of hydrophobic
amino acid residues in the interior and hydrophilic amino acid residues on the surface, thus
reflecting an opposite distribution of properties when compared to the transmembrane GPCR
proteins.
3.2.6 Perscan and Other Tools
Apart from the application of, e.g., helical net representations [102], specially developed neural
networks by B. Rost [105, 106] 3, the computation of helical moments is implemented in Per-
scan [107, 67, 108]. Both are claimed to be useful in predicting TMDs. The reliability of the
later approach for the purpose of GPCR modelling was also tested in this study.
3.3 Results
3.3.1 Transmembrane Sequence Stretches
The TMDs of membrane proteins are usually determined using a hydrophobicity plot of the
individual sequence of the membrane protein, generally based on the hydrophobicity scale of
Kyte-Doolittle [78]. The plot of the average hydrophobicity against the sequence number iden-
tifies regions of the amino acid sequence with overall hydrophobic character such as expected
of a TMD. In general, a hydrophobic region is identified as a TMD if it spans at least 18 amino
acids. In this study, this procedure was carried out for all nine sequences of the CCK-A &
B receptors, not only based on the hydrophobicity scale of Kyte-Doolittle, but also applying
2 now moved to the Center for Molecular and Biomolecular Informatics (CMBI) in the Netherlands:
http://www.gpcr.org/7tm
3 URL: http://www.embl-heidelberg.de/predictprotein
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other amino acid property scales. In Figure 3.1, an example of the profile of the sequence of
the human CCK-B-receptor with the polarity scale of Zimmerman and the hydrophobicity scale
Kyte-Doolittle with different window sizes is shown. It is obvious, that the TMDs cannot be
determined straightforward from this plot, also because the result is strongly influenced by three
factors: notably the applied scale, the window size and the threshold value, that determines a se-
quence as hydrophobic or hydrophilic. Furthermore, only a few mutations within the sequence
significantly influences the property profile plot and therefore the determination of the TMDs.
Consequently, this method is considered as not practicable for the exact determination of the
TMDBs, which is a prerequisite for the molecular modelling of a GPCR.
The separate multiple alignments of the 10 different peptide binding GPCR families were gener-
ated using the computer programs from the University of Wisconsin Genetics Computer Group
(GCG). The resulting 10 multiple alignments exhibit high similarity in a single family, espe-
cially in the regions were the TMDs are expected. Supported by the fingerprint of Baldwin [66],
the seven potential TMSSs could be determined in all sequences. Strongly conserved amino
Table 3.2: The fingerprint of Baldwin for the Transmembrane Domains 2, 5 and 7 of the
rhodopsin-like family of G protein-coupled receptors is given along with the potential Trans-
membrane Sequence Stretches of the human CCK-A and B receptors, the human neuropeptide-Y
receptors and the endothelin receptors. Yellow-amino acids = inside the receptor, pale-yellow-
amino acids = on border of protein, red-numbers = centre amino acids, blue line = end of
transmembrane sequence, red line = end of core sequence, and magenta line = possible end of
core sequence.
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Zimmerman Kyte-Doolittle
score score
A
Zimmerman Kyte-Doolittle
score score
B
Figure 3.1: Property profiles of the single amino acid sequence of the human CCK-B receptor
with the polarity scale of Zimmerman (black) and the hydrophobicity scale of Kyte-Doolittle
(blue, score reversed plotted) in (A) with window size 5 and in (B) with window size 17.
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acids, indicated by Baldwin with a percentage of conservation above 70%, were almost always
identified in all 101 sequences. In each TMSS, amino acids could be used as anchor points for
the aligning of the TMSSs of all 101 receptors for each TMD. In Table 3.2 the fingerprint of
Baldwin [66] is given along with the potential TMSSs of the human CCK-A and B receptors,
the human neuropeptide-Y receptors, as well as the endothelin receptors.
3.3.2 Amino Acid Property Profiles
For each of the seven TMDs, 11 multiple alignments with a length of 36 amino acids (10
from 10 different receptor families and one for all the 101 receptors) were generated. Property
profiles were computed for all 77 alignments with 12 different scales and 9 different window
sizes, resulting in total (77 x 12 x 9 =) 8316 profiles.
In order to circumvent the problem of an unambiguously assignment of a meaningful threshold
value for, e.g., hydrophobicity, we have normalised all profiles, also to ensure comparability of
profiles generated with different scales. For better comparison we have also reversed the score
of the profiles for hydrophobicity, thus regions of high hydrophobicity display similar scores
when compared to regions of low polarity.
In general, the property profiles for the larger window sizes (> 7) are not useful for identifi-
cation of the TMDBs, they can only be used for the identification of a TMD in a sequence.
In Figure 3.2 the normalised property profiles based on the polarity scale of Zimmerman and
the hydrophobicity scale of Kyte-Doolittle for the TMSSs 2, 3 and 4 are depicted for different
window sizes (3, 7, and 17 respectively). The profiles with window size 17 are generally flat-
ter and fail to display a high resolution, which is required to determine the TMDBs. On the
other hand, the profiles with the smaller window size of 3 are more noisy and have occasionally
discontinuity in their plots, which renders determination of the TMDBs questionable.
In the following, thorough sequence analysis is based on the profiles derived from the multiple
alignment of all 101 sequences, thus revealing a more general picture of sequence characteris-
tics, less influenced by mutations within distinct sequences or less populated families.
From the normalised profiles shown in Figure 3.3, it turns out that the bulkiness scale of Zim-
merman, the helical parameter of Chou-Fasman, the mutability scale of Dayhoff, and the scale
of buried residues of Janin do not produce distinct regions of approximately 18 amino acids
length with a significant decreased or increased value as diagnostic indication for the existence
of a TMD. The profiles vary over the entire TMSS and no consistency among the different
TMDs can be obtained. Consequently, the scales of Janin, Chou-Fasman, Dayhoff and the
bulkiness scale of Zimmerman cannot be used for the determination of the TMDBs, while the
hydrophobicity scale of Kyte-Doolittle, Eisenberg, and the polarity scale of Zimmerman pro-
duce more promising results.
No significant differences between the profiles generated with window sizes 3, 4 and 5, and
between 6, 7 and 9 could be determined. After the optimisation process discussed above, 8
scales (the hydrophobicity scales: Kyte-Doolittle, Abraham, Eisenberg, Roseman, Sweet and
Wolfenenden; the hydropathy scale of Hopp-Woods and the polarity scale of Zimmerman) and
4 window sizes (3, 7, 11 and 17) were chosen for further analysis.
The profiles of the hydrophobicity scales are not always identical, but they have in general
the same pattern (see e.g. TMSS 7 in Figure 3.3B). Figure 3.2 and 3.3 clearly proves that the
hydrophobicity scales do not allow a straight identification of potential borders of the TMDs,
they display more than one discontinuity in the profile and they not necessarily encompass
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Figure 3.2: The property profiles of the Transmembrane Sequence Stretches 2, 3 and 4 with a
window size of 3 (black), 7 (magenta) and 17 (blue) and in the first row with the polarity scale of
Zimmerman (A, B and C) and in the second row with the hydrophobicity scale of Kyte-Doolittle
(D, E and F).
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A B
Figure 3.3: The property profiles with a window size of 3 of Transmembrane Sequence Stretch 2
with in A : the scales of Zimmerman for bulkiness (blue), the helical parameter scale of Chou-
Fasman (green), the mutability scale of Dayhoff (black) and the scale of buried residues of
Janin (red). In B the polarity scale of Zimmerman (red), the hydrophobicity scales of Wolfenden
(grey), Eisenberg (black), Abraham (pink), Kyte-Doolittle (light green), Roseman (dark green)
and Sweet (light blue), and the hydropathy scale of Hopp-Woods (dark blue).
18 amino acids with a clear decreased normalised value. This phenomenon occurs in a much
lesser extent in the profiles of the polarity scale of Zimmerman. Therefore, the profiles with
the polarity scale of Zimmerman are used as basis for the determination of the TMDBs. Border
residues are identified as flanking stretch of approximately 18 amino acids with a normalised
value ≤ 0.2 in the profile of Zimmerman, determined with a window size of 3. It turns out
that in TMSSs 3, 6 and 7, these stretches of amino acids with a value smaller than 0.2 are
interrupted at the extracellular side by a small region of 2 amino acids. However, these regions
are included in the determined TMD since they are flanked by regions of at least 2 amino acids
with a normalised value significantly smaller than 0.2. The determined TMDBs are listed in
Table 3.3A according to the numbered positions in the graphs (Figures 3.1-3.3).
Table 3.3B gives also the centres of the TMDs which were determined as the average of the first
and the last residues of a region with a normalised value smaller than 0.2 for at least seven of
the eight property profiles, generated with a window size 17. For reasons of comparison, the
corresponding parameters by Baldwin [60, 6, 66] are also given.
3.3.3 Amino Acid Occurrence Profiles
The occurrence profiles for different amino acids over the TMSSs of both, the family of peptide
binding GPCRs, and the family of opsine receptors, show that the distribution of key amino
acids is clearly not random, thus depending on the transmembrane protein topology. These
results compare well with the findings of von Heijne [95, 109] and Landolt-Marticorena [98].
From the occurrence profiles for arginine and lysine a preference of these positively charged
amino acids for TMD-flanking regions on the intracellular side of the TMSSs can be deduced.
However, they also occur in a lesser extent at the extracellular side of the TMSSs, as depicted in
Figure 3.4A. The occurrence profiles of negatively charged residues are a mirror image of that
of positively charged residues. They occur on both sides of the TMDs, with in general clear
preference for the extracellular side (normal pattern for peptide binding GPCRs Figure 3.4C,
deviating pattern for opsine receptors Figure 3.4D).
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A
TMDB determined by Baldwin TMDB determined with window size 3
amino acid num-
bers of TMDB in
TMSSs.
length
of
stretch
position of
TMSS in
graph †
determined
with only
prop. prof.
determined
with prop.
prof.
length
of
stretch
difference
to TMDB
determined
extrac. intrac. + aa distr. by Baldwin
Helix 1 10 27 18 10 27 7 30 9 27 19 1 0
Helix 2 27 10 18 10 27 4 30 10 27 18 0 0
Helix 3 10 27 18 10 27 8 27 11* 27 17 -1 0
Helix 4 26* 11 16 11 26 9 26 10* 26* 17 1 0
Helix 5 11* 28 18 11 28 10 30 12 28 17 -1 0
Helix 6 27 11 17 10 26 8 27 10 27 18 0 1
Helix 7 12* 27 16 12 27 7 29 12* 28* 17 0 1
* = some difficulties with the determination of these transmembrane boundaries, see text.
† = the positions of the odd transmembrane sequence stretches are reversed numbered in the graphs.
B
Middle Points of the determined Transmembrane Domains
middle point
of the TMDBs
determined by
Baldwin
middle point of the
TMDBs determined
with only prop. prof.
and window size 3
middle point of the
TMDBs determined
with prop. prof. + aa
distr. and window size 3
middle point of the
TMDBs determined
with only prop. prof.
and window size 17
Middle
point
difference
to Baldwin
Middle
point
difference
to Baldwin
Middle
point
difference
to Baldwin
Helix 1 18,5 18,5 0,0 18,0 -0,5 18,0 -0,5
Helix 2 18,5 17,0 -1,5 18,5 0,0 17,0 -1,5
Helix 3 18,5 17,5 -1,0 19,0 0,5 18,0 -0,5
Helix 4 18,5 17,5 -1,0 18,0 -0,5 17,5 -1,0
Helix 5 19,5 20,0 0,5 20,0 0,5 18,5 -1,0
Helix 6 18,0 17,5 -0,5 18,5 0,5 19,0 1,0
Helix 7 19,5 18,0 -1,5 20,0 0,5 19,0 -0,5
Table 3.3: (A) The Transmembrane Domain Boundaries elucidated from the amino acid prop-
erty profiles (prop.prof.) and the amino acid distribution profiles (aa distr.) with the window
size 3 as described in the text, and the Transmembrane Domain Boundaries determined by Bald-
win are listed. The numbers are the positions in the graphs (the odd transmembrane sequence
stretches are reversed numbered). (B) The middle points of the Transmembrane Domains, de-
termined by three procedures, notably by Baldwin, by averaging the Transmembrane Domain
Boundaries of (A), and by taking the middle point of the Transmembrane Domain Boundaries
elucidated from the amino acid property profiles with window size 17. Also the deviations with
the Baldwin middle points are listed (a negative value is a shift to the extracellular side of the
membrane and a positive shift is a shift to the intracellular side of the membrane).
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Figure 3.4: Several amino acid distribution profiles of the Transmembrane Sequence Stretches of the
multiple alignment of the peptide binding GPCRs and of the multiple alignment of the opsine receptors.
In each diagram the percentage of occurrence of an amino acid versus the position within the transmem-
brane domain is depicted with a balk. Thereby represent the different colours the seven different TMDs
(1 = red, 2 = dark blue, 3 = light blue, 4 = pink, 5 = green, 6 = black, 7 = purple). The odd numbered
TMDs are aligned antiparalel to the even numbered TMDs. The distribution profiles are: A. Arginine
peptide GPCRs, B. Proline peptide GPCRs, C. Glutamate peptide GPCRs, D. Glutamate opsine recep-
tors, E. Phenylalanine peptide GPCRs, F. Cysteine peptide GPCRs, G. Valine peptide GPCRs, and H.
Glycine opsine receptors.
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Charged residues are not necessarily excluded from the TMDs. Arginine appears with a low
occurrence in the TMDs of the peptide binding GPCRs (Figure 3.4A). Lysine and aspartate
occur both with a very high percentage at a number of distinct places in a few TMDs (TMD 7
of the opsine receptors and in TMD 2 of both families respectively).
The polar residues asparagine and glutamine have similar patterns of occurrence when com-
pared to the negatively charged residues, although they seem to appear preferentially closer to
the central region of TMSSs.
Proline residues can be found in transmembrane helices, accompanied with a high degree of
conservation (see von Heijne [97, 109] and Williams [96]). Four strictly conserved prolines are
found in the peptide binding GPCRs, in TMSS 4, 5, 6 and 7 respectively, and seven occur in the
opsine receptors. Less conserved proline residues are found mostly at the extracellular side of
the TMSSs (Figure 3.4B), which was also observed by Landolt-Marticorena [98].
The aromatic residues tryptophan, histidine, tyrosine and phenylalanine do not share a common
occurrence pattern. The profile of histidine is similar to that of charged residues, i.e., histidine
residues occur mostly at the termini of the TMDs, but they seem to have no preference for a
particular side. Also tryptophan residues are found at the terminal regions. However they are
found a few positions more to the central region of the TMDs, as is expected for the typical
membrane boundary residue. In both receptor families, tryptophan occurs at two positions with
a percentage of occurrence > 95%, notably in TMD 4 and TMD 6. The opsine receptors have a
third very conserved (80%) tryptophan in TMD 3.
In contrast to tryptophan and histidine, tyrosine and especially phenylalanine frequently occur
in the TMDs (Figure 3.4E). In the peptide binding GPCRs four positions were identified with
a very high percentage of occurrence for tyrosine residues, namely in TMSS 5 and 7 at the
intracellular border of the TMD, in TMSS 3 at the intracellular side (from the well know DRY-
motif [79]) and in TMSS 1 at the extracellular border of the TMD, respectively.
Landolt-Marticorena [98] observed that phenylalanine was located within the TMD and in the
intracellular flanking region. In contrast, the occurrence profiles discussed here clearly showed
that they are found preferentially in the TMDs and in the extracellular flanking regions of both
families (Figure 3.4E).
In the peptide binding GPCRs, cysteine residues seem to have a preference for the TMD (Figure
3.4F). Two positions have a percentage of occurrence > 75% (TMD 6 and TMD 7). The most
conserved cysteine residue is found in the extracellular region of TMSS 3 with a percentage of
occurrence of 99%. The occurrence of cysteine in the opsine receptors is slightly different in
that more cysteine residues seem to occur. Also the strongly conserved cysteine residue in the
extracellular flanking region of TMSS 3 is found, but those in TMD 6 and 7 are significantly
less conserved, 56% instead of 82% and 20% instead of 79% respectively.
In contrast to cysteine, methionine seems to be randomly distributed over the TMSSs of the
peptide binding GPCRs. They have a low occurrence in all the TMSSs, only three positions
have a percentage of occurrence higher than 40%. Methione has a higher occurrence in the
opsine receptors, but again, the distribution seems to be random over the TMSSs.
The distribution of the hydrophobic residues valine, leucine and isoleucine are not significantly
different. They have a preference for the TMDs, but they are certainly not excluded from
the flanking regions. According to Landolt-Marticorena [98], these residues have also a non-
random distribution within the TMD. Along a path from the extracellular to the intracellular side
an isoleucine, a valine and a leucine-enriched region is analysed. Such a distribution could not
be observed in the occurrence profiles of these amino acids in both GPCR families investigated
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here. The distribution of the valine residues in the peptide binding GPCRs is shown in Figure
3.4G.
The occurrence profiles of alanine, serine and threonine residues reveal a random distribu-
tion. In contrast, the occurrence of glycine is not entirely random, as mentioned by Landolt-
Marticorena [98], these residues have a low percentage of occurrence in the intracellular regions
of the TMSSs. This is especially the case for the opsine GPCRs (Figure 3.4H).
3.3.4 Determination of the Transmembrane Domain Boundaries
By combining the amino acid distribution profiles and with the amino acid property profiles, a
more precise determination of the TMDBs can be made, since the distribution of certain amino
acids is clearly depending on the membrane topology. The TMDBs, listed in Table 3.3A, are
adapted by including the amino acid distribution profiles of the peptide binding GPCRs. The
following rules were derived for this determination:
• Arginine and lysine residues are preferable located outside the TMD. When the TMD is
found too short, arginine and lysine can be found on the first or the last three positions of
the TMD, since the long side chain can extent over one helical turn so that the hydrophilic
head group reaches the hydrophilic environment of the lipid headgroups.
• The same rule accounts for the glutamate residues.
• Since aspartate has a considerably shorter sidechain, only the first start and the terminal
two positions of a TMD are accessible for aspartate.
• Tryptophane residues are situated close to the borders of the TMDs, displaying a clear
preference for the membrane boundary region as was found for other membrane proteins.
• Non-highly-conserved proline residues can be found on the first three positions at the
amino-terminal side and at the last position of the carboxy-terminal side of a transmem-
brane helix, due to the helix-breaking capability of this residue [79].
3.3.4.1 TMD 1
In the following, characteristic sequential details are introduced for each putative transmem-
brane helix, extracted from the multiple sequence alignment and the fingerprint of Baldwin
[60, 6, 66]. In TMD 1 the positions 9 and 10 are occupied in several instances by proline
residues (Figure 3.5A). The human Bradykinin-2 receptor shows prolines on both positions.
Since these prolines are not widely conserved, are they estimated as transmembrane helix ter-
minators. These positions are on the N-terminal side, therefore the first position of the TMD
is position 8. However on position 8 the occurrence of arginine is 6%, that of tryptophan is
16.8%, rendering that position still being extracellular. From that finding, the first TMD po-
sition is adapted by the residue in position 9. For the intracellular end of TMD 1, a similar
observation can be made. Position 28 is occupied by 16.8% tryptophan residues, 2% lysine
residues, and 10% arginine residues. From this fact it can be concluded that the TMD ends at
position 27. The final length of TMD 1 appears to be 19 amino acid residues, ranging from
position 9 to 27.
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Figure 3.5: With the combination of the property profiles of the polarity scale of Zimmerman and
the hydrophobicity scales of Kyte-Doolittle (dark blue), Sweet (dark green), and Hopp-Woods
(purple) and the distribution profiles of the tryptophan (magenta), the arginine/lysine (black),
the aspartate/glutamate (light green), the histidine (blue) and the proline (light blue) residues,
the boundaries of the transmembranes are determined. In the two diagrams the normalised
scores of the different property profiles and the percentage of occurrence (divided by 100) of the
different amino acids are depicted for the transmembrane sequence stretches 1 (A) and 4 (B).
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3.3.4.2 TMD 2
In TMD 2, the positions 9 and 10 exhibit proline residues with an occurrence of 32.7% and
50.5% respectively. Consequently, position 10 is the C-terminal end of TMD 2; corroborated
by the occurrence of 16.8% tryptophan residues on position 9. The terminal residue on the op-
posite end of TMD 2 is position 27, since 12.9% aspartate and 5% glutamate residues are found
in position 28, thus indicating a typical membrane boundary property. TMD 2 is obviously
composed of a stretch of 18 residues, i.e. 10-27.
3.3.4.3 TMD 3
The identification of TMD 3 with its precise boundaries appears to be problematic. On positions
9 and 12 proline residues appear with 17.8% and 14.9% occurrence, respectively. Since this
describes the N-terminal boundary, position 10 can be considered as the first transmembrane
residue. However, on position 12 and 13 charged residues occur, i.e., aspartate (16.8%) and
lysine (11.9%) at position 12, glutamate (12.9%) and lysine (10.9%) at position 13, respectively.
From this observation, position 14 emerges as likely terminus of TMD 3, thus leading to a
sequence stretch that would be too short to span the membrane. Therefore, the exception rules
mentioned above are employed and position 11 is assigned as the N-terminal residue of TMD 3.
According to the amino acid property profiles, position 27 appears as the last residue of TMD
3. Sequence analysis reveals position 28 as not being occupied by charged residues, tryptophan,
or proline, which would indicate TMD termination. Position 29 is the first position where such
residues occur, namely aspartate (81.2%), glutamate (16.8%), respectively. According to the
amino acid distribution profiles, position 28 is assigned as C-terminal TMD 3 residue.
3.3.4.4 TMD 4
Similarly to the determination of TMD 3, the analysis of TMD 4 appears difficult. Even though
proline is found at position 10 with an occurrence of 10%, position 11 is occupied by glutamate
in 11.9% of all cases. The first observation (Figure 3.5B) suggests the residue at position 10
as the terminal TMD residue, while the second finding indicates the residue at position 12
as the boundary position. The opposite extracellular interface is defined by position 25 since
glutamate is found in 9.9% and lysine in 2% of all cases at position 26. The resulting helix
ranging from residue 12 to 25 would be too short to span the bilayer membrane, thus charged
residues are obviously part of the transmembrane helix in its boundary regions. In position 27,
arginine occurs with 6%, lysine with 2.9%, while position 28 is occupied by arginine with an
occurrence of 10% and by lysine in 52.4% of all cases, respectively. Due to the high percentage
of occurrence of charged residues in position 28, the preceeding position 27 is assigned as the
last residue of TMD 4. This is further supported by the occurrence of tryptophan, a typical
boundary residue, in this very position, although it is with a low percentage. Thorough analysis
of the three hydrophobicity profiles and the polarity profile reveals position 26 as the boundary
residue. This because the polarity scale of Zimmerman and the hydrophobicity scale of Kyte-
Doolittle are at position 26 below the threshold value of 0.2 and at position 27 they have a
significant higher value. This rises in the score from position 26 to 27 is also observed for the
two other hydrophobicity scales.
Ranging from position 10 to 26, the TMD 4 helix has an extension of 17 residues.
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3.3.4.5 TMD 5 and 6
The determination of the TMDBs of TMD 5 and 6 are obtained straightforward. The distribution
of indicative residues such as arginine (position 11), lysine (position 29), tryptophan (position
10) and proline (position 11) results in the assignment of TMD 5 covering the sequence range
from position 12 to 28. Similar findings allow the identification of TMD 6, encompassing
residues between the positions 10 and 27.
3.3.4.6 TMD 7
The boundary determination of TMD 7 requires a more detailed analysis. On positions 9 and
12 aspartate and glutamate residues are found while position 13 displays tryptophan with en-
hanced probability. At the intracellular side, the first charged residues are found in position 31,
tryptophan on position 28, respectively. Taking tryptophan as main indication for the boundary
region, positions 14 and 27 define the extension of TMD 7, which results in a sequence stretch
with insufficient length to span the membrane in an α-helical conformation. Taking into account
that Cα-Cβ bond vectors of residues adopting an α-helical conformation are oriented towards
the N-terminus, it can be assumed that a tryptophan residue at position 13 is part of TMD 7
while still exposing its sidechain into the extracellular aqueous compartment. In contrast, a
tryptophan at position 28 has to be considered as boundary residue. Based on this assumption,
TMD 7 comprises residues from position 12 to 28.
In summary, while comparing the TMDBs determined by the described sequence analysis tools
with those published by Baldwin [66], the maximal derivation accounts for only one single
sequence position, as is shown in the last column of Table 3.3.
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3.3.5 Helical Wheel Analyses
In the previous section the results of thorough bioinformatical analysis of multiple GPCR se-
quence alignments were described, resulting in a type of a generic 1D typology of the receptor
proteins in that the linear protein sequence was partitioned into seven TMDs and connecting
loop regions. In the following, these results are transformed into a 2D representation by con-
ducting extensive helical wheel analyses. For the seven TMDs, we calculated the sequence
property moments following a consensus approach by applying 8 distinct property scales from
Table 3.1, notably: the hydrophobicity scales of Abraham, Eisenberg, Kyte-Doolittle, Roseman,
Sweet and Wolfenden, the hydropathy scale of Hopp-Woods, and the polarity scale of Zimmer-
man. The sequence property moments were calculated for (i) the multiple alignments of the
TMDs of the separate peptide binding GPCR families, (ii) the multiple alignment of all the 101
sequences of peptide binding GPCRs, (iii) the multiple alignment of 50 opsine receptors, and
(iv) the multiple alignment of 623 rhodopsin-like GPCRs. The property moment vectors were
drawn in a 2D graph according to the following conventions:
• the first residue of every TMD is aligned at 0◦ (this is at the +Y-axis) and the central helix
axis is at the origin
• helices 1, 3, 5 and 7 proceed clockwise through the membrane seen from the extracellular
side
• helices 2, 4 and 6 proceed counter clockwise through the membrane seen from the extra-
cellular side
• the second residue of an odd numbered TMD is at +100◦
• the second residue of an even numbered TMD is at -100◦
• the third residue is at +200◦ and 200◦, respectively, etc.
• each residue covers an angular region of 100◦, thus accounting for an ideal α-helical
conformation
In an ideal arrangement of the seven α-helices the following points would be met (see Figure
3.6):
• every TMD is a perfect α-helix with a periodicity angle of 100◦
• the seven TMDs have a perfect circular arrangement
• the axis of every α-helix is perpendicular to the membrane plane and perfect parallel or
anti-parallel to the other α-helices
• every TMD is an ideal amphiphilic α-helix with its vectors for polarity and hydropa-
thy pointing to the exact centre of the protein bundle and the vector for hydrophobicity
orientated anti-parallel to the inside pointing vectors
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Property scale Rec. family HELIX 1 HELIX 2 HELIX 3 HELIX 4 HELIX 5 HELIX 6 HELIX 7
angle length angle length angle length angle length angle length angle length angle length
Zimmerman peptide rec. 21.1 23.0 0.1 2727.9 56.0 317.6 36.5 132.9 -31.8 66.4 141.0 436.5 -5.2 375.2
Opsine rec. 15.9 15.1 18.9 1668.3 170.3 354.1 60.9 94.5 -35.9 461.5 -123.5 8.2 53.4 1921.1
623 seq. 26.4 19.3 3.9 1872.0 27.3 217.5 29.6 71.3 -22.2 47.5 155.8 69.6 -2.9 321.3
HoppWoods peptide rec. 3.9 2.3 -13.4 15.3 21.1 16.0 103.0 2.5 -50.0 9.5 -26.9 7.0 -43.4 18.1
Opsine rec. 23.0 8.4 27.0 37.7 42.5 24.3 54.1 0.8 -47.5 8.2 -15.2 14.0 14.8 32.6
623 seq. 15.5 3.5 -5.5 17.8 22.2 12.2 91.7 1.1 -47.0 7.1 -14.4 6.1 -29.4 19.5
KyteDoolittle peptide rec. -149.3 118.8 -122.5 43.3 -148.5 17.2 130.0 19.4 -161.2 92.5 5.7 51.1 155.6 284.2
Opsine rec. -168.8 62.2 -110.0 53.6 -94.6 10.6 -137.2 72.5 178.4 33.7 43.7 80.0 158.1 126.7
623 seq. -153.0 66.9 -131.4 20.4 -155.7 9.4 148.0 31.2 -166.2 34.6 1.4 24.9 160.6 229.1
Abraham peptide rec. -147.8 13.3 -97.4 3.4 -169.7 9.3 140.6 4.2 151.2 5.3 47.7 1.3 135.2 43.0
Opsine rec. -162.3 28.9 -125.0 16.0 -143.2 21.9 -174.9 2.4 122.2 7.3 114.3 2.0 166.0 30.3
623 seq. -154.2 14.5 -140.9 1.3 -160.3 5.7 145.1 2.6 138.9 4.2 -41.1 0.0 143.9 33.6
Sweet peptide rec. -175.0 2.4 151.6 2.7 -171.6 7.7 160.9 0.9 133.5 7.2 150.0 0.4 144.2 13.7
Opsine rec. -161.7 6.6 -146.5 13.7 -133.5 14.9 -171.6 6.6 125.8 7.6 172.0 2.3 174.7 25.8
623 seq. -162.6 3.4 169.8 4.1 -161.7 4.1 163.1 2.3 127.7 6.4 -174.9 1.7 159.2 12.4
Eisenberg peptide rec. -136.5 5.0 -133.6 2.4 -164.9 2.7 132.4 0.5 -174.2 3.0 26.8 1.2 146.5 13.5
Opsine rec. -169.2 5.4 -124.9 4.3 -115.8 0.9 -148.0 1.8 159.2 3.2 62.9 2.5 168.9 8.3
623 seq. -146.6 3.7 -145.2 1.3 -155.9 1.3 148.5 0.7 178.4 1.6 27.7 0.7 152.9 11.9
Roseman peptide rec. -164.5 20.8 -165.7 10.6 -162.6 6.3 155.4 1.9 161.5 9.0 0.0 4.9 150.5 38.9
Opsine rec. -173.6 21.2 -141.6 16.8 -71.7 2.8 -174.7 7.4 142.7 6.2 46.8 3.1 177.2 32.0
623 seq. -162.4 15.7 -174.2 13.6 -136.5 3.0 152.3 3.7 151.4 2.7 36.8 0.4 154.0 34.8
Wolfenden peptide rec. -123.5 323.4 -113.9 229.5 -159.3 35.9 155.0 220.7 -138.0 142.4 -4.6 246.7 154.2 510.8
Opsine rec. -167.1 199.0 -91.3 95.2 20.8 156.1 -151.6 125.1 -177.0 47.8 27.6 227.7 136.7 93.4
623 seq. -135.4 201.0 -113.4 76.4 -156.3 15.6 155.8 156.6 -141.4 48.3 -1.5 166.4 155.3 360.4
Baldwin Variability -175.7 3326.6 -150.0 1543.0 -137.0 165.9 164.6 2100.9 -142.1 4760.9 7.5 1811.4 166.1 189.4
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A B
Figure 3.6: An ideal arrangement of the seven α-helices. All α-helices are perpendicular to the
membrane plane (A: horizontally and perpendicular to the paper; B: the plane of the paper)
and parallel or anti-parallel to each other. The inward pointing property moment is pointing to
the centre of the protein bundle and the outward pointing property moment is anti-parallel to
this property moment and is in the middle of hydrophobic side of the α-helix.
The angles and lengths of all vectors of the three comprehensive multiple alignments are listed
in Table 3.4, together with the angles and lengths of the vectors determined with the variability
determined by Baldwin [66, Figure 2 therein]. Table 3.5 gives the averaged angular orienta-
tions of the vectors from Table 3.4 clustered in two groups; notably, the group of the vectors
expected to point inside the protein bundle (the vectors of the polarity scale of Zimmerman and
of the hydropathy scale of Hopp-Woods) and the group of vectors expected to point to the lipid
environment (the vectors of the six hydrophobicity scales). The averages were calculated with
normalised vector lengths in order to compensate for the high vector lengths of the polarity
scale of Zimmerman and the hydrophobicity scale of Wolfenden, respectively.
3.3.5.1 TMD 1 and TMD 2
For TMD 1 the vectors of the hydrophobicity scales have a very similar angular orientation
with an average at -154.4◦, thus being in close proximity to the variability vector of Baldwin
(-175.7◦).
The angles of the hydrophobicity vectors of TMD 2 vary between -91.3◦ and +169.8◦. In
general, the vector lengths of the hydrophobicity scales are smaller compared to those of TMD
1, however, the vector lengths of the Zimmerman and the Hopp-Wood scales are significantly
larger. The deviation from an antiparallel alignment of the inside vectors and the outside vectors
is decreased when compared to TMD 1, the total average of all vector graphs results in an
angular orientation of 141.6◦. Again, the variability vector of Baldwin (-150.0◦) is close to the
hydrophobicity vectors.
3.3.5.2 TMD 3
Figure 3.7 illustrates that the hydrophobicity vectors of the different peptide binding receptor
families for TMD 3 based on, e.g., the Wolfenden and the Kyte-Doolittle scales hardly show a
preferred orientation. However, the vectors computed from the total group of peptide binding
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Figure 3.7: The vectors representing the sequence property moments of the transmembrane do-
main 3. In the first upper row the vectors of the different families of peptide binding GPCRs
(small symbols) and of the total multiple alignment of the peptide binding GPCRs (large
squares) are depicted. In the second row the vectors of the three major multiple alignments
are shown, notably, the peptide binding GPCRs (square), the opsine receptors (triangle) and
the 623 rhodopsin-like GPCRs (dot). The right part is always a blow-up of the left part. Blue =
polarity of Zimmerman, green = hydrophobicity of Kyte-Doolittle, black = hydropathy of Hopp-
Woods, magenta = hydrophobicity of Wolfenden, purple = hydrophobicity of Eisenberg, light
blue = hydrophobicity of Sweet, red = hydrophobicity of Abraham, and yellow-red = variability
of Baldwin.
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Vector Helix 1 Helix 2 Helix 3 Helix 4 Helix 5 Helix 6 Helix 7
Av. Angle Zimm.+ HW all 17.7 5.1 43.2 62.3 -39.1 -52.4 -3.0
Zimm.+ HW pept. 12.5 -6.6 38.6 69.7 -40.9 57.0 -24.3
Zimm.+ HW ops. 19.5 22.9 106.4 57.5 -41.7 -69.3 34.1
Zimm.+ HW 623 seq. 21.0 -0.8 24.8 60.7 -34.6 70.7 -16.1
Hydro. All -156.4 -136.5 -145.4 165.3 164.7 34.6 155.2
Hydro. Pept. GPCRs -149.4 -138.0 -162.8 145.7 175.3 24.8 147.7
Hydro. Opsine -167.1 -123.4 -101.2 -159.7 151.8 70.6 163.7
Hydro. 623 seq. -152.4 -148.9 -154.5 152.1 167.7 5.3 154.3
∆ Angle All 174.0 141.6 171.4 103.0 156.3 87.0 158.2
Peptide receptors 161.9 131.4 158.7 76.0 143.9 32.2 172.0
Opsine receptors 173.4 146.3 152.4 142.8 166.5 140.0 129.6
623 sequences 173.3 148.1 179.2 91.5 157.8 65.5 170.5
Table 3.5: The average angles of the vectors are expected to point inside the protein bundle
(these are the vectors of the polarity scale of Zimmerman and of the hydropathy scale of Hopp-
Woods) and the average angles of the vectors are expected to point to the lipid environment
(the vectors of the hydrophobicity scales). These angles are listed for the three major multiple
alignments; notably, the peptide binding GPCRs, the opsine receptors and the 623 rhodopsin-
like GPCRs. For comparison, also the smallest angles between the averages of the inside and
the outside pointing vectors are listed.
GPCRs have similar angles for the different hydrophobicity scales, but the vector lengths are
small when compared to those of other TMDs. The property moments calculated from the 623
aligned sequences are in close proximity of those originating from the peptide binding GPCR
alignment (Figure 3.7). The property moments derived from the opsine receptor alignment show
great discrepancies. The vectors of the Wolfenden, Kyte-Doolittle, Roseman and Zimmerman
scales are spread over the entire graph encompassing a variety of different angles (Table 3.4).
The average angle of the hydrophobicity vectors for the opsine receptors is 101.2◦, whereas
it is 162.8◦ and 154.5◦ for the peptide binding GPCRs and the 623 rhodopsin-like sequences,
respectively. The variability of Baldwin results in the smallest vector for this TMD, but its
direction is similar to that of the hydrophobicity moments of the total peptide binding GPCR
and rhodopsin-like GPCR alignments (-137.0◦ versus 162.8◦ and 154.5◦, respectively). The
Hopp-Woods scale derived vectors are in close agreement among the different GPCR sequence
alignments.
The differences in the vectors of the Hopp-Woods scale are in contrast rather small, 42.5◦ ver-
sus 21.1◦ and 22.2◦. They cannot be pinpointed to one residue which is responsible for these
differences. However, the most significant differences between the peptide binding GPCRs and
the opsine receptors in this TMD, is that the opsine receptors have a moderately conserved glu-
tamate residue on position 17 and that on position 12 of the peptide binding GPCRs there are
different polar residues found, whereas on the same position in the opsine receptors no polar
residues are present.
3.3.5.3 TMD 4
Within TMD 4, the hydrophobicity moments are pointing in very similar directions, the vari-
ation is found between -137.2◦ to 130.0◦. The angle of the variability moment of Baldwin is
again in the area of the hydrophobicity based vectors (164.6◦ versus -159.7◦ - opsins; 145.7◦
63
CHAPTER 3. BIOINFORMATICS
- peptide binding GPCRs; 152.1◦ - rhodopsin-like GPCRs). The differences between the three
groups for the inward oriented moments is not that significant.
Interestingly, the most important observation for this TMD is that the angle between the aver-
ages of the inside- and outside-pointing moments is deviating dramatically from an antiparallel
orientation (180.0◦), notably 76.0◦ for the peptide-binding GPCRs, and 91.5 for the rhodopsin-
like GPCRs, respectively.
Figure 3.8: The vectors representing the sequence property moments of the transmembrane do-
main 5. In the first upper row the vectors of the different families of peptide binding GPCRs
(small symbols) and of the total multiple alignment of the peptide binding GPCRs (large
squares) are depicted. In the second row the vectors of the three extensive multiple alignments
are shown, notably, the peptide binding GPCRs (square), the opsine receptors (triangle) and
the 623 rhodopsin-like GPCRs (dot). The right part is always a blow up of the left part. Colours
see Figure 3.7.
64
CHAPTER 3. BIOINFORMATICS
3.3.5.4 TMD 5
Figure 3.8 depicts the vectors computed for the eight property scales based on 11 different mul-
tiple alignments of the peptide binding GPCRs of TMD 5. The vectors of the different receptor
families (small symbols) display severe variation in orientation, however, not significantly dif-
ferent compared to the other TMDs. In contrast, the vectors of the three comprehensive multiple
alignments, comprising the 101 peptide binding GPCRs, the 50 opsine receptors, and the 623
rhodopsin-like GPCRs show similar lengths and orientations. It is further noteworthy that vec-
tor pairs, expected to be aligned in an antiparallel orientation, such as hydrophobicity/polarity
vectors, or Baldwin variability/hydropathy vectors encompass an average angle of 155.0◦.
3.3.5.5 TMD 6
As found for TMD 3, some hydrophobicity moments of the different peptide binding receptor
families are widely spread over the graph for TMD 6. The moments derived from the hydropho-
bicity scales of Abraham, Sweet, Eisenberg and Roseman display one of the smallest values
when TMD 6 is compared to the other TMDs. The averages of the angles for the Kyte-Doolittle
and Wolfenden moments (0.6◦, 35.7◦ and 0.1◦ for the peptide binding GPCRs, the opsine re-
ceptors and the rhodopsin-like GPCRs) are similar to the angle of the variability moment of
Baldwin (7.5◦).
Remarkably, the moments of the Hopp-Woods scale are orientated entirely different when com-
pared to the moments of the Zimmerman scale. The Hopp-Woods moments align well with
the Kyte-Doolittle and the Wolfenden moments. The Zimmerman moments are aligned almost
anti-parallel to the Kyte-Doolittle and the Wolfenden moments; 140.5◦, 159.2◦ and 155.9◦ for
the peptide binding GPCRs, the opsine receptors and the rhodopsin-like GPCRs, respectively.
3.3.5.6 TMD 7
The vector moments for TMD 7 are given in Figure 3.9. The two vector groups are closer to
an antiparallel orientation when compared to, e.g., TMD 5 (Figure 3.9), and the angular spread
of the same property scale vectors is smaller. Only the vectors of the polarity-scale of Zim-
merman and the hydropathy scale of Hopp-Woods of the opsine receptors show significant dis-
crepancies with respect to the ideal pattern. The variability moment of Baldwin is found in the
same direction (166.1◦) as the hydrophobicity moments, which are spread between 135.2◦ and
177.2◦. The inside-pointing moments for the peptide binding GPCRs, the opsine receptors and
the rhodopsin-like GPCRs show averaged orientations at 24.3◦, 34.1◦ and 16.1◦ respectively.
In summary, the average of the sequence property moments of the inward pointing vectors and
the average of the sequence property moments of the outward pointing vectors are in TMDs 1,
2, 3, 5 and 7 in a fairly anti-parallel orientation analogous to the theoretically ideal situation
(Figure 3.6). Although, sometimes individual property moments do not follow the theoretical
rules. The sequence property moments of TMDs 4 and 6 are deviating from the ideal situation.
In the case of TMD 4 the averages of the inward and the outward pointing vectors are almost
perpendicular to each other, whereas the property moments of TMD 6 have a rather large spread
of angles within the two vector groups.
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Figure 3.9: The vectors representing the sequence property moments of the transmembrane do-
main 7. In the first upper row the vectors of the different families of peptide binding GPCRs
(small symbols) and of the total multiple alignment of the peptide binding GPCRs (large
squares) are depicted. In the second row the vectors of the three extensive multiple alignments
are shown, notably, the peptide binding GPCRs (square), the opsine receptors (triangle) and
the 623 rhodopsin-like GPCRs (dot). The right part is always a blowup of the left part. Colours
see Figure 3.7.
3.3.6 2D Projection Map of Helical Wheels
The sequence property moments are subsequently projected onto the 2D structure map of rho-
dopsin. Figure 3.10 illustrates this attempt for the projection of the sequence property moments
computed for the peptide binding GPCRs. The variability vectors of Baldwin were positioned
in the centre of the lipid bilayer at a level of 0 Å along the membrane normal of the 2D map.
Since the helices are not exactly orthogonal to the membrane plane and because they are not
exactly parallel to each other, the helical wheels differ significantly in the maps at +12 and
-8 Å when compared to the initial 0 Å map. Due to this orientational and rotational tilt, the
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Figure 3.10: The vectors of the property moments of the peptide binding GPCRs are projected
on the 2D maps of rhodopsin at the levels of +12, 0 and -8 Å, with the variability vectors of
Baldwin positioned in the centre of the helical face exposed to the lipid bilayer at a level of
0 Å along the membrane normal of the 2D map. Blue = variability of Baldwin, magenta =
hydrophobicity of Abraham, green = hydrophobicity of Kyte-Doolittle, black = hydrophobicity
of Eisenberg, purple = hydrophobicity of Wolfenden, yellow = hydropathy of Hopp-Woods, and
light blue = polarity of Zimmerman.
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variability moments of Baldwin deviate from the ideal orientation when the 0 Å map of, e.g.,
TMD 3 (Figure 3.10) is compared with the boundary maps at +12 and -8 Å.
3.3.7 Property Moments for Proteins with Known 3D Structure
To validate our considerations, the sequence and the structural property moments were calcu-
lated for two proteins with determined high resolution 3D structures. As the closest topolog-
ical analogue to GPCRs, the X-ray structure of the light-driven ion pump bacteriorhodopsin
was analysed together with the four-helix-bundle protein Felix (PDB-code: 1FLX and 3FLX)
[110, 111]. The later is a de-novo designed globular protein with helices adopting ideal confor-
mations without significant kinks.
For the computation of the sequence property moments of bacteriorhodopsin, a multiple align-
ment of 12 sequences of the bacteriorhodopsin family was used, including, e.g., halorhodop-
sin [51, 52, 112] and archaerhodopsin. Combining the 3D structure of bacteriorhodopsin with
the property profiles of Zimmerman (window size = 3) derived from the multiple alignments of
the seven potential TMSSs of the bacteriorhodopsin-family revealed the TMDBs. According to
the numbering scheme of the Brookhaven Protein Databank entry 2BRD the TMDs extend over
the following seven stretches: 11-29, 44-60, 80-97, 108-125, 136-153, 173-190 and 205-222.
The vectors for the sequence property moments based on the multiple alignments of the TMDs
of bacteriorhodopsin were calculated for exactly the same eight scales as described above (Table
3.6).
HELIX 1 HELIX 2 HELIX 3 HELIX 4 HELIX 5 HELIX 6 HELIX 7
Angle Length Angle Length Angle Length Angle Length Angle Length Angle Length Angle Length
Zimmerman 23.6 1.8 -12.3 3.8 115.2 96.7 142.9 48.0 13.26 2.7 -18.0 46.7 140.8 94.8
HoppWoods 46.8 2.8 30.6 1.0 97.9 11.0 -160.1 3.8 149.5 2.2 -93.2 5.3 14.0 9.0
KyteDoolittle -154.6 8.2 144.5 11.2 -47.1 8.6 57.4 9.6 -115.4 3.6 173.5 18.0 -31.6 16.5
Abraham -136.6 4.2 -164.3 2.7 -68.3 8.6 74.6 6.2 -35.0 2.0 102.9 4.3 -24.3 8.0
Eisenberg -149.1 2.0 151.8 2.3 -54.5 4.7 51.3 2.4 -100.2 1.2 155.9 3.6 -30.8 5.2
Roseman -169.5 2.0 -173.1 2.9 -58.7 9.1 17.7 3.1 3.3 2.1 149.4 5.7 -19.0 8.3
Sweet -136.7 1.4 -119.6 1.1 -83.7 4.7 60.3 3.4 -41.4 1.1 113.8 3.7 -23.8 3.8
Wolfenden -156.7 8.4 159.1 16.2 -36.8 31.2 34.1 9.9 -174.3 8.5 178.8 30.6 -33.9 31.4
Average
Zimm.+HW
35.2 9.1 106.5 171.4 81.3 -55.6 142.49
Average Hydro. -150.5 -180.3 -58.2 49.2 -77.2 145.7 -27.2
Delta 174.3 170.6 164.7 122.2 158.5 158.7 169.6
Inside 3D structure 42 -17 -139 149 0 66 160
Table 3.6: The different sequence property moments of the bacteriorhodopsin multiple align-
ment, together with the average over the hydrophobicity moments, the average over the polarity
plus the hydropathy moments, the delta angle between these two average moments and the an-
gle of the middle of the inside region of the helix within the 3D-structure of bacteriorhodopsin
(2BRD) are shown.
Comparable to the results obtained for the GPCRs, the property moments of TMD 1 of bac-
teriorhodopsin show an expected antiparallel pattern. The hydrophobicity moments have an
average orientation of -150.5◦, which is almost anti-parallel (174.3◦) to the average orientation
of the moments derived from the polarity scale of Zimmerman and the hydropathy scale of
Hopp-Woods (average: 35.2◦).
The hydrophobicity moments of TMD 2 cover a much larger area (144.5◦ to -119.6◦), while
the moments of Zimmerman and Hopp-Woods deviate mutually by 42.9◦. However, the delta
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angle between the corresponding averages accounts for an almost ideal antiparallel orientation
(170.6◦).
Together with TMD 1, the TMDs 3, 6, and 7 display this same anti-parallel pattern (164.7◦,
158.7◦ and 169.6◦, respectively), as is theoretical expected. The spread for the hydrophobicity
vectors of TMDs 3 and 7 is moderate, (46.9◦ and 15.0◦, respectively), but for TMD 6 it is
somewhat higher (75.9◦). A similar spread is also found for the inward oriented moments. The
found values are 17.3◦, 75.2◦ and 3.1◦ for TMDs 3, 6 and 7, respectively.
The spread of the angles of the moments of TMD 4 is moderate (56.8◦ and 57.0◦ for the hy-
drophobicity and the Zimmerman-Hopp-Woods moments, respectively), but the averages of
these two groups are far from anti-parallel (122.2◦). Therefore it can be summarised, that be-
side for TMD 4, the sequence property moments of the TMDs of bacteriorhodopsin show the
expected anti-parallel orientation of the average of the hydrophobicity vectors versus the aver-
age of the polarity/hydropathy vectors.
The structural property moments were calculated for the 3D structure of bacteriorhodopsin
taken from the Brookhaven Protein databank (entry: 2BRD) with the use of equation 3.2. As
mentioned above, the unit vector for a certain residue is aligned with the Cα-Cβ bond in direc-
tion of the sidechain. In order to allow a comparison of the sequence property moment vectors
with those calculated from the 3D structure, the vectors derived from the structure need to be
projected into a corresponding plane. The required vector components need to be perpendicular
to the main helix axis. Furthermore, the helices are rotated in such a way that the best agreement
with the ideal helical wheel of the TMSSs is achieved in order to achieve a good comparison.
Table 3.7 lists the lengths of these projected vectors as well as the lengths and angles of the
vectors derived from the 3D structure.
Comparison of the alignment-based computed vectors with those from the 3D structure wheels
reveals no uniform deviation. Differences in orientation range from, e.g., 19.5◦ for the Eisenberg-
vector of TMD 2 up to 176.9◦ for the Abraham-vector of TMD 5. A comparable result is ob-
tained for the average vector orientations. Only the deviations from antiparallel orientation of
inside- and outside-pointing vectors show satisfactory correspondence, but again without any
regularity.
From the 3D structure of bacteriorhodopsin the angles of the helices between the start residue
of the helix and the point representing the inside of the protein were determined in order to
compare these angles with the angles of the calculated property moments. These inside 3D
structure angles are also listed in Tables 3.6 and 3.7. When these angles are compared with the
sequence property moments, the centres of TMDs 1, 2, and 7 are rather well predicted. The
average of the Zimmerman and Hopp-Woods vectors are almost parallel and the averages of the
hydrophobicity vectors are almost antiparallel to the determined inside-angle. For the residual
four TMDs, angles smaller than 90◦ can be observed.
The structural property moments predicted the centres of TMDs 2, 3, 4, 5 and 7 with accep-
table accuracy, while the prediction for TMDs 1 and 6 revealed deviations of 109◦ and 162◦,
respectively. This is almost the opposite direction.
For the Felix four-helix-bundle were the sequence property moments were from a single se-
quence. Since the helices of Felix are almost ideal, one would expect the differences between
the sequence and structural property moments to be small. In Table 3.8A, the angles and the
lengths of the eight different sequence property moments are listed, while Table 3.8B gives the
values for the structural property moments.
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HELIX 1 HELIX 2 HELIX 3
Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L.
Zimmerman 95.0 5.8 2.9 -59.9 7.4 1.4 -172.4 126.7 107.5
HoppWoods -152.3 13.3 4.2 73.4 8.1 1.9 -179.7 13.4 9.2
KyteDoolittle -92.9 19.1 5.2 92.3 10.2 4.0 46.7 14.1 10.7
Abraham 7.4 13.7 4.2 -113.6 7.6 2.6 28.4 14.9 6.8
Eisenberg -11.3 4.9 1.2 170.9 4.0 0.4 38.9 6.5 4.6
Roseman 52.9 8.1 1.4 165.6 5.2 2.4 20.8 10.3 9.8
Sweet 22.9 8.7 2.6 -94.0 3.6 1.7 -3.8 6.1 4.4
Wolfenden -87.2 13.6 10.7 107.2 10.2 4.4 40.1 40.5 35.2
Average
Zimm.+HW
151.4 6.8 -176.1
Average Hydro. -18.0 174.7 28.5
Delta 169.48 168.0 155.4
Inside 3D-structure 42 -17 -139
HELIX 4 HELIX 5 HELIX 6 HELIX 7
Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L.
Zimmerman 77.6 50.6 38.2 56.9 7.2 2.4 -67.7 59.6 48.8 -144.7 101.2 82.1
HoppWoods 105.0 5.0 1.9 -33.9 13.0 1.5 -136.2 13.5 7.48 -144.7 8.5 5.4
KyteDoolittle -30.9 14.6 2.7 174.3 14.4 3.7 123.7 21.1 16.6 16.9 19.3 10.9
Abraham 21.5 7.7 2.6 148.1 12.1 2.0 43.0 12.8 6.7 37.5 10.5 4.1
Eisenberg -60.3 6.1 0.4 167.6 6.0 0.9 93.1 6.2 4.2 26.3 4.5 2.7
Roseman -94.4 2.7 1.8 121.1 6.8 4.3 62.9 4.4 4.4 61.1 7.9 7.1
Sweet 1.0 2.0 1.8 176.2 6.0 2.4 56.4 5.7 3.5 50.8 6.4 2.0
Wolfenden -77.2 12.0 5.9 -135.5 9.9 5.0 124.9 37.0 31.7 33.7 24.7 21.0
Average
Zimm.+HW
91.3 11.5 -102.0 -144.7
Average Hydro. -40.1 168.6 84.0 37.7
Delta 131.4 157.1 174.1 177.6
Inside 3D-structure 149 0 66 160
Table 3.7: The same structural property moments as in Table 3.6, but now for the 3D-structure
of bacteriorhodopsin (pdb-entry 2BRD). The projected length (Proj. L.) is the length of the
moment projected on the 2D helical wheel of the helix.
Due to the fact that Felix is a globular soluble protein, the hydrophobicity vectors are oriented
towards the centre of the helix bundle, while the Zimmerman and Hopp-Woods vectors point
to the exterior. In helix 1, the inside and outside-pointing vectors are in an almost anti-parallel
orientation irrespective of the applied method for computation. However, the inside-pointing-
vectors of the sequence property moments are in closer agreement with the 3D structure than
those of the structural property moments. Comparable results are obtained for helix 2. The
vectors of helix 2 have a remarkable small spread, which is in contrast to those of helix 3. In
helix 3, the sequence and the structural property moments are oriented in entirely different di-
rections with angular deviations of larger than 90◦. In terms of accuracy, the structural property
moments are more in accordance with the structural requirements referring to the orientation
of opposite vector pairs. For illustration, the structural property moments for the Hopp-Woods
and Kyte-Doolittle scales are depicted within the 3D structure of bacteriorhodopsin and the
four-helix bundle protein Felix in Figure 3.11A and Figure 3.11B, respectively.
Helix 4 exhibits a smaller spread of their vectors, but again, a large deviation between the
sequence and structural property moments in the range of 60◦ is found. In contrast to helix 3,
the sequence property moments yield the more accurate vector pattern.
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A
HELIX 1 HELIX 2 HELIX 3 HELIX 4
Angle Length Angle Length Angle Length Angle Length
Zimmerman 168.3 200.0 -94.1 179.3 172.6 146.7 -109.5 100.1
HoppWoods 158.2 22.5 -93.49 11.7 -164.1 8.6 -94.4 7.0
KyteDoolittle -19.4 32.3 91.8 28.4 6.6 10.7 81.2 17.7
Abraham -14.0 14.4 93.6 9.6 26.3 5.0 90.2 6.2
Eisenberg -9.29 10.6 91.9 7.5 -6.9 2.6 86.6 4.5
Roseman -9.0 19.3 91.2 13.8 11.1 5.7 90.3 8.6
Sweet -30.9 10.1 96.5 5.9 50.4 3.8 96.1 4.7
Wolfenden 2.0 52.6 89.6 54.1 -48.9 14.8 87.0 25.7
Average
Zimm.+HW
163.2 -93.8 175.8 -102.0
Average
Hydro.
-13.4 92.4 6.4 88.6
Delta 176.7 173.8 169.4 169.5
Inside Angle -27 80 68 62
B
HELIX 1 HELIX 2 HELIX 3 HELIX 4
Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L.
Zimmerman -158.2 220.3 169.5 -137.7 196.1 154.3 -112.6 207.0 133.1 -161.4 183.8 117.9
HoppWoods -169.3 18.2 18.2 -138.6 8.8 8.6 -96.2 9.3 8.9 -161.4 7.1 7.0
KyteDoolittle 15.0 26.5 26.3 46.0 20.9 20.8 86.2 17.2 14.3 30.1 17.7 16.7
Abraham 19.5 12.6 11.6 47.1 6.4 6.3 99.0 6.7 6.4 20.9 5.2 5.2
Eisenberg 24.9 8.5 8.5 46.4 6.2 6.2 97.1 4.2 3.6 32.0 4.2 4.0
Roseman 24.9 16.6 15.6 47.5 11.1 10.5 98.3 11.8 9.0 36.1 10.1 8.3
Sweet 5.0 8.3 8.3 46.9 3.8 2.8 100.9 6.0 5.0 13.7 4.6 4.0
Wolfenden 36.3 64.0 49.5 46.7 56.1 50.1 105.7 57.8 24.8 20.8 53.4 30.2
Average
Zimm.+HW
-163.8 -138.2 -104.4 -161.4
Average
Hydro.
20.9 46.8 97.9 25.6
Delta 175.3 175.1 157.7 173.0
Inside Angle -27 80 68 62
Table 3.8: The sequence (A) and the structural (B) property moments of the globular four-helix
bundle protein Felix.
3.3.8 Property Moments for a 3D Model of a GPCR
Apart from the experimentally derived protein structures, a molecular model of a GPCR, no-
tably the human CCK-B receptor was used as template structure for vector correlations. This
model was constructed on the basis of the α-carbon trace model of Baldwin and with the TMDs
determined in this study (a more detailed description of the modelling procedure will be given
in Chapter 4). The angles and the lengths of the structural property moments are listed in Table
3.9. The structural property moments for the Hopp-Woods and Kyte-Doolittle scales within the
3D model of the human CCK-B receptor are depicted in Figure 3.11C.
It is obvious that the discrepancies between the sequence property moments of the peptide
binding GPCRs and the structural property moments calculated for the CCK-B receptor model
are in the same order as the discrepancies found for bacteriorhodopsin.
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Figure 3.11: Structural property moments with the Hopp-Woods (grey) and the Kyte-Doolittle
(black-stratched) scales for the 3D structure of bacteriorhodopsin (pdb-entry: 2brd) (A), for the
four-helix bundle protein Felix (pdb-entry: 1flx and 3flx) (B) and for a 3D model of the human
CCK-B receptor (C).
HELIX 1 HELIX 2 HELIX 3
Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L.
Zimmerman 71.6 7.2 2.9 -27.5 52.5 43.2 -20.0 6.5 1.2
HoppWoods 22.8 9.3 2.4 12.6 8.5 2.9 32.4 6.4 1.0
KyteDoolittle -130.0 16.3 11.9 -167.7 18.4 5.6 -118.9 13.9 3.0
Abraham -127.6 9.3 4.3 -115.2 10.3 1.9 -134.3 5.6 0.9
Eisenberg -129.5 5.5 2.9 -174.8 5.6 1.5 -152.1 4.5 0.9
Roseman -110.4 5.7 3.6 107.7 5.3 1.7 0.0 3.7 1.3
Sweet -147.5 4.5 1.4 -153.4 3.2 1.0 -23.7 1.6 0.5
Wolfenden -111.4 19.6 18.4 165.3 10.9 9.9 167.2 7.9 5.0
Average Zimm.+HW 47.2 -7.5 6.2
Average Hydro. -126.1 -176.4 -103.6
Delta 173.3 168.9 109.8
Inside 3D-structure 70 35 111
HELIX 4 HELIX 5 HELIX 6 HELIX 7
Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L. Angle Length Proj.L.
Zimmerman -24.9 7.2 4.9 116.1 4.5 3.2 -114.0 5.0 1.7 80.0 60.6 43.8
HoppWoods -177.5 10.5 1.2 -27.4 12.2 4.0 -47.7 13.8 3.9 -7.3 7.8 3.6
KyteDoolittle 143.0 17.3 9.3 -114.9 21.9 7.6 41.9 20.6 4.0 -125.7 20.8 19.5
Abraham 103.7 11.6 3.8 156.3 14.2 2.7 79.3 14.5 2.5 162.3 9.0 6.5
Eisenberg 132.9 5.7 1.8 -166.8 7.6 2.0 89.5 6.6 0.9 -133.0 4.5 3.5
Roseman 89.0 5.70 3.0 132.3 8.5 3.4 67.3 7.7 3.0 -145.1 5.7 5.4
Sweet 44.8 5.0 1.3 147.4 6.5 2.6 79.8 9.0 4.2 -154.8 3.4 3.0
Wolfenden 128.8 22.6 22.5 -92.2 15.3 11.0 -10.4 6.8 6.8 -122.2 35.5 31.8
Average Zimm.+HW -101.2 44.4 -80.9 36.4
Average Hydro. 107.0 -169.7 57.9 -146.4
Delta 151.8 146.0 138.8 177.2
Inside 3D-structure 12 20 -168 35
Table 3.9: The structural property moments of the 3D-model of the human CCK-B-receptor.
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3.3.9 TMD Determination with Perscan
Apart from the comprehensive sequence analysis study described above, an automated TMD
determination with the computer program Perscan was performed with the multiple alignments
of the different peptide binding GPCRs and with the comprehensive multiple alignment of the
101 sequences of peptide binding GPCRs. In order to evaluate the influence of the window size,
numerous different ranges were tested: 7-19, 10-30, 10-36, 16-30, 16-36, 16-28, 18-26, 19-24,
24-28, 5-30 and 15-22. Thereby the first number corresponds to the minimum length and the
second number the maximum length for a determined transmembrane sequence. A window size
of 18-26 emerged as yielding the best results.
Perscan [107, 67, 108] creates a so-called power spectrum for each calculation from which the
periodicity angle, the regular angle between subsequent residues, is extracted. A maximum in
the power spectrum at approximately 100◦ accounts for the presence of a region with α-helical
periodicity. Not all calculations revealed the desired peak at 100◦. However, the residues per
Figure 3.12: Transmembrane domains determined with the computer program Perscan for
TMSS 5. The black columns are the predicted transmembrane domains and the light columns
are situated at the extracellular side of the transmembrane domain and the dark grey columns
at the intracellular side. For each alignment are three determination methods depicted in the
order conservation, hydrophobicity and substitution method.
turn (RPT) value, which is calculated from the power spectrum and yields a value of 3.6 for an
ideal α helix, was found near the ideal value for 80% of all alignments. A further parameter
determined from the power spectrum is the α-helical periodicity index (AP). The AP gives a
ratio of the extent of the periodicity in the helical region of the spectrum compared with that
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over the whole spectrum. It is suggested that a value higher than 2.0 would indicate the presence
of a region with significant helical periodicity. This is the case for 86% of the alignments, only
6% of the alignments show a value smaller than 1.6.
Figure 3.12 illustrates the TMDs which were calculated for the different alignments of TMSS 3
with three different determination methods of Perscan (hydrophobicity, conservation and sub-
stitution). It can clearly be seen that the TMDs calculated for the different alignments and
determination methods are completely different, a finding that emerged for the analysis of all
TMSSs.
3.3.10 TMD Determination with PredictProtein
By means of the PredictProtein Server 4 transmembrane helices were predicted via a system of
neural networks. The multiple alignments of the peptide binding GPCRs of the seven TMSS
were used as input data. The predicted TMDs for the seven TMSSs were found as: 8-30, 5-23,
11-28, 8-25, 10-29, 8-26 and 10-27, respectively. The reliability for all the seven predicted
TMDs indicated by the note for reliability for the best model can reach a value of 9 on a scale
of 0-9. All TMDs are longer than the TMDs obtained by Baldwin or obtained in this study,
especially TMD 1 (23 residues). Except for TMD 2, all predicted TMDs from applying the
neural network overlap almost completely with the TMDs predicted by Baldwin and by this
study. It is remarkable, that the TMDs predicted by the neural network are extended towards the
extracellular side of the membrane compared to the TMDs obtained by Baldwin. The prediction
of the topology of all seven TMSSs is correct and is based on the difference between the positive
charges at the extracellular and the intracellular side.
3.4 Discussion
The multiple alignments of the different families are considered as a first step for the identifica-
tion of the potential TMSSs. Due to the low homology between the families in the loop regions a
multiple alignment of only the putative TMSSs is beneficial. The fingerprint of Baldwin, which
identifies the very conserved amino acids in the potential TMSSs, gives several anchor points
for each multiple alignment of a TMSS. However, a precise determination of the boundaries of
the TMDs is more reliable when it is based on a consensus approach comprising a variety of
methods.
Studies carried out earlier by, e.g., von Heijne and Landolt-Marticorena have shown that the dis-
tribution of the amino acids in a TMD depends on its environment and on the membrane topol-
ogy. The results obtained in this study confirmed their observations in great lines, only small
disagreements were found for distribution profiles of, e.g., the residues valine and isoleucine.
However, the membrane topology dependent distribution of charged residues is comparable
with earlier studies. The distribution of tryptophan residues as a diagnostic membrane bound-
ary residue is also observed by Landolt-Marticorena [98]. Woolf and Roux [113] claim that
tryptophan is crucial for the orientation of gramicidin in the membrane and that the confor-
mation of its sidechain fluctuates around well-defined orientations and is capable of forming
hydrogen bonds with ester carbonyl groups of the lipids and with interfacial water. However,
4 located at http://www.embl-heidelberg.de/predictprotein/predictprotein.html
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this specific role of tryptophan could not be verified by Tieleman in molecular dynamics simu-
lations on OmpF, Influenza M2, and alamethicin systems. Probably only a molecular dynamic
simulation of a GPCR in a lipid environment will give detailed insights in this problem.
From this study it is clear that not all property profiles can be used for the determination of
TMDs, since not all properties of the amino acids are membrane topology dependent. Especially
the indices for bulkiness and α-helical conformation fail to display any correlation with the
membrane topology.
The overall results stress the determining influence of the utilised scales and threshold values
on the results, thus leading to mis-interpretations. Therefore, we preferred to follow a stringent
approach by using normalised scores together with a threshold value of 0.2 for each TMSS.
The property profiles of the polarity scale of Zimmerman allow for a straightforward determi-
nation of the potential border residues of TMDs and turned out to be the profiles of choice,
thus being superior to any hydrophobicity profile. In some cases, the property profiles show a
clear α-helical periodicity (TMD 3 in Figure 3.2). The combination of the above-mentioned
diagnostic profiles with the distribution profiles of characteristic residues such as Trp, Pro, Arg,
Lys, Asp, and Glu clearly extends the reliability of the TMDBs determination.
The TMDs determined with the neural network system and predicted by the computer program
Perscan deviate significantly from the TMDs determined by Baldwin and by the property and
distribution profiles discussed here. Due to the large deviations in the TMDs from the different
alignments and different determination methods of Perscan, the predicted TMDs are highly
questionable.
It is generally accepted that the boundaries of the TMD cannot be assigned exactly, however
they vary within approximately 2 amino acids at each side. This variation is not only due to
the difficulties in determining the TMDBs by the applied methods, the property scales or the
interpretation of the results. Also the dynamical structure of the membrane is an important
factor for this uncertainty. The complexity of the dynamics of lipid molecules is a major reason
for the membrane bilayer dynamics. The dynamics of lipids is not restricted to a lateral position,
but they move also in the direction of the normal of the membrane. This mode of dynamics
modulates the bilayer thickness and thus might influence the length of certain TMDs. Also
the interfacial region between membrane and water is not a simple demarcation between a
hydrophobic and hydrophilic environment, but it is considerably more complex than expected
from simple macroscopic models.
A further structural factor, that is not considered in the applied methods, refers to the spatial
extend of amino acid residues and the conformational flexibility of their sidechains. For ex-
ample, arginine and lysine might be part of a TMD, while their long sidechains still reach the
boundary region of the membrane, thus establishing interactions with the polar head groups of
the membrane constituents. Indeed, these residues are capable of spanning two helical turns.
Further problems are imposed by the amphiphilic nature of entire helices, thus severely modu-
lating the appearance of property and distribution profiles. For example, the property profiles of
TMSS 2 (Figure 3.2) is strongly influenced by a highly conserved aspartate residue in the centre
of the TMD giving rise to a significant distortion when compared to a typical TMD profile. Also
the length of the property moment has influence on the variability in the angle of the property
moment, e.g., a small vector can be strongly influenced by a single mutation.
A further aspect strongly influencing the property moments refers to the conformations of the
transmembrane helices that are far from being ideal. Apart from kinks, these helices expose
variable lipid accessible surfaces along their main helix axis. From the low resolution structure
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of rhodopsin determined by Unger [62] it can be observed that helix 3 is more exposed to the
lipid environment on its intracellular side, than on its intracellular part. This results in a dramatic
change in size of property moments, thereby also modulating the angular orientation.
Helices 5 and 6 of the low resolution structure of bovine rhodopsin reveal significant kinks
along their main axis, thereby rendering property moments for the entire helix questionable. A
distinction of the kink in preceeding and following helical segments is therefore recommended.
These factors influence not only the angular spread of the property moments for different align-
ments, but also influence the ideal anti-parallel conformation of the inside- and outside-pointing
moments.
The results obtained from analysis of the experimentally determined protein structures (bac-
teriorhodopsin and the four-helix-bundle Felix) clearly showed that the property moments not
always predict the inside of the corresponding helix bundle correctly. Most interestingly, not
even the sequence and structural property moments were capable of predicting the TMDs con-
sistently. Consequently, it is not sufficient to rationalise the low quality of predictions by non-
ideal helix conformations.
The non-ideal conformation of the 3D structure of helices and the different surface exposure to
the lipid environment seem to be important reasons for the discrepancy of the property moments
at levels of +12 and -8 Å in (Figure 3.10) when compared to those computed for the 0 Å
map. Figure 3.10 clearly reveals the interhelical space at the -8 Å level (intracellular) to be
significantly smaller when compared to the +12 Å map (extracellular). This is underlined by the
profiles of the bulkiness scale of Zimmerman where for the TMDs 2, 4, 5, 6 and 7 a significant
lower score was observed for the intracellular side of the TMD.
3.5 Conclusion
From the above studies it turns out that automated methods for the prediction of TMDs fail to
deliver reliable results, also because they are generally used as black box tools. Only a consen-
sus approach comprising a combination of different methods based on a variety of parameter
sets, which was applied on a series of different GPCR sequence alignments, yielded reliable
results in terms of TMD determination. However, the TMD determination with a single residue
resolution bears the danger of overinterpretation, since the dynamics of both, the protein as well
as the membrane render a single residue resolution as a pseudo-accuracy.
Determination of TMDs with the discussed bioinformatic tools for the modelling of a GPCR
are only a first step in this direction. The process of GPCR modelling is an iterative process
comprising methods from bioinformatics, protein modelling, biochemistry, physics and further
related scientific areas.
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Receptor-Modelling
A 3D model of the human CCK-B
receptor based on the 3D structure of
bovine Rhodopsin. A Molecular
Modelling and Molecular Dynamics
study.
"I believe the best test of a model is how well can the modeller answer the questions;
what do you know now that you did not know before? And how can you find out if it
is true."
• Jim Bower
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4.1 Introduction
Transduction of extracellular signals across the plasma membrane is generally achieved by the
interaction of regulatory compounds with specific transmembrane receptor proteins. Appro-
ximately 80% of known hormones and neurotransmitters activate cellular signal transduction
mechanism through binding to G protein-coupled receptors (GPCRs) [114], thus rendering
members of this receptor superfamily as attractive targets for therapeutic intervention in a broad
range of human diseases. While the biogenic monoamine-binding GPCRs are among the classi-
cal and well-established drug targets, the potential of the peptide- and protein-binding receptors
from that superfamily is by far not yet exploited. Consequently, current medicinal chemistry
programs pursued in pharmaceutical research are aimed to develop low-molecular weight, and
non-peptide receptor agonists and/or antagonists respectively.
In this context, the development of active cholecystokinin (CCK) mimetics, selectively addres-
sing the CCK-A or CCK-B receptor, has attracted the attention of biomedical research over
the last decade [115, 69, 71]. The endogenous peptide ligand CCK exists in multiple forms of
variable length, all generated from a 115-residue pre-prohormone, which possess a common C-
terminus as shown, e.g., in CCK-8: Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asn-Phe-NH2. Precur-
sor forms such as CCK-58, CCK-39, or CCK-8 are capable to bind to both CCK-receptors with
nanomolecular affinities, while the non-sulphated analogues, the shorter penta- and tetrapep-
tideamides CCK-5, and CCK-4, as well as the related gastrointestinal hormone gastrin exhibit
subnanomolecular affinities only towards the CCK-B receptor subtype [69, 71].
CCK-peptide derivatives used to be viewed predominantly as gut hormones responsible for the
regulation of digestive processes with vague neurotransmitter activity in the central nervous
system. This has drastically changed in recent years in that the CCK-A as well as the CCK-B
receptors in the brain have emerged as mediators or modulators of anxiety, neuroleptic activity,
arousal, analgesia and satiety [69]. Consequently, low-molecular weight compounds that selec-
tively act on these receptors can serve as promising leads for the development of drugs for the
aforementioned human disorders.
We have chosen the human CCK-B receptor as a working platform for proving the validity of a
novel integrated molecular modelling procedure aimed to generate 3D structures of the receptor
protein. The availability of 3D structure information on both interaction partners, that establish
an activated ligand-receptor complex, will undoubtedly enrich our understanding on affinity,
selectivity and receptor activation mechanisms.
Extensive biophysical, biochemical and immunological studies have revealed an enormous
amount of structural data on these receptor proteins. These data suggest that the entire receptor
superfamily show a common protein topology based on a membrane-spanning seven-helix bun-
dle, generally termed the 7TM domain [6]. The amino terminus of the receptor protein is located
within the extracellular compartment, while the carboxy-terminus resides in the cytoplasm. The
transmembrane helices are sequentially connected by extra- and intracellular loops.
Apart from the X-ray structure of rhodopsin [5, 61] published in 2000, no experimentally deter-
mined high-resolution 3D structure of any GPCR, derived either by NMR-spectroscopy or X-
ray crystallography, is available mainly due to the vagaries in purification and crystallisation of
these membrane proteins. A low resolution 2D map of the electron density of bovine rhodopsin
[57], a true GPCR accommodating the visual pigment retinal, provided first experimentally
derived evidence for the existence of seven transmembrane helices. A low-resolution 3D struc-
ture of bovine rhodopsin [62] combined with projection structures of frog [58] and squid [59]
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rhodopsin clearly confirmed the seven-helix bundle topology. These moderately resolved struc-
tures further demonstrated that although the membrane topology of bacteriorhodopsin and the
GPCRs are similar, their 3D structures are significally different. The fact that bacteriorhodopsin
is not a GPCR and displays only low sequence homology to any representative of this recep-
tor family clearly disproves the idea that the X-ray structure of bacteriorhodopsin [42] could
serve as a template structure for a molecular modelling driven attempt to generate GPCR mod-
els [116], even though this has been done for several years in numerous studies [117, 118, 119].
In those cases where bacteriorhodopsin was not used as structural core, the projection maps
together with the low-resolution structures of rhodopsin were exploited, or models were con-
structed de novo [120, 121, 122].
Here we report on the application of a tailor-made modelling methodology especially suited for
the generation of GPCR protein structures. The first and most critical step is the identification
of the putative transmembrane sequence portions based on analysing multiple sequence align-
ments. In a previous study [123, Chapter 3], we performed a comparative evaluation of various
protein sequence analysis tools for their capability to precisely predict the transmembrane do-
main boundaries. The study was conducted on the most prominent members of peptide-binding
GPCRs, i.e., the human receptor sequences of angiotensin, bradykinin, CCK/gastrin, endothe-
lin, interleukin-8, neuropeptide-Y, neuromedin, somatostatin, substance P & K and tachykinin
receptors (ag22, ag2r, ag2s, brb1, brb2, cckr, gasr, et1r, etbr, il8a, il8b, ny1r, ny2r, ny4r, ny5r,
nk3r, nmbr, ssr1, ssr2, ssr3, ssr4, ssr5, nk1r, nk2r, txkr). The different bioinformatics tools
utilise algorithms tailor-made for the determination of potential transmembrane domains, such
as periodicity analyses of different amino acid-associated properties, multiple sequence analy-
ses, distribution analyses of amino acids, and directional helix descriptors of, e.g., hydropho-
bicity or conservation moments. In this comprehensive sequence analysis study [123, Chapter
3] we showed that the application of different methods leads to contradictory results in the
prediction of transmembrane sequence stretches (TMSSs). However, by an especially elabo-
rated combination of the results of the different methods, the putative TMSSs for a series of
peptide-binding GPCRs could be determined reliably.
Based on these findings, we further expand our study on the question of a 3D structure model of
the human CCK-B receptor. Special emphasis was laid on the computational refinement proce-
dure applying specially developed simulation protocols explicitly accounting for the transmem-
brane environment of the receptor protein.
4.2 Methods
4.2.1 Bioinformatics
All Bioinformatics-based sequence analyses and molecular simulations were carried out on Sil-
icon Graphics O2 workstations and a Silicon Graphics Origin parallel computer equipped with
20 R12000 processors. The overall strategy comprising the sequential application of different
methodologies from bioinformatics, homology-related protein modelling and molecular simu-
lation is summarised in Figure 4.1.
The amino acid sequences of the CCK-receptors of different species were retrieved from the
protein sequence database SWISSPROT :
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amino acid sequence (SWISSPROT)
multiple sequence alignment (GCG)
putative TMSS
with Baldwin Fingerprint
boundaries TMDs
(property profiles, amino acid distributions, ...)
periodicity analysis /
helical wheels
co-ordinates assignment
with Cα-trace-model
protein sidechain modelling
energetic relaxation in triphasic-box
loop generation and energetic
relaxation of the loops in triphasic-box
energetic relaxation of
total model in triphasic-box
molecular dynamics simulation
in triphasic-box
3D MODEL GPCR
Optional
Figure 4.1: The general flow chart of the modelling of a 3D model of a G protein-coupled
receptor.
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entry-codes CCK-B receptors species ref.
gasr_prana Praomys natalensis [124]
gasr_rat Rattus norvegicus [125]
gasr_human Homo sapiens [126]
gasr_rabit Oryctolagus cuniculus [127]
gasr_canfa Canis familiaris [128]
entry-codes CCK-A receptors
cckr_cavpo Cavia porcellus [129]
cckr_human Homo sapiens [130]
cckr_rat Rattus norvegicus [131]
cckr_xenla Xenopus laevis [132]
Multiple sequence alignments were obtained using the pile-up program as included in the GCG-
package (Wisconsin Package Version 9.1, Genetics Computer Group, Madison wisc.; http://-
www.gcg.com), considering the pam250 scoring matrix. The resulting sequence alignment
was used to determine the putative TMSSs by superimposing the fingerprint-derived consensus
patterns elaborated by Baldwin [60, 66].
The fine-tuning of the TMSS assignment of the human CCK-B receptor sequence was achieved
following the procedure outlined in detail in ref [123].
Property profiles were computed for multiple sequence alignments based on a variety of amino
acid-associated property scales, thus avoiding misleading conclusions that might arise from
analyses based on one single amino acid sequence that eventually could be biased by single
mutations. Profiles for four distinct properties were calculated: hydrophobicity according Kyte-
Doolittle [78], hydrophobicity according to Sweet [91], polarity according to Zimmerman [92],
and hydropathy according to Hopp-Woods [88]. The computations were performed on two mul-
tiple sequence alignments comprising: (i) 101 distinct sequences of peptide-binding GPCRs,
and (ii) 9 sequences of CCK-receptors, respectively. For reasons of comparison the score of
hydrophobicity profiles has been reversed and normalised, thus achieving that, e.g., regions of
enhanced hydrophobicity exhibit a low score, similar to regions of reduced polarity. In addition
to the property profiles, the distribution of particular amino acid residues [98, 133, 95] was used
to differentiate between the transmembrane domains and membrane/water interface regions.
4.2.2 Molecular Modelling/Molecular Dynamics Simulations
Interactive model building and graphical analysis were done using the programs included in
the molecular modelling software INSIGHT II (version 98.0) from Biosym Technologies (San
Diego, CA). Molecular dynamics simulations were performed using the consistent valence force
field without Morse potential or cross terms as implemented in the DISCOVER simulation
package (version 2.98). According to the integrated modelling procedure, depicted in Figure
4.1, the transmembrane domain consisting of the seven helix bundle was generated based on the
Cα-trace suggested by Baldwin [66] (co-ordinates were kindly provided by Joyce Baldwin). To
account for favourable sidechain orientations, values for χ1 and χ2 of each helical residue were
extracted from the rotamer library of Dunbrack and coworkers [134, 135, 136, 137]. Even
though this library was derived from experimentally determined structures of globular, soluble
proteins, it is assumed to provide reasonable starting conformations, due to the correlation of
backbone conformation and sidechain orientation. The energetically most favourable rotamers
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were assigned for χ1 and χ2 of each residue. In case of interatomic clashes between two
sidechains of the same helix or two sidechains of adjacent helices, the second best rotameric
state as assigned from the library to the affected amino acid sidechains.
After modelling the sidechain rotamers, a combined energy minimisation and molecular dynam-
ics run was applied to energetically relax the structure of the transmembrane domain. The de-
tails of the simulation protocol employing an especially developed fixing and tethering scheme
is given in Table 4.1. All simulations were carried out in the triphasic H2O:CCl4:H2O solvent
box [74, 75, 138] applying periodic boundary conditions. For this purpose, the receptor model
was centred in the lipophilic core phase, with the helix-long axis aligned parallel with the Y-
axis spanning across the bilayer. Consequently, both membrane-water interfaces, terminating
the centre-membrane compartment, are parallel to the XZ-plane (Figure 4.1).
For the initial relaxations, the box dimensions were chosen to be 60x70x50 Å (X, Y, Z), whereby
the thickness of the lipophilic phase was approximately 30 Å along the membrane normal (Y-
axis). The remaining 20 Å along the Y-axis were soaked with water molecules on either sides.
A cut-off radius of 10 Å for calculating non-bonded interactions was used, while the neighbour
list was updated every 10 fs. For the MD simulations, a time step for numerically integrating
Newton’s equation of motion of 1 fs was used with a weak temperature bath coupling.
In the initial phase of the simulation the helix backbone was fixed in order to prevent a substan-
tial drift from the Baldwin template. The main emphasis of this simulation period is to remove
conformational deficiencies from the crude starting conformation, while the overall seven-helix
topology is allowed to relax in a later stage of the simulation protocol. Upon release of the
backbone from fixation, distance restraints were introduced between Oi and NHi+4 to retain
the internal hydrogen-bonding network of the helices. In contrast to the initial part, each helix
is now allowed to perform translational and rotational reorientations within the context of the
seven helix bundle.
After sufficient relaxation (Table 4.1) of the isolated transmembrane receptor protein domain,
the extra- and intracellular loops were incorporated. In order to save computer time, the N-
terminal 43 amino acids as well as residues 249 to 325 forming a large intercellular loop be-
tween helices 5 and 6 were not included into the model, since no conformational rationale for a
meaningful co-ordinate assignment can be suggested. All included loops were constructed with
an initially extended, unbiased backbone conformation avoiding intramolecular clashes with
helix residues. For the subsequent simulations, the box dimension in the X- and Y-direction had
to be expanded to 70x80x50 Å (X, Y, Z), whereby both aqueous phases occupy 25 Å and the
central lipid phase 30 Å along the Y-axis.
A significant and experimentally confirmed [139, 140, 141] conformational restraint was in-
troduced by forming a disulphide bridge between Cys-127 at the extracellular end of helix-3
and Cys-205 in the helix-4-helix-5 connecting loop, thus dramatically reducing conformational
space principally accessible for this loop. For loop relaxation, the backbone atoms of all trans-
membrane residues were spatially fixed together with all sidechain atoms of the transmembrane
core residues. To account for conformational consequences for interface residues due to the
interactions with the loops, the sidechains of the terminal six transmembrane residues of each
helix were allowed to move. Comparable to the simulation procedure of the transmembrane do-
main, all atoms were released for the final energetic relaxation using energy minimisation and
molecular dynamics simulations. However, to retain the α-helical transmembrane structure,
distance restraints were defined between the Oi and NHi+4 backbone atoms. The force constant
scaling these hydrogen-bond restraints was gradually reduced in the course of the simulation.
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Table 4.1: The steps of the modelling procedure. The calculation method, the fixed atoms, the
tethered atoms and the distance constains are listed for each calculation step.
To guarantee a sufficient consideration of the H-bonding network, a residual restraint was kept
in our simulation protocol.
After the final minimisation, an extended molecular dynamics simulation covering a total of
1.15 ns was performed up to a target temperature of 300K. Snapshots were stored every 1.0 ps
resulting in a trajectory comprising more than 1000 distinct structural frames.
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4.3 Results and Discussion
4.3.1 Transmembrane Domain Determination
The multiple sequence alignment of nine CCK receptor sequences is depicted in Figure 4.2 (the
Swissprot sequence identifier CCKR and GASR correspond to CCK-A and CCK-B receptor
sequences, respectively). With respect to sequence identity, the CCK-receptor from the African
clawed frog (CCKR_XENLA) cannot be clearly assigned to either the class of CCK-A or CCK-
B receptors, since the identity ranges from 46% to 48% for any pairwise sequence comparison
with CCKR_XENLA. Generally, the identity among sequences within a distinct subclass is
found to be higher than 85%, while it drops to approximately 45% for sequence comparisons
across the two subclasses [132].
Corresponding to its comparable sequence similarities with either CCK-A and CCK-B recep-
tors, the Xenopus laevis CCK receptor displays indifferent binding characteristics to selective
agonists and antagonists. Even though CCKR_XENLA seems to be a unique representative of
CCK receptors, it was included in the subsequent procedure aimed at determining the trans-
membrane boundaries based on the multiple sequence alignment [132].
To identify the putative transmembrane sequence stretches of the CCK-B receptors, the fin-
gerprint analysis based on the results elaborated by Baldwin [60, 66] was used. In Table 4.2
the alignment of the putative transmembrane sequence stretches of both, the human CCK-A
and CCK-B receptor with the fingerprint signature reveals a significant mutual agreement, thus
allowing for a preliminary determination of the transmembrane helical sequence portions.
The most commonly applied method to determine the transmembrane domains is the compu-
tation of a hydrophobicity profile based on a parameter set derived from the protein sequence
under investigation. Apart from various hydrophobicity scales, several different amino acid-
based property scales can be used to physicochemically characterise a protein sequence. A
property profile is generated by a sliding window approach in that the desired property for
a certain sequence position is computed as the mean value of that property averaged over a
certain sequence window encompassing a certain number of flanking residues. For proteins
with putative transmembrane sequence stretches, the choice of an appropriate window size is
crucial [123, 79]. Most commonly, the window size is selected taking the entire span of the
membrane bilayer and the insertion mode and angle of the transmembrane sequence into ac-
count. The minimal number of residues required to span a typical lipid bilayer is estimated to
be 16 to 18 residues, when assuming a regular α-helical conformation and an orthogonal inser-
tion mode. Consequently a window size of 17 is generally used to assign the transmembrane
domains [79]. To achieve an enhanced resolution, especially at the transmembrane boundaries,
a reduced window size of about one single helical turn (3 to 4 residues) was found to be more
appropriate.
We computed property profiles solely based on the multiple sequence alignments of the putative
TMSSs of the CCK receptors and additionally, based on the multiple sequence alignment of 101
GPCR sequences from ten different peptide binding GPCR families. The different profiles from
different alignments and for different properties are depicted in Figure 4.3. By combination of
selected property profiles with the distribution profiles of diagnostic amino acid residues such
as Trp, Arg, Lys, His and Pro, the transmembrane domain boundaries were assigned. For
example, according to the “positive-inside-rule” of von Heijne [95], Arg and Lys residues will
be found more frequently in the cytoplasmic loops of a membrane protein, thus causing a non-
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Figure 4.2: Multiple sequence alignment of the nine sequences of the CCK-receptors (black-
box-yellow-letter conserved residue in all CCK-sequences, black-box-white-letter identical
residue in 80% of the CCK-sequences, grey-box-black-letter similar residue in 80% of the
CCK-sequences, X = extracellular, O= intracellular and m = core segment of the helix
of the Cα-trace model of Baldwin, inclusive number of the helix (alignment coloured with
the program boxshade v3.31 of Kay Hofmann and Michael D. Baron; http://www.isrec.isb-
sib.ch/software/Box-form.html)
86
CHAPTER 4. RECEPTOR-MODELLING
Table 4.2: The fingerprint of Baldwin [60, 66] for the transmembrane domains of the rhodopsin-
like GPCRs together with the sequences of the TMDs of the human CCK-A and CCK-B recep-
tors.
symmetric charge distribution across the membrane, opposite to the charge distribution of the
lipid molecules in the membrane bilayer [142, 143]. The putative TMSSs 4 and 6 of the CCK
receptors and of the 101 peptide binding GPCRs clearly follow this “positive-inside-rule” of
von Heijne, as can be seen in Figure 4.3.
The extracellular and cytoplasmic transmembrane domain boundaries are assigned based on
tripeptide stretches exhibiting a steep decrease on the property profile followed by an extended
sequence stretch with constantly low scores and a clear breaking point in the distribution pro-
file. When comparing the property and distribution profiles based on the few CCK receptors
(left panels in Figure 4.3), a less striking discrimination can be achieved. This finding can be
attributed to the significant influence of a single mutation on the occurrence of the property and
distribution profiles derived from the CCK receptor-base multiple alignments. The property
profiles for TMD4 reveal a very flat non-conclusive profile for the CCK receptor-based align-
ment, while the property profile computed for the 101 GPCR sequence alignment displays the
expected curve for a transmembrane sequence stretch. According to these results, we decided to
use the profiles of the multiple alignments of the 101 peptide-binding GPCRs for determining
the boundaries of the transmembrane domain.
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Figure 4.3: Property profiles and amino acid distributions of the multiple alignments of the
Transmembrane Sequence Stretches 4 (A) and 6 (B) of the CCK-receptors (A1 & B1) and of the
101 sequences of peptide binding GPCRs (A2 & B2). In the upper part of each graph property
profiles are shown with a window size of 3 (red: polarity scale of Zimmerman; blue: hydropathy
scale of Hopp-Woods; light blue; hydrophobicity scale of Sweet; and purple: hydrophobicity
scale of Kyte-Doolittle) and in the lower part amino acid distributions are shown (light blue:
tryptophan; blue: tyrosine; red: aspatate & glutamate; green: proline; black: arginine &
lysine; pink: asparagine & glutamine; and purple: histidine). Because these two TMSSs are
even, the amino acid sequence numbering is in opposite direction in comparison to the position
numbering (extracellular→ intracellular = C-terminus← N-terminus). The yellow strife is the
determined transmembrane domain.
From a comparison of the different properties monitored over the sequence alignments, the
property scale introduced by Zimmerman worked best in our hands. Boundary residues were
assigned as amino acids flanking a stretch of at least 18 residues with scores smaller than 0.2 in
the normalised Zimmerman polarity profile computed with a window size of 3. Within TMSSs
3, 6 and 7, residues are found in the transmembrane domain with score values between 0.2 and
0.3. Despite this slightly increased polarity score, these regions were assigned to be transmem-
brane domains since they are proceeded by sequence stretches with significantly smaller score
values.
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The transmembrane domain assignment obtained by analysing the fingerprint and property pro-
files was further refined by applying the following rules:
• Arg, Lys and Glu residues prefer to only occupy loop regions outside the transmembrane
domains. However, if the TMD is too short to span the membrane, these residues might
be found within the first helical turn (three residues), since their sidechains can extend be-
yond one helical turn to still place their charged sidechain functionalities into the aqueous
compartment or near the polar headgroups of the lipids. [79]
• Due to their shorter sidechain, Asp residues can only occupy the terminal two positions
of a transmembrane helix. [79]
• Trp residues are typical boundary amino acids and therefore indicate helix termination.
[144, 98, 145]
• Non-highly conserved Pro residues can be found on the first three positions at the N-
terminus and at the last position of the C-terminus of an α-helix, since the lost of a
hydrogen-bond donor facility, disrupts the H-bond network within an helix. [98]
The final assignment of the transmembrane domain boundaries, together with the deviation
from the Baldwin fingerprint approach, is listed in Table 4.3.
TMDB determined by Baldwin TMDB determined with window size 3
amino acid num-
bers of TMDB in
TMSSs.
length
of
stretch
position of
TMSS in
graph †
determined
with only
prop. prof.
determined
with prop.
prof.
length
of
stretch
difference
to TMDB
determined
extrac. intrac. + aa distr. by Baldwin
Helix 1 10 27 18 10 27 7 30 9 27 19 1 0
Helix 2 27 10 18 10 27 4 30 10 27 18 0 0
Helix 3 10 27 18 10 27 8 27 11* 27 17 -1 0
Helix 4 26* 11 16 11 26 9 26 10* 26* 17 1 0
Helix 5 11* 28 18 11 28 10 30 12 28 17 -1 0
Helix 6 27 11 17 10 26 8 27 10 27 18 0 1
Helix 7 12* 27 16 12 27 7 29 12* 28* 17 0 1
* = some difficulties with the determination of these transmembrane boundaries, see text.
† = the positions of the odd transmembrane sequence stretches are reversed numbered in the graphs.
Table 4.3: The numbers of the endings of the transmembrane domains of the helices deduced in
a previous study of us. The used numbers are the numbers of table 4.2.
4.3.2 Molecular Modelling
The amino acid sequence stretches, identified as constituting the transmembrane domain, were
mapped onto the Cα-trace model of Baldwin [66]. The amino acid sidechain torsions were
assigned to the most favourable conformations extracted from the backbone-depending rotamer
library for proteins developed by Dunbrack and coworkers [134, 135, 136, 137]. The resulting
coordinate set for the helix bundle was subjected to an energy relaxation employing minimisa-
tion and dynamics simulation (for details refer to Table 4.1).
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The initial model of the human CCK-B receptor revealed the termini of helices 5 and 6 to be
separated too far for a compact helix bundle. Consequently, the simulation procedure was mo-
dified by introducing an elaborated distance constraint protocol attempting to bring the termini
of helices 5 and 6 into close spatial proximity. Over these distinct template forcing and energy
minimisations, helices 1, 2, 4 and 7 were kept fixed, while the sidechains atoms of helices 3
and 6 were allowed to move. A tethering scheme was applied to helix 5, in which the scaling
force constant was gradually decreased from 1000 kcal/Å to 10 kcal/Å over the course of the
minimisation.
Non-constrained standard minimisation concluded the refinement of the initial structure of the
transmembrane domain of the human CCK-B receptor (for details refer to Table 4.1).
A
B C
Figure 4.4: The Ribbon representation of the model from different modelling steps: (A) the
start conformation with the co-ordinates of Baldwin for the Cα-trace, (B) the structure after the
whole minimisation procedure, just before the final MD-run, and (C) the frame at 500 ps of the
final MD-run. (The pictures are made with the program MolMol [146].)
The ribbon presentations shown in Figure 4.4 reveal the starting conformation that displays
almost ideal α-helices. They are slightly distorted during the initial refinement process in favour
of locally relaxed conformations and mutually attractive interhelical contacts.
After refinement of the seven-helix bundle, the extracellular and cytoplasmic loops were incor-
porated into the protein model by connecting the corresponding helical termini with the loop
stretches in an expanded conformation. The modelled loops were minimised following the
simulation protocol shown in Table 4.1.
In the initial part, the central core residues of the transmembrane helices were fixed, while the
sidechains of the residues forming the terminal two helical turns (6 amino acid residues) were
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A B
C D
Figure 4.5: The topview (A) and the sideview (B) of the start conformation and the top view (C)
and the side view (D) of the minimised conformation, respectively. Extracellular loops (blue),
except extracellular loop 2 (cyan), intracellular loops (red), helix 3 (purple), helix 5 (orange)
and two cysteine residues with CPK-model depicted. (The pictures are made with the program
MolMol [146].)
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free to move, since these can be estimated to be involved in interactions with loop residues.
A distance constraint was introduced to allow for the formation of a disulfide bridge between
the sidechains of Cys-127 at the extracellular end of helix 3 and Cys-205 within the second
extracellular loop (see Figure 4.5). The distance between the two involved sulfur atoms of the
bridging Cys residues changes from initially 40 Å to approximately 2 Å. In the final part of that
relaxation strategy, the entire model of the receptor protein was energetically minimised.
After energy minimisation, an annealing strategy, employing MD, was chosen composed of
a tailored temperature profile characterised by a heating and cooling procedure (Table 4.1).
To allow for translational and rotational freedom of each transmembrane helix, no fixing or
positional restraining was imposed on the protein model in the final refinement simulation.
Distance constraints between backbone carboxyl oxygen atoms (hydrogen bonds acceptors)
and amide groups (H-bond donors) were applied in a Oi←→ H-Ni+4 relation to conserve the
helical conformation of the transmembrane helices.
After sufficient relaxations, the entire system was subjected to a 1.15 ns molecular dynamics
run that is used for structure analysis. The stability of the receptor protein model is monitored
over the simulation by following the root-mean-square deviation for structural superposition of
the transmembrane domain residues of distinct conformations onto the starting conformation
(Figure 4.6). Apart from a significant deviation in the initial part of the refinement procedure,
Figure 4.6: The Root Mean Square (RMS) deviation of the backbone (black) and heavy atoms
(grey) of the TMDs during the total modelling procedure. The start conformation is taken as
the reference structure. The frames of three MD sections, the second part of the minimisation of
the TMD-model, the second part of the minimisation of the total model and the final molecular
dynamics simulation, were shrinked (spacing is 10% of that of the other frames) for a better
view.
the protein structure exhibits a reasonable stability as indicated by an rms deviation of around
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1 Å within the final MD simulation conducted over 1.15 ns after initialisation. This finding
is corroborated by the energy diagrams monitored over the production period of the long-term
MD simulation (Figure 4.7). After the initial 300 ps of initialising, the entire system reaches
steady energy and temperature levels without any remarkable fluctuations within the remaining
simulation period.
Consequently, the final 750 ps (frames 301 to 1050) were used for analysis.
Figure 4.7: The total (black), kinetic (green) and potential (red) energy of the complete system
during the final molecular dynamics simulation and the temperature (blue) during this MD-run
(right Y-axis).
4.3.3 Production Period of the Molecular Dynamics Simulation
The final 750 ps of the 1.15 ns MD simulation were used to analyse the conformational stability
of the generated receptor protein model. For assessment of the vertical alignment of the recep-
tor protein’s location within the tri-phasic membrane-type environment, the standard deviations
of the Y-coordinate component of selected atoms were computed, Y being oriented perpendicu-
larly to the membrane surface plane (XZ). Large deviations of especially the backbone atoms of
the CCK-B receptor core domain would indicate a migrational component of the protein during
the MD simulation, thus revealing an incompatibility of the protein model with its non-isotropic
environment. The analysis of 750 snapshots stored in intervals of 1 ps uncovers only minor
standard deviations for the Cα atoms of the entire protein model (Figure 4.8A) with respect to
the Y-coordinates. From the same analysis applied to sidechain atoms, moderately increased
flexibility in the ±Y direction is observed for the transmembrane residues, while flexibility is
increased for loop residues (Figure 4.8B). The entire analysis depicted in Figure 4.8 clearly
reveals that the protein model perfectly aligns with its location in the tri-phasic solvent system,
since no overall migrational component along the Y-axis can be observed. This provides ad-
ditional confidence on the overall compatibility of the different protein domains (extracellular
loops / transmembrane helix bundle / cytoplasmic loops) with the exposed environment.
The distribution pattern of the protein flexibility profile monitored over the final 750 ps of the
MD simulation is illustrated in the ribbon model shown in Figure 4.9, in which the thickness
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A
B
Figure 4.8: The average Y-positions of the Cα-atoms (A) and one atom of the sidechain (B)
of each residue during the 750 ps of the production period of the final MD-run. The length of
the coloured bar on each point represents the standard deviation in the Y-position of the atoms.
On the right hand the probabilities of the water (black) and the CCl4-molecules (magenta) are
depicted. The Y-postions of the boundary planes (dark grey) and the interfacial regions (grey)
are depicted with horizontal lines.
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Figure 4.9: ”Sausage” representation of the flexibility of the backbone atoms of the total model
during the production period of the final molecular dynamics simulation (Cys-bridge = red,
helix 3 = cyan, helix 4 = dark green, helix 5 = magenta, helix 6 = light green, helices 1, 2 and
7 = dark violet, loops = yellow, and ’cutted intracellular loop 3’ = white, the pictures are made
with the program MolMol [146].)
of the backbone ribbon correlates with the computed root mean square deviations from the
average structure for all Cα atoms. Not surprisingly, the N-terminus which is exposed to the
extracellular aqueous compartment exhibits highest flexibility. The first and third extracellular
loops together with the second intracellular loop display remarkable conformational flexibility
as well, while the second extracellular loop is clearly constrained by the explicitly depicted
disulfide bond. The 7TM helical domain demonstrates a remarkably reduced flexibility with
helix 3 being most restrained (Figure 4.9).
The overall stability of the receptor protein, monitored over the MD simulation within its
native-like environment, is highlighted in this context by the observation that even distinct wa-
ter molecules emerge as integral components of the receptor protein structure, as exemplified
in Figure 4.10. The depicted water molecule is engaged in a stable hydrogen-bond network,
thus relaying hydrogen-bonds between residues Cys-107, Thr-111 (sidechain OH), and His-
376 (sidechain imidazole), respectively. This particular water molecule is found to be engaged
in this interaction network within all 750 snapshots covering the final production part of the MD
simulation.
Further details of the analysis of the final 750 ps of the MD simulation are depicted in the
Tables 4.4 - 4.7. Available structure-relevant information as the fingerprint of Baldwin [60, 66]
(row 3), general structure information of GPCRs (e.g. positive-inside rule data; row 4) and
site-directed mutagenesis data of both CCK-receptors [147, 148, 149, 150, 151, 152, 153, 154]
(row 5) are aligned with structural dynamical properties as hydrogen bond occurrences (row 8
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Figure 4.10: Side-by-side stereoview of a structural detail including a water molecule which is
strongly bound between the residues Cys107, Thr111 and His376 and remains fixed during the
whole 750 ps production period of the final molecular dynamics simulation (helix 1 = magenta,
helix 2 = dark violet, helix 3 = white and helix 7 = dark green and the hydrogen bonds are
represented by cyan coloured bonds, the picture was made with the program MolMol [146]).
and 9) and spherical distribution functions with a radius of 5 Å of the solvent (row 6) and of the
protein atoms (row 7) around both, backbone and sidechain atoms of all the modelled amino
acid residues. It can clearly be seen that the spherical distribution function of both, the solvent
and the protein atoms follow the fingerprint of Baldwin almost perfectly, indicating that the
model of the human CCK-B receptor is in good agreement with this fingerprint. Furthermore,
the mutated transmembrane domain amino acids with no effect on ligand binding are almost all
pointing to the membrane environment and the amino acids within the transmembrane domains
showing any effects on ligand binding are pointing towards the protein interior. The Oi←→
H-Ni+4 hydrogen bond network to conserve the helical conformation of the transmembrane
helices is retained throughout the entire MD simulation and also several interhelical hydrogen
bonds were found within more than 80% of all 750 snapshots covering the final production part
of the MD simulation.
Summarising, the modelling-derived protein structure of the human CCK-B receptor, described
above, remains stable over a 1.15 ns MD simulation and displays a conformational flexibility
pattern that is expected for a transmembrane protein.
Furthermore, the modelled protein structure of the human CCK-B receptor was compared with
the crystal structure of bovine rhodopsin [5]. The root mean square deviations between the
model of the receptor and the X-ray structure were comparable with those found by Bourne
and Meng. Bourne and Meng [61] described the superposition between the crystal structure of
rhodopsin and three recent model structures and found that the Cα-trace of the transmembrane
helices fitted reasonably well (RMS-deviations of 3.1 - 3.2 Å for the Cα-trace of the seven
transmembrane helices). The root mean square deviation between the X-ray structure (PDB-
code 1F88 [5]) and the model structure of this study was for the backbone atoms (Cα, C and N)
of the complete α-helices 4.5 Å and for the transmembrane domains 3.9 Å, respectively. The
two α-helices with the highest RMS-deviations in their transmembrane domains were α-helices
2 and 5, namely 2.3 and 2.6 Å, respectively. Helix 6 is a rather straight α-helix and has only a
RMS-deviation of 0.9 Å for its backbone atoms within the transmembrane domain.
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4.4 Conclusion
Given the conformational characteristics described above that were obtained from a sophisti-
cated molecular modelling and simulation procedure developed in this study, we feel confident
to use the derived protein model for further studies that are aimed to shed light on the structural
details that govern ligand binding.
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Table 4.4: The amino acid sequence of the human CCK-B receptor PART I, colour-coding see
Table 4.7.
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Table 4.5: The amino acid sequence of the human CCK-B receptor PART II, colour-coding see
Table 4.7.
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Table 4.6: The amino acid sequence of the human CCK-B receptor PART III, colour-coding see
Table 4.7.
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row 1 amino acid sequence of the human CCK-B receptor
row 2 different amino acids of the human CCK-A receptor compared to the human CCK-B receptor
row 3 Fingerprint of Baldwin; red = extracellular region, blue = intracellular region, yellow = inside protein, grey = on border of
the protein, x = conserved amino acid, + = polar residue in a few sequences, # = polar residue in >10% of the sequences
row 4 general concepts; F = important for folding, G = G-protein binding, mo = binding ligand monoamine GPCRs, + = positive-
inside rule, kn = knick in helix
row 5 known mutations of the CCK-B receptor: red = affect antagonist binding, blue = affect agonist binding, magenta = affect
agonist and antagonist binding, green = no affect on binding agonist or antagonist or signal transduction, horizontal grey
strifes = affect signal transduction; same effects but than for the CCK-A receptor: spickeled red, blue, green, dunkle magenta
and vertical grey strifes.
row 6 spherical distribution function around Cα-atom of each residue (5Å); first part: blue = >70% water, >70% magenta = CCl4
and grey = mixed; second part: green = inside protein, white = outside protein
row 7 spherical distribution function around specific sidechain atom; colours idem to row 6
row 8 H-bonds excisting in >80% of the 750ps for the main atoms; w-blue-box = H-bond with water, blue-residue-number = with
backbone atoms of that residue, residue-number-in-orange-box = α-helical H-bond with that residue, residue-number-in-
green/yellow-box = H-bond with sidechain of that residue.
row 9 H-bonds excisting in >80% of the 750ps for the sidechain atoms; colours idem to row 8
Table 4.7: The amino acid sequence of the human CCK-B receptor PART IV.
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Chapter 5
CCK Ligands
Overview on CCK agonists and
antagonists.
"Words are, of course, the most powerful drug used by mankind."
• Rudyard Kipling
(1865-1936), poet/writer and Nobel
Prize in Literature laureate
CHAPTER 5. CCK LIGANDS
5.1 Introduction
As mentioned in section 2.2, CCK-8 is the predominant form of CCK (cholecystokinin) which
displays biological activities, both in the peripheral and central nervous system. These different
areas are responsible for the notation of the two different CCK receptors, notably CCK-A (ali-
mentary) and CCK-B (brain), even though it has been indicated that CCK-B also occurs in the
periphery and CCK-A in the brain, respectively.
The broad therapeutic potential of CCK-ligands (Figure 5.1) resulted in considerable research
efforts. The complexity of CCK-receptor modulation in different physiological processes ren-
ders the exact prediction of its physiological and therapeutic interference somewhat difficult,
accordingly the role of agonism as well as antagonism of CCK-A or CCK-B receptors is not
entirely understood.
Potent and selective peptide and non-peptide agonists and antagonists have been discovered for
both types of CCK-receptors. It has become obvious in recent years that therapeutic application
of CCK-receptor antagonists provides a broader spectrum of therapies than the use of agonists.
However, this can be partly attributed to the fact that the nonpeptide CCK agonists were discov-
ered only recently. The discovery of the benzodiazepine containing asperlicin in 1985 [115], a
natural product isolated from fungus, marks a milestone in the design of CCK-ligands. Based
on this structure, several very potent and selective compounds have been synthesised. The pro-
totype antagonist for the CCK-A receptor subtype is L-364,718 (devazepide). For the CCK-B
receptor subtype L-365,260 emerged from asperlicin-based medicinal chemistry projects (Fi-
gure 5.2).
Over the past decade, a large number of highly selective agonists and antagonists acting se-
lectively on CCK-A or CCK-B receptors have been developed (reviewed in [155, 29, 156,
157, 158]). This chapter will give a brief overview on the principally devised types of lead
compounds. A thorough and exhaustive discussion of CCK-A and CCK-B receptor mediating
compounds is clearly beyond the scope of this thesis. Special interest will be focused on those
compounds acting on the CCK-B receptor which is the receptor of our predominant interest.
5.2 CCK-A Agonists
For the design of CCK-A agonists the CCK peptide was used as lead compound. Since it was
known that the C-terminal portion of the peptide is mainly responsible for receptor binding,
systematic variation of chain length together with the concept of conformational restriction
revealed compounds with enhanced selectivity and considerable proteolytic stability.
A research group at Hoffmann-La Roche changed different positions of the acylated heptapep-
tide CCK-7, e.g., Phe into MePhe, Met into Nle and Asp into Thr(SO3). Two compounds,
Ro 23-2154 (3) 1 and Ro 23-7014 (4) [161] (Figure 5.3), displayed improved selectivity for
the CCK-A receptor when compared to ac-CCK-7 (2) together with enhanced stability towards
degradation.
Efforts to modify the ac-CCK-7 (2) compound at Abbott resulted in heptapeptide derivatives, A-
71378 (5) and A-71623 (6) (Figure 5.3), with similar potency to Ro 23-2154 (3) and Ro 23-7014
(4), but with enhanced selectivity towards the CCK-A receptor (5: 1140 and 6: 1216 versus 3:
225 and 4: 425). Astra-Zenaca published a series of peptide-type CCK-A agonists [166, 167].
1 the numbers behind compound names are the compound numbers which are used in the figures and the tables.
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cholecystokinin ligands
CCK-A agonists CCK-A
antagonists CCK-B agonists
CCK-B
antagonists
satiety agent
in obese patient
treatment of
pancreatic
disorder
hypervigilance
agent
treatment of pain
potentiation of
opioid effect
prevention of
gallbladder stasis
on low fat diet
antiproliferation
agent in
some carcinoma
enhancement
of memory
treatment of
drug dependence
prevention
of gallstones
treatment of
motility disorders
treatment of
anxiety
treatment of
functional
bowel disease
treatment of
panic attack
treatment of
biliary colic
treatment of
shizophrenia
anti-anorexic
agent
treatment of
gastric acid
hypersecretion
(peptic ulcers)
treatment of
secretory
disorder
treatment of
gastro-oeso-
phageal reflux
Figure 5.1: Potential therapeutic applications of CCK-receptor ligands [29].
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Figure 5.2: Example ligands for the CCK-A and CCK-B receptors.
CCK-A CCK-B
Nr. Name affinity affinity ref.
[nM] [nM]
1 (sulf.)CCK-8 0.28 0.64 [159]
2 Ac-(sulf.)CCK-7 0.60 4.4 [160]
3 Ro 23-2154 0.4 90 [161]
4 Ro 23-7014 0.4 170 [161]
5 A-71378 (Abbott) 0.5 570 [156]
6 A-71623 (Abbott) 3.7 4500 [156]
7 PD170292 1.2 6.7 [162]
8 SR146131 (Sanofi Recherche) 0.56 168 [163]
9 GW 7854 126 10 [164]
10 GW 5823 22.9 1000 [165]
Table 5.1: Selectivity profile of selected CCK-receptor agonists (Figure 5.3).
Only few studies report on the design of potent non-peptide agonists with substantially re-
duced peptide character as potential drugs for , e.g., the treatment of obesity. The compound,
PD-170292 (7), was reported [162] as a simplified analogue of A-71623 (6) (both having a
lysine bearing a phenylurea at the amino group). Remarkably PD-170292 (7) acts as an ago-
nist towards the high-affinity and as an antagonist towards the low-affinity state of the CCK-A
receptor, and as an antagonist towards the CCK-B receptor [162].
SR146131 (8) (Sanofi Recherché) [163, 168] can be envisioned as a peptidomimetic agonist
which has even more structural similarities with the nonpeptide antagonist SR27897B (11) than
with the endogenous peptide, it attempts to mimic. Obviously the attachment of a lipophilic
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1 2
3 4
5 6
7 8 9 10
Figure 5.3: selected CCK-A agonists
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cyclohexyl sidechain onto the thiazole ring interconverts an agonist (SR146131 (8)) to an an-
tagonist (SR27897B (11)) (See Figure 5.4).
8 11
Figure 5.4: Structural similarity between the agonist, SR146131 (8) and the antagonist
SR27897B (11) [163, 168].
Researchers at Glaxo Wellcome disclosed 1,5-benzodiazepines (e.g. GW 7854 (9) and GW
5823 (10)) with CCK-A receptor agonist activity by rationally altering the different side chains
of 1,5-benzodiazepines [169, 170, 165, 171]. GW 7854 (9) has affinity for both CCK receptors,
but it acts as CCK-A agonist and CCK-B antagonist. This mixed character is ideally suited
for a potential drug candidate, since CCK-B agonist activity would be not desirable due to
the potential peripheral (enhanced gastric acid secretion) or central (enhanced anxiety) side
effects [164]. Also GW 5823 (10) shows CCK-B antagonist activity and even better CCK-A
agonist activity. Despite this promising profile, pharmacokinetic studies carried out on rats
revealed for this compound poor bioavailability and relative high clearance [165, 171].
This close structural similarity among nonpeptide agonists and antagonists suggests, the ex-
istence of similar binding pockets within the receptor protein, even though the steric overlap
might be marginal. These two binding pockets are probably less distinct than the divergence
between these two sites and the binding site of the endogenous peptide ligand. In summary, one
can assume the existence of multiple binding sites within one receptor for the different classes
of ligands. This hypothesis has to be considered when comparing antagonists with agonists in
the context of docking studies of low-molecular weight ligands into the receptor protein.
5.3 CCK-B Agonists
Potent and selective CCK-B agonists were obtained by restricting the conformation of the C-
terminus of the CCK peptide. Again a group at Hoffmann-La Roche rationally changed several
positions of the CCK-7 peptide and derived various selective peptidic CCK-B agonists, 14-17.
(Figure 5.5) [172, 160].
Based on the finding that a CCK-4 peptide derivative, Boc-Trp-(NMe)Nle-Asp-Phe-NH2 (13)
[173], was found to be a potent and selective CCK-B agonist, cyclic CCK-B agonists were
synthesised (18-20 in Figure 5.5) [159]. Different bridge moieties between the N-terminus of
the tetrapeptide derivative and the Nle/Met residue were designed. A disulfide bridge moiety
in the cyclic peptide increased CCK-A receptor recognition. It is not surprising that the nature
of the ring system has influence on the CCK-A versus CCK-B selectivity, because also the
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12 13
14 15
16 17
18 1=R, 19 1=S 20 1=S 21 22
Figure 5.5: selected CCK-B agonists
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CCK-A CCK-B
Nr. Name affinity affinity ref.
[nM] [nM]
1 (sulf.)CCK-8 0.28 0.64 [159]
12 CCK-4 > 35000 19.5 [159]
13 Boc-Trp-(NMe)Nle-Asp-Phe-NH2 N.D.1 0.8 [173]
14 Tilley91-34 3.0 0.50 [172]
15 Tilley91-28 2.6 54 [172]
16 Tilley92-26 25 0.029 [160]
17 Tilley92-20 2.1 0.48 [160]
18 RB 360 I (1 = R) N.D.1 4372 [159]
19 RB 360 II (1 = S) 2210 15 [159]
20 RB 380 (1 = S) 271 51 [159]
21 A-63387 (Abbott) 6300 0.7 [29]
22 L-740,093 (S) N.T.2 19.5 [154]
1N.D. = not determined, beyond the measurable boundary, 2 N.T. = not tested
Table 5.2: binding affinity for the two CCK-receptors of selected CCK-B Agonists (Figure 5.5).
replacement of the Met residue in Boc-CCK4 by a Nle residue (Ro 23-2154 (3)) or by a lysine
bearing a phenylurea in place of the amino group (A-71623 (6)), resulted in CCK-A agonists
with enhanced selectivity. (Figure 5.3).
Abbott designed an even more restricted structure, A-63387 (21). This tetrapeptide (21) has a
9000 fold CCK-B selectivity over CCK-A and an affinity similar to that of CCK-8 (1). [29]
Due to their peptide or pseudopeptide nature, all these ligands show low bioavailabilities and
unsatisfactory pharmacokinetics, which renders their application as orally-active drugs rather
questionable.
A compound which might be not only a pharmacological tool, but also a therapeutic agent is
L-740,093 (S) (22). L-740,093 (R) (73) is a potent CCK-B antagonist, however inversion of
the stereogenic centre of the benzodiazepine moiety converts this ligand into a CCK-B agonist,
L-740,093 (S) (22) [154] (Figure 5.5).
5.4 CCK-A Antagonists
In many investigations a large number of CCK-A antagonists were developed. Modifications of
the C-terminus of the peptide CCK were the basis for the search of peptide antagonists. Deletion
of the C-terminal phenylalanine residue, inversion of L-Trp to D-Trp or changing the Met into a
Nle residue, have resulted in, e.g., Boc-Tyr(SO3H)-Nle-Gly-D-Trp-Nle-Asp-O-CH2-CH2-C6H5
(23) (Figure 5.6) [174]. However, this compound is only marginally selective for the CCK-A
receptor.
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Figure 5.6: selected CCK-A antagonists
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CCK-A CCK-B
Nr. Name affinity affinity ref.
[nM] [nM]
1 (sulf.)CCK-8 0.28 0.64 [159]
23 Boc-Tyr(SO3H)-Nle-Gly-D Trp-Nle-Asp-O-CH2-CH2-C6H5 50 500 [174]
24 benzotript 84000 102000 [175, 115]
25 proglumide 6300 875000 [175, 115]
26 lorglumide (CR 1409) 130 (49) 300000 [176, 177] ( [178])
27 loxiglumide (CR 1505) 330 9900 [176, 177]
28 CAM-1481 (PD 140,548) 2.82 260 [179]
29 IQM-95,333 0.62 >5000 [180]
30 asperlicin 1400 >100000 [115]
31 L-364,718 (Merck) 0.08 270 [115]
32 vdBent92-6 90 N.T.1 [178]
1 N.T. = not tested.
Table 5.3: binding affinity of selected CCK-A antagonists for the two CCK-receptors (Figure
5.6).
Structural departure from the peptide character towards the development of peptidomimetic and
nonpeptide antagonists revealed compounds with enhanced selectivity and acceptable pharma-
cokinetic profile. These CCK-A antagonists can be classified into four large families:
• peptidomimetic or peptoid family
• dipeptoid family
• tetrapeptide restricted family
• benzodiazepine family
The first family comprises well known members such as benzotript (24), proglumide (25), lor-
glumide (CR 1409) (26) and loxiglumide (CR 1505) (27) [181, 176, 177] (Figure 5.6), the last
three compounds being potent and selective glutamic acid derivatives.
Extensive SAR studies were derived on proglumide and its analogues. It turned out that the
R-isomers were more potent than the corresponding enantiomers. This influence on the stereo-
chemistry parallels the findings of stereoisomerism of the Trp position. Loxiglumide (27) and
Lorglumide (26) display increased affinity and selectivity towards the CCK-A receptor. These
compounds have been evaluated by Rotta Labs in clinical studies [29]. However, only proglu-
mide (25) (Milide (tm) or Milid (tm)) has been marketed and is used for treating gastric ulcers.
The structures of the dipeptoid family were based on the two most important amino acid residues
of CCK-8 and CCK-4, namely tryptophan and phenylalanine. This research led to potent and
selective CCK-A receptor antagonists such as CAM-1481 (PD 140,548, 28, see Figure 5.6)
[179].
As mentioned before, rigidification of the tetrapeptide structure in order to mimic the bioactive
conformation of the C-terminus of CCK-8 turned out to be an important direction in the search
of novel CCK-A antagonists, exemplified with the 1,3-dioxoperhydropyrido[1,2-c]pyrimidine
derivatives, IQM-95,333 (29) being the most potent member of this series [180].
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One of the most important findings in the development of CCK-A and CCK-B ligands was
the discovery of the CCK-A antagonist activity of asperlicin (30) by receptor-based screening
technology at Merck (Figure 5.6). Asperlicin (30) is a fermentation product from Aspergillus
alliaceus [115]. This discovery paived the route towards the design of nonpeptide antagonists
and agonist for both CCK-receptors. Efforts to simplify its structure, to enhance affinity and
oral activity, stimulated Merck scientists to design, synthesis and evaluate several series of
compounds with a hybrid structure encompassing the 1,4-benzodiazepine part and an aromatic
part (for example ref. [182, 183, 184, 185, 186, 187]). These hybrid structures were designed to
mimic the asperlicine structure [188]. L-364,718 (devazepide) (31) was the best compound of
these benzodiazepine derivatives for the CCK-A receptor with a high (0.08 nM) binding affinity
and high CCK-A receptor selectivity (3375 fold) . Devazepide (31) has been used in the last few
years for enhancing our understanding of CCK receptor location, function and pharmacological
actions. The benzodiazepine family emerged over the last decade to one of the largest and most
important families of the CCK-A antagonist types.
On the basis of the structural homology between lorglumide (26) and L-364,718 (31), a novel
series of nonpeptide CCK-A antagonists was designed and synthesised [178]. Compounds of
this series (Figure 5.6) are clearly nonpeptide antagonists, since the peptidic character is com-
pletely abolished.
5.5 CCK-B Antagonists
CCK-B antagonists cluster in different compound classes, the most important members will be
introduced in the following sections.
5.5.1 Glutamic Acid Structure
Modifications of CCK-A antagonist Lorglumide (26) (Figure 5.6) led to the specific CCK-
B antagonist spiroglumide (CR2194) (33), with only a 11 fold selectivity enhancement for
the CCK-B receptor [189]. Further modifications led to CR2622 (34) with higher affinity (70
fold) and better CCK-selectivity (369 over 9.6) (Figure 5.7) [190]. The authors rationalise this
affinity of CR2622 (34) by its capacity to mimic the bioactive conformation of the terminal
gastrin pentapeptide. The low-energy conformation of CR2622 (34) superimposed well on the
low-energy pentagastrin structure (see Figure 5.8 for a possible superpositioning).
5.5.2 Tryptophane Dipeptoid Derivatives
Comparable to the CCK-A antagonist programs, a series of tryptophane and phenylalanine
derivatives were synthesised and evaluated as putative CCK-B antagonists by Parke-Davis. One
of the most potent compounds is CI-988 (PD 134,308) (35) [191], which suffers from a poor
bioavailability. This clinical finding was attributed to poor absorption and efficient hepatic ex-
cretion. Consequently, compounds were developed with reduced molecular weight, that should
lead to better absorption. In this process the key moieties, α-methyltryptophan and adamanty-
loxycabonyl, were kept intact, while the C-terminus was extensively modified. CI-1015 (36)
emerged as a good CCK-B antagonist with excellent CCK-B selectivity. Its bioavailability in rat
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Figure 5.7: selected glutamic acid and tryptophane dipeptoid CCK-B antagonists
is improved by 10 fold over CI-988 (35) and also the blood-brain permeability was enhanced rel-
ative to CI-988 (35), which rendered CI-1015 (36) as a promising development candidate. [192]
The French research group of B.P. Roques designed potent and selective dipeptoid CCK-B an-
tagonists by incorporating non-natural hydrophobic amino acids together with conformational
restrictions achieved by proline [195, 196]. Affinity and selectivity of these analogues was
probed systematically. As similarly observed for the CCK-A antagonists chirality of the Trp
residue plays in all six structures (37-42) an important role in the binding affinity [195, 196,
194, 193]. In contrast, the two other stereogenic centres of compounds 39 and 40 possess
significantly less influence on the binding affinity [195]. Remarkable is the fact that the bind-
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Figure 5.8: Stereoview of a possible superpositioning of the CCK-B antagonist CR22 (34, ma-
genta) and the terminal gastrin pentapeptide (green).
CCK-A CCK-B
Nr. Name affinity affinity ref.
[nM] [nM]
1 (sulf.)CCK-8 0.28 0.64 [159]
33 CR 2194 (spiroglumide) 13500 1400 [189]
34 CR 2622 7380 20 [190]
35 CI-988 (PD 134,308) 4300 1.7 [192]
36 CI-1015 2900 3.0 [192]
37 Boc-Trp-Phg-Asp-1Nal-N(CH3)2 1000 39 [193]
38 2Adoc-D-αMeTrp-N-[2-(4-chlorophenyl)ethyl]glycine (RB211) 1060 6.1 [194]
39 2Adoc-D-αMeTrp-Phg-Asp-NalN(CH3)2 (Weng96-13) 54 3.5 [195]
40 2Adoc-D-αMeTrp-Phg-Asp-NalNH2 (Weng96-16) 250 3.4 [195]
41 2Adoc-D-αMeTrp-D-cis-Hyp(Ph-pCl)-OH (Bellier97-6e) 1560 24 [196]
42 2Adoc-D-αMeTrp-D-cis-Hyp(Ph-o,pF2)-OH (Bellier97-11e) 394 17.6 [196]
Table 5.4: binding affinity of selected glutamic acid and tryptophane dipeptoid CCK-B antago-
nists for the two CCK-receptors (Figure 5.7).
ing affinity of the restricted compound 41 is a factor 2 lower than RB211 (38), but it is 3 times
more potent in the inositol phosphate formation induced by CCK-8 (a common CCK-antagonist
activity experiment) [196]. Compound 42 on the contrary has similar binding affinity as com-
pound 41, but has a similar potency as RB211 (38) [196]. The only difference between these
two structures are the substituents on their phenyl ring. On the basis of these results, it can be
suggested that there exist high-affinity and high-potency antagonists (41) and high-affinity and
low-potency antagonists (38 and 42) [196], whereby the structures do not differ significantly.
This could imply that there are two CCK-B receptor states of distinct affinity as is suggested
by Bellier et al. [196]. However, slightly different CCK-B antagonist binding sites or different
binding modes of the ligands can also explain these results.
It is also remarkable that, although the bindings affinities towards the CCK-B receptor of com-
pounds 39 and 40 are very similar, their capacity to influence the inositol phosphate formation
is different. Compound 39 functions as a full CCK-B antagonist with similar potency as CI-988
(35) and L-365,260 (the prototype CCK-B antagonist), while compound 40 is a partial agonist.
Furthermore, compound 40 is a partial agonist in the IP formation, an agonist by pentagastrin
acid secretion and an antagonist in the firing rate of rat CA2 hippocampal neurons (CCK-B
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agonist have shown to stimulate the firing rate of these neurons in a dose-dependent manner).
The only difference in the structure of these two compounds is the more bulky C-terminus of
compound 40 [195].
5.5.3 Quinazolinone Series
A research group at Lilly [197] (successfully) focused on alternative substructures embedded
within the molecular framework of the natural product asperlicin (30). These substructures
provided a rational starting point for the effort to design structurally novel series of nonpep-
tide CCK receptor ligands derived from asperlicin (30). By disconnecting several bonds of
the asperlicin structure, two compound classes were obtained with reduced chemical complex-
ity (Figure 5.9). The first class refers to the tryptophan-derived CCK-ligands, as for example
the CCK-A antagonist benzotript (24). The second class describes novel compounds, notably
quinazolinones. An advantage of this structural class is that it lacks the asymmetric centres
found in, e.g., the tryptophan dipeptoid derivatives (35-42) and asperlicin (30). By synthesis-
ing and evaluating a series of quinazolinones [197, 198, 199], the influence of the substitution
pattern of this heterocyclic system was investigated. It is remarkable that all these structures
display excellent CCK-B receptor selectivity, whereas the natural product asperlicin (30) is a
selective CCK-A receptor antagonist.
Parke-Davis [200, 201] developed a new series of quinazolinone derivatives by combining key
fragments of the Lilly and Merck series (Figure 5.9). They investigated the indole moiety (re-
placed by a phenyl ring with different substituents), introduced an urea functionality in the linker
between the quinazolinone ring and the indole moiety and investigated the optimal substitution
pattern at the phenylring attached to the quinazolinone N-3.
A small fraction of compounds synthesised by Lilly and Parke-Davis is given in Table 5.5.
Special emphasis is put on the elaborated structure activity relationship, since various low-
molecular weight antagonists used for our docking study (Chapter 6) were selected from this
series of congeneric compounds.
Clearly, the 3-isopropoxyphenyl is the preferred substitution on the N-3 quinazolinone. Fur-
thermore, the CCK-B affinity is enhanced by electron-withdrawing substitutions on the termi-
nal phenyl ring attached to the urea moiety. The perfect linker is -NH-NH-CO-NH [200, 201].
This optimised linker has good structural similarity with the structure of asperlicin (30) (Figure
5.10), although it is a longer linker as previously anticipated by the structural comparison in
Figure 5.9.
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A
B
Figure 5.9: (A) Two possible bond disconnection strategies of the asperlicin structure. The three
aromatic domains are preserved and the chemical complexity is reduced. The first (above) yields
a substructure common to tryptophan derivatives of CCK-receptor ligands. The second (below)
yields the novel series of 3-phenyl-4(3H)-quinazolinone structures. (B) Further development by
Parke-Davis by combining key fragments of the Lilly and the Merck series.
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Table 5.5: Binding affinities of selected quinazolinone
derivatives for the CCK-receptors.
Nr. R1 Linker 1 Linker 2 R2 CCK-A CCK-B ref.
[nM] [nM]
43 - N.D. 1 670 [197]
44
LY-247348 - N.D.
1 26 [197]
45 - N.D.1 >1000 [198]
46 - N.D.1 >1000 [198]
47 - >1000 >1000 [200]
48 1630 585 [200]
49 984 137 [200]
50 3430 14 [200][201]
51 17300 108 [200]
52 8110 29 [201]
53 2560 1.0 [201]
54 6400 11 [201]
55 N.D. 1 97 [201]
56 4900 63 [201]
1 N.D. = not determined, beyond measurable boundary.
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Figure 5.10: Similarity between asperlicin and quinazolinone derivative with optimised urea
linker.
5.5.4 Diphenylpyrazolidinone Series
Following a random screening approach, Lilly identified a pyrazolidinone derivative as CCK-B
receptor ligand. Again, the stereochemistry of the compounds 57-62 plays a crucial role in the
binding affinity of the compounds (Figure 5.11).
5.5.5 Ureido-Acetamide Derivatives
Bertrand et al. [202] at Rhône-Poulenc Rorer developed a further family of non-peptide CCK-B
receptor antagonists, notably the ureido-acetamide family. The three representative members
of this family, RP 69758 (63), RP 71483 (64) and RP 72540 (65) (Figure 5.11), displayed
nanomolar affinity for the CCK-B receptor with decreased binding to the CCK-A receptor. In
vitro tests demonstrated these three compounds (63-65) to be potent CCK-B antagonists in vivo.
The ureido-acetamides do not interact with a wide array of other neurotransmitter or hormone
receptors, such as histamine H1, dopamine D2, neuropeptide Y, neurotensin, serotonine 5-HT2,
somatostatin, tachykinin NK1, and bradykinin receptors, rendering them as highly selective
drug candidates [202].
CCK-A CCK-B
Nr. Name affinity affinity ref.
[nM] [nM]
1 (sulf.)CCK-8 0.28 0.64 [159]
57 LY 288512 (Lilly) 6400 370 [156]
58 LY 288513 (Lilly) 20500 19 [156]
59 LY 262691 (Lilly) 11600 31 [156]
60 LY 294920 (Lilly) 17 1900 [156]
61 LY 294919 (Lilly) 810 550 [156]
62 LY 219057 (Lilly) 42 880 [156]
63 RP 69758 (Rhône-Poulenc Rorer) 1254 9.0 [202]
64 RP 71483 (Rhône-Poulenc Rorer) 2338 2.4 [202]
65 RP 72540 (Rhône-Poulenc Rorer) 164 0.76 [202]
Table 5.6: Bindings affinities of selected diphenylpyrazolidone and ureido-acetamide CCK-B
Antagonists for the CCK-receptors (Figure 5.11).
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57=RS, 58=SR, 60=RS, 61=SR
59=racemic trans 62=racemic trans
63 64
65
Figure 5.11: selected diphenylpyrazolidinone and ureido-acetamide CCK-B Antagonists.
5.5.6 Benzodiazepine Family
As described in Section 5.4, the selective and potent CCK-A antagonist, L-364,718 (31), was
designed from the natural product asperlicin (30) [115]. In the development of L-364,718 (31)
hundreds of analogues of this benzodiazepin derivative were synthesised and evaluated. These
compounds revealed the information that subtle structural modifications resulted in loss of re-
ceptor subtype selectivity. Replacing the indole substituent by a 4-chlorobenzoyl group (67)
revealed an equivalently potent and selective derivative as L-364,718 (31). Subsequent ex-
change of the N-1 methyl substituent by an ethoxycarbonyl group, or the 3-amide linkage by an
urea and the N-1 methyl substituent with an H-atom decreased the CCK-A affinity substantially
while the CCK-B affinity increased slightly. Combination of these two features (N-1 ethoxy-
carbonyl substituent and urea linkage) resulted in the first nonpeptide derivative (69) with a
selective nanomolar potency for the CCK-B receptor (Table 5.7). Two other compounds with a
urea linkage, the N-1 methyl-4-chlorobenzoyl derivative and the N-1 methyl-3-methylbenzoyl
derivative (70), have a slightly decreased potency (23 and 7.1 nM versus 1.0 nM of the N-
1 hydrogen-4-chlorobenzoyl derivative (69)). Again, stereochemistry is the reason for target
discrimination since in both instances, the enantiomers with the 3S-configuration (71) showed
selectivity for the CCK-A receptor whereas the 3R-configuration (72) showed selectivity for
the CCK-B receptor. This is in contrast to the enantiomers of the N-1 methyl-4-chlorobenzoyl
derivative (67 and 68) with the amide linkage, which are both highly selective for the CCK-A
receptor. The 3R-enantiomer of the N-1 methyl-3-methylbenzoyl derivative is the well known
L-365,260 (72), the prototype nonpeptide antagonist for the CCK-B receptor.
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Table 5.7: Binding affinities of selected benzodiazepine
derivatives for the CCK-receptors.
CCK-A CCK-B
Nr. R1 R2 R3 Stereo affinity affinity ref.
[nM] [nM]
31 L-364,718
66
S
R
0.08
8.3
270
3700
[184]
[203]
67
68
S
R
0.39
2.9
2900
11000 [184]
69 RS 370 1.0 [197]
70
71
72 L-365,260
RS
S
R
8.1
3.0
280
7.1
151
2.0
[184]
73 L-740,093 R 1604 0.1 [204]
74 L-708,474 R 1820 0.28 [204]
75 YM-022 R 150 0.11
[158]
[155]
[29]
76 L-368,935 R 1434 0.14
[158]
[155]
[29]
77 L-738,425 R 4080 0.11 [205]
78 R 3000 0.58 [205]
79 R 3000 7.5 [205]
80 R 3000 1.1 [205]
81 L-736,380 R 400 0.054 [205]
82 R 480 137 [205]
83 R 3090 1.5 [205]
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Table 5.8: Binding affinities of selected 2,4-dioxo-1,5-benzodiazepine derivatives with a plane
of symmetry [206] for the CCK-receptors.
CCK-A CCK-B
Nr. R1 R2 affinity affinity ref.
[nM] [nM]
84 860 54 [206]
85 380 18 [206]
86 >10000 >1000 [206]
87 2400 480 [206]
88 860 23 [206]
89 23 8 [206]
90 100 2 [206]
91 11000 >1000 [206]
92 >10000 84 [206]
93 2900 8 [206]
94 4400 16 [206]
95 1800 4 [206]
96 500 2 [206]
97 1300 1 [206]
98 2500 48 [206]
99 >10000 >1000 [206]
100 2600 26 [206]
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Due to the low bioavailability the development of a second generation of benzodiazepine CCK-
B antagonists was pursued by scientists at Merck and Yamonouchi. These new compounds (73-
83) were designed to show high potency and selectivity, which by adding of a water solubilising
group should improve bioavailability as exemplified by L-740,093 (73). A selection of these
compounds are given in Table 5.7. Again it is attempted to give an impression of the SAR of
these derivatives, since the most selected compounds were used for our docking studies (Chapter
6).
It should be emphasised that the 2,4-dioxo-1,5-benzodiazepines (84-100) (Table 5.8) possess a
plane of symmetry and therefore do not possess a stereogenic centre at the C3 position [206].
5.6 Receptor Binding for CCK-A and CCK-B
Since the benzodiazepine were first developed as CCK-A antagonists, extensive QSAR analyses
and pharmacophore modelling have been applied to this compound class.
Based on molecular shape and QSAR analysis, Tokarski et al. [207] derived an 3D-pharmacophore
model for the 3-amino substituent of the benzodiazepine CCK-A antagonist series. This phar-
macophore model shows that the lipophilicity of the substituent in the para position increases the
binding affinity, which is in contrast to the ortho substituent on the 3-amino phenyl ring [207].
However, there is a trade-off between size and lipophilicity. Compounds with atoms extending
above and/or below the plane of the aromatic ring of the 3-amino substituent have a significantly
lower activity. Therefore, Tokarski [207] suggested that there must be a non-allowed volume
A B
Figure 5.12: 3D-pharmacophore model for the 3-amino substituents of the benzodiazepine
CCK-A antagonists developed by Tokarski et al. [207] (A) 1.3-2.0 Å above and below the aro-
matic ring-plane and 9.65 Å from the carbonyl carbon is the receptor limiting the accessible
volume of the substituents. A hydrophobic sphere of 1.5 Å at the end of the pocket could be
significant for a good binding affinity. (B) Planar view of the accessible volume depicted with
three example substituents (3,4-di-Cl-phenyl - red; 2-naphthyl - green; o-NH2-p-Cl-phenyl -
magenta and 2-indolyl - blue).
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about 2.0 Å above and below the plane of the aromatic ring, causing steric interaction between
the receptor and the antagonists. Additionally, the receptor-excluded volume is defined at 9.65
Å from the carbonyl carbon, thus limiting the size of the substituents. The steric bulk of the
3-amino substituent is also restricted to 4.5 - 5.0 Å from the axis through the para substituent
(see Figure 5.12). Accordingly, only a limited volume is available for the 3-amino substituent,
giving rise to a constrained conformation of the aromatic ring. Therefore, the angle of the aro-
matic ring towards the plane of the 3-amino moiety is of crucial importance [207]. This angle
of the aromatic ring (phenyl or indole) is depending on the physico-chemical properties of its
substituents [208].
Furthermore, the substituents in the para position should be hydrophobic, since the para-OH
and the para-Cl have only poor and moderate activity. Therefore, a hydrophobic sphere of 1.5
Å around the Iodinium-atom at the para position of the phenyl ring has to be considered in the
3D pharmacophore.
The fact that the 3-amino substituents of the benzodiazepine CCK-A antagonist have a limited
bulk tolerance was also suggested by Sinha et al. [209] and van der Bent et al. [208]. Sinha
postulated that the NHCO is favourable for the CCK-A antagonist, but the NHCONH-moiety
is mediating CCK-B selectivity. The additional NH should perform a sterically unfavourable
interaction with the CCK-A receptor, whereas it introduces an additional hydrogen bonding
facility in the CCK-B receptor. Furthermore, they concluded that CCK-B binding of the benzo-
diazepine compounds is significantly depending on logP, suggesting that the compounds should
bind in a large lipophilic binding pocket. In contrast to the CCK-A receptor, this pocket should
be more flexible and sterically less constrained [209].
A B
Figure 5.13: Benzodiazepine-derivatives in different conformations; (A) white structure: R
isomer with the dark blue side chain in the pseudo-euatorial orientation; orange structure: R
isomer with pseudo-axial; yellow structure: S isomer with pseudo-equatorial; and magenta
structure: S isomer with pseudo-axial. (B) the dark blue side chains of the R-equatorial (white)
and the S-equatorial (yellow) overlap however their purple and green side chains are pointing
in opposite directions; the same is true for the R-axial (orange) and the S-axial (magenta).
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Van der Bent et al. [208] suggested that the relatively low affinity difference between R and S
isomers of the benzodiazepine CCK-A antagonists could be rationalised by the mutual steri-
cal overlap of the two enantiomers in which both adopt either pseudo-axial or -equatorial side
chain orientations (Figure 5.13). In this superposition, the bulky C5-phenyl rings of the two
enantiomers are pointing in opposite directions (see Figure 5.13). From this conclusion it can
further be postulated that the pockets on both sides of the benzodiazepine rings are relatively
large and could even exhibit a certain symmetry, thus explaining the binding affinity of the
symmetrical 2,4-dioxo-1,5-benzodiazepines. Although the slight preference for the S-isomer
suggests that the pockets could have minor differences. With this data it can not be determined
whether the benzodiazepine CCK-A antagonist have either pseudo-axial or -equatorial orien-
tation. Experimentally determined structures of benzodiazepine compounds generally adopt
the pseudo-equatorial orientation (Figure 5.14), but calculations of van der Bent [208] demon-
strated a preference for the pseudo-axial orientations (orange and green structures of Figure
5.13). However, these calculations were performed in vacuum neglecting any explicit solvent
A
B
Figure 5.14: Stereo top and sideview of the superposition of the structures found in the CSD-
database with a benzodiazepine ring and an NHCO-moiety; the entries SABKJEK (2x, orange),
PIHFOB (green) and ZOVJUP (magenta).
environment, thus the resulting conformations might be artefacts, since vacuum-derived confor-
mations tend to adopt an overall compact, folded conformation. In our docking study described
in Chapter 6 it has been investigated whether the pseudo-axial or the pseudo-equatorial orienta-
tions are preferred in the binding site.
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Antagonist Binding Site
Identification of Antagonist Binding site:
A Molecular Docking Approach.
"The major discriminating force between different molecules that bind to a single
receptor is repulsion. This is another way of saying that the most important feature
is fitting in the simple geometrical sense."
• Graham Richards
(1992)
CHAPTER 6. ANTAGONIST BINDING SITE
6.1 Introduction
6.1.1 Direct and Indirect Drug Design
Designing new drug candidates is a challenging task for which structural information on the
target protein or protein-ligand complexes is of utmost importance. However, for many phar-
maceutical interesting areas no-high-resolution structure of the target protein is available, due
to the fact that the majority of these target proteins are membrane-bound proteins [26] for which
structure determination is a very time-consuming and difficult task. Our knowledge about the
three-dimensional structure of globular proteins has grown exponentially in the last decades.
Combining this structural information with low-resolution structures of a target protein of in-
terest with all the available biochemical experimental data for the target protein, enables re-
searchers of creating a three-dimensional model structure of the protein. We pursued this ap-
proach for the human CCK-B receptor as described earlier in Chapter 4.
A model of the protein, especially of the ligand binding site, can be improved by including
three-dimensional structure-activity relationship (3D QSAR) data of known ligands. These
structure-activity data of ligands can be derived by extracting common structural features be-
ing prerequisite for strong binding [38] or by using methods such as CoMFA (Comparative
Molecular Field Analysis) [210, 211] or CoMSIA (Comparative Molecular Similarity Index
Analysis) [212, 213]. When these comparative studies are pursued without accounting for the
protein, a so-called indirect drug design is employed. In contrast, a direct design approach
utilises an experimentally derived or a modelled protein structure for the purpose of molecular
design.
A pronounced disadvantage of indirect design methods refers to the alignment of the ligand set
which can be performed in several cases only ambiguously. Slight changes in the conformation
of the ligands or a modified selection of alignment features can have a huge influence on the re-
sulting molecular superposition. A much better and less ambiguous alignment is defined using
a protein binding site as restraint to define the ligands in their bound conformation and orienta-
tion. However, also in this case flexibility of the target protein, which can alter its conformation
while accommodating individual ligands properly, can not be taken into account. Therefore the
generated approximative binding sites do not necessarily resemble in detail the actual binding
modes.
The strength of the in the following applied method in this study results from a combination
of both design approaches. The ligand molecules are aligned to approximate the molecular
description of the putative protein binding site. This is in contrast to other 3D-QSAR meth-
ods (e.g. CoMSIA [212, 213]) in which an overall superposition is achieved by matching the
individual molecules sequentially onto a preselected reference molecule.
The unique feature of the applied DRAGHOME method is that the binding site of the protein
and the different ligand molecules are translated into abstract molecular descriptions. These
descriptions are, in analogy to the ligand alignment method SEAL (Steric and Electrostatic
Alignment) [214] and the 3D-QSAR method CoMSIA, soft Gaussian functions, which approx-
imate different molecular properties by functional property distributions in space.
In the following section, the theoretical foundations of this method are described.
129
CHAPTER 6. ANTAGONIST BINDING SITE
6.1.2 The DRAGHOME Docking Method
The total molecular property field p(−→r ) of a molecule is composed of single properties pi
located at −→ri declining with a distance depending Gaussian type function [equation 6.1].
p(−→r ) =
∑
i
pie
−α(
−→r −−→ri )2 (6.1)
The most important advantage of these functions is that, due to their ’smooth’ nature, any sin-
gularity at the origin of the individual properties is avoided. Therefore, no cut-off values are
required. The property distributions describe the features of the molecules which matter for
protein-ligand interactions; notably:
• volume occupancy in the binding site
• electrostatic properties
• H-bond donor
• H-bond acceptor
• lipophilicity
By the subsequent superpositions of the property distribution functions, the different molecules
are compared by determining their relative spatial similarity in terms of overlap of their prop-
erty distributions. Therefore, the similarity score S is proportional to the scalar product of the
different property densities of the superimposed molecules [equation 6.2].
S = −
∑
i∈p
∑
j∈L
pipje
−
1
2
α(
−→ri −
−→rj )2 (6.2)
The weighted sum of the contributions [equation 6.3] of the different property types results in
an overall description that is used to evaluate the placement of a ligand onto the binding site
representation.
Stotal = wvolumeSvolume + welectrostaticSelectrostatic + wacceptorSacceptor+
wdonorSdonor + wlipophilicitySlipophilicity
(6.3)
After determination of the orientation of the ligand molecule and the most representative model
of the protein, a ligand-receptor complex can be generated and relaxed in a subsequent MD-
simulation. The resulting minimised structures of ligand molecules and protein can be used as
subsequent input structures for a next alignment cycle. Following this approach, conformations
of the ligand molecules and the protein can be refined and optimised in an iterative manner. A
summary of the DRAGHOME method is given in the flowchart depicted in Figure 6.1.
6.1.2.1 Protein Binding Site Representation
A binding site is roughly assigned manually by selecting those protein atoms that fall into a
volume occupied by a set of overlapping spheres with a 6 Å radius centred around the key atom
of the side chain of an amino acid identified by mutagenesis supposedly as being involved in
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ligand molecule pharmacophore
model from alignment protein model
property distribution
property distribution
ligand molecule
average
property distribution
ligand molecules
average
property distribution
=
binding site
representation
superposition of property
distribution(s) of ligands
onto binding site
representation
protein-ligand
complexes
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interactions by
MD-simulation(s)
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• binding mode
• binding pocket
• SAR of ligands
flexible/optimized
conformation(s)
ligand molecule(s)
flexible/refined
protein models
Figure 6.1: The docking procedure in this study mutually superimposes molecular property dis-
tributions of ligand molecules (gray-border boxes) and protein models (dashed boxes). Through
an iterative refinement of both protein models and ligand conformations, the overlay is opti-
mised and 3D-QSAR can be derived.
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ligand binding. This area is then translated into a spatial description for the molecular properties
of the protein using the above-mentioned Gaussian functions.
The donor, acceptor and lipophilicity property distributions are described by putative interaction
sites generated with the program LUDI [215, 216]. LUDI maps the possible range of interac-
tions by placing multiple interaction sites around the exposed functional groups of the protein
residues according to rules derived from experimental information. Thereby, hydrogen-bond
acceptors are represented by CO-groups, hydrogen-bond donors by NH-groups, and lipophilic
sites by C-atoms, respectively. A weighting factor is applied according to the total number of
sites placed around a particular functional group. The LUDI assignment of donor and acceptor
functionalities is completed by searching over all protein N and O atoms, which could serve as
putative hydrogen-bonding partners for a docked ligand, within an 5 Å sphere around the gen-
erated LUDI sites. Furthermore, the volume principially available to the ligand, is generated by
merging all generated LUDI sites.
The volume occupied by the protein is approximated by Gaussian functions located at the posi-
tions of the protein atoms weighted by the radii of the respective atoms. In order to consider this
protein volume in relation with the aforementioned distribution functions, the protein volume
function is given an opposite sign. In addition, type-specific atom charges are assigned using
Kollman charges [217] as implemented in TRIPOS’ biopolymer force field.
In summary, the following molecular property functions are accounted for:
• ligand-accessible volume determined by LUDI
• ligand-inaccessible volume occupied by the protein atoms
• lipophilic sites of the accessible volume determined by LUDI
• putative H-bond donor partners determined by LUDI
• putative H-bond acceptor partners determined by LUDI
• charges attributed to the modelled protein atoms
The binding-site area is demarcated by applying soft boundaries, thus restricting the ligand to
binding site.
The molecular property distribution functions assigned to the protein binding site can be deter-
mined for different models of the same protein. By averaging the assigned functions of different
protein models a composite function is obtained, which reflects the flexibility and/or the uncer-
tainty of the protein model.
For a given position −→r with property pm in model m, the resulting average for N models is
given by equations [6.4] and [6.5]:
parithmetic(−→r ) =
1
N
∑
m∈M
pm(−→r ) (6.4)
pgeometric(−→r ) =
( ∏
m∈M
pm(−→r )
) 1
N
(6.5)
The resulting averaged property distribution is a new property distribution function. Arithmetic
averaging can be regarded as logical OR. If there is a finite property value in at least one of the
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models, the average will also possess a finite value at this point. On the contrary, the geometric
averaging is a logical AND. Only if all models possess a finite property value at a given position
the geometric average will also have a finite property value at his point. Since in this study a
global model of the protein should be achieved, the arithmetic average procedure was used for
averaging the distribution functions of the protein.
6.1.2.2 Ligand Representation
Similar to the representation of the repulsive protein volume, the volume of the ligand molecules
is described by Gaussian functions associated to the atoms and weighted by the atom radii
of the involved ligand atoms. The lipophilicity distribution function is assigned by using the
parametrisation of Ghose and Crippen [218] for the ligand atoms similar to the determination
of the volume distribution function.
The evaluation of the donor and acceptor distribution functions is based on the algorithms im-
plemented into SEAL [214]. The putative hydrogen-bonding interaction sites around the ligand
donor and acceptor groups are determined using a small set of predefined rules derived from
small molecule crystal data. Similar to the protein donor and acceptor distribution functions,
the ligand donor and acceptor distribution functions are weighted by the total number of sites
assigned to a particular functional group of the ligand. In addition, charges are assigned using
the Gasteiger-Hückel charges [219]
In summary, the following molecular property functions for the ligand are considered:
• ligand volume
• ligand lipophilicity
• putative H-bond donor partners
• putative H-bond acceptor partners
• charges attributed to the ligand atoms
Based on an alignment of the ligand molecules, an averaged property distribution for the aligned
ligands can be determined. Usually the geometric average (equation [6.5]) and not the arith-
metic average (equation [6.4]) is used, because the properties only present in all structures are
then highlighted. The property distribution functions of such a ligand alignment can be consid-
ered as field-based pharmacophore of the ligands. (Figure 6.1)
6.1.2.3 Docking Ligands onto the Binding Site Representations
In order to reduce computational efforts, data reduction is applied. The initial distribution func-
tions of volume and lipophilicity based on the atoms are approximated by distribution functions
based on a reduced set of centres. After this data reduction, the superposition can be achieved
straightforward.
The method for generating and optimising the ligand orientations during superpositioning was
adapted from the ligand alignment program SEAL [214]. In the first step, a number of starting
orientations is generated using a clique search algorithm. For each such starting orientation the
similarity score (equations [6.2] and [6.3]) is calculated. The ligand orientation with respect
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to the binding-site representation is optimised until the nearest local minimum of the simi-
larity score is reached [220, 214]. Hereby, only the best-scored starting orientations beyond
a pre-defined threshold were used. According to findings by Schafferhans et al., 50 starting
orientations allow for a satisfactory sampling of orientation space [221].
As a result of the ligand superpositioning onto the binding-site representation, a number of
possible solutions ranked according to their similarity score emerges for each ligand. Valida-
tion studies, preformed by Schafferhans [221] on crystallographically determined protein-ligand
complexes, have shown that the experimentally determined structures are not always found as
best solution. However, considering in addition the mutual similarity of the different ligand
molecules onto the binding-site representation, the experimentally determined orientation of
these ligands could be ranked as the best solution. This strategy to identify the best ligand-
docking solutions was also applied in this study. For this purpose, a combination of visual
inspection and computational analysis was performed.
6.1.3 Evaluation Docking Results
The difficult task to find the correct binding mode of a ligand with respect to its receptor is as old
as the lock-and-key concept of Fischer [222]. It plays not only an important role in molecular
docking, but also in the area of virtual database screening as well as for the scoring of de novo
designed molecules. For these application a reliable, but nevertheless rapid method is needed
to predict approximate binding affinities of a large and diverse set of ligands. Böhm [223]
developed such a general-purpose empirical function to estimate the free energy of binding for
a given protein-ligand complex of known 3D structure.
6.1.3.1 Binding Affinity
A quantitative knowledge of the binding process is essential to understand molecular recogni-
tion. This requires a detailed understanding of the physical forces involved in the interaction and
a measure to what extent these forces contribute to the overall binding process. The receptor-
ligand interactions are dependent on the concentration of the ligand and the protein, the type of
solution and the salts in the solution. A simple equilibrium process is given in equation [6.6].
RL
k+1
⇀↽
k−1
R + L (6.6)
In equation [6.6], R is the receptor, L the ligand, RL the receptor-ligand complex, k−1 the
association rate constant and k+1 the dissociation rate for the equilibrium, respectively. The
equilibrium constant for this reaction is given in equation [6.7].
Kd =
[R][L]
[RL]
(6.7)
Through fundamental thermodynamic equations, the relation of the binding constant and the
change in free energy (Gibbs energy) can be described as in equation [6.8].
4G = 4H − T 4 S (6.8)
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where4G is the change in free energy of a reaction,4H the change in enthalpy,4S the change
in entropy, and T is the temperature of the system, respectively. The relationship between the
free energy change and the dissociation of RL is given in equation [6.9]:
4G = 4G◦ + RT ln Kd (6.9)
At equilibrium under standard conditions4G = 0:
4G◦ = −RT ln Kd (6.10)
and:
4G◦ = 4H◦ − T 4 S◦ (6.11)
4G◦ is the standard free energy chance of the reaction when all of its reactants and products
are in their standard states.
Combining the two equations [6.10] and [6.11] yields equation [6.12]:
ln Kd =
4G◦
−RT
= −
4H◦
R
(
1
T
)
+
4S◦
T
(6.12)
where R is the gas constant (8.3143 J mol−1K−1), T is the absolute temperature (in K) and
4G◦ is the free energy change (in J) associated with the reaction under standard conditions (all
products/reactants present at 1M concentration, T = 298K and pressure 1 atm). This means that
a 10-fold variation of Kd at 25◦C corresponds to a 5.7 kJmol−1 change in4G◦, which is about
the free energy of even a weak to medium hydrogen bond.
The binding constant of a potent drug is about Kd = 10−9 M = 1 nM. At physiological tempera-
ture (310K) this relates to a change of -53.4 kJ/mol in free energy.
6.1.3.2 Scoring Function
In order to determine the binding constant, the difference between the free energies of the com-
plexed (c) and the uncomplexed (u) states have to be calculated according to equation [6.13]:
4G = 4Gc −4Gu (6.13)
Ajay and Murcko reviewed the complexities and the different approaches in calculating the free
energy differences of ligand-protein complexes [224]. Apart from the molecular mechanics
method to calculate the free energy difference, the “Master Equation” approach is another im-
portant and intensively used method. In this approach, the first step is to factorise the binding
free energy into different components, such as:
• Overall loss in entropy due to association (loss in translational and rotational entropy of
the rigid components (protein and ligand))
• Hydrophobic energy (entropy gain of water due to the binding of the ligand)
• Entropy loss of receptor and ligand due to immobilising rotational and translational de-
grees of freedom of ligand and receptor
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• Interaction energy between ligand and receptor in which water molecules can play an
important role. A major portion of this interaction energy is the electrostatic interaction.
• Changes in steric interaction energy on binding.
• Changes in conformational energy of the receptor and ligand upon binding.
An assumption which is made in approaches using this factorisation, is that the components
of the free energy change can be calculated separately and that they are additive (equation
[6.14]) [224].
4Gbinding = 4Gmotion +4Ginteraction +4Gsolvent +4Gconformation (6.14)
An important simplification in the calculation of free energy is that the computed complex is
expressed by only one unique structure. A more realistic picture has to consider an ensemble
of structures which dynamically interconvert. However, it is assumed that the dynamic nature
of the complex will not significantly affect the total estimate of binding energy difference. The
components and accuracy of scoring functions have been reviewed [225, 226, 227, 228, 229].
6.1.3.3 Pharmacophore Determination
Apart from binding affinity prediction using a scoring function, pharmacophore determination
is a further method to evaluate docking results of a series of ligands.
A pharmacophore is a 3D-model describing in a semi-quantitative manner the requirements
imposed on to a ligand compound in order to experience a certain binding affinity towards the
receptor protein. The quantitative correlation of molecular structure with binding affinity of a
ligand towards its receptor is the goal of a quantitative structure-activity relationship (QSAR)
study. Subsequently, the derived correlation model can be used to predict the binding affinity
for novel compounds. A variety of methods are available, such as the classical QSAR methods,
e.g., the Hansch-Analyse or the Free-Wilson method, but also 3D-QSAR methods, e.g., CoMFA
[210, 211], CoMSIA [212, 213] and SEAL-field comparisons [214, 230]. In this study, we have
applied the three mentioned 3D-QSAR methods.
The 3D-QSAR methods CoMFA [210, 211] and CoMSIA [212, 213] are grid-based approaches
to derive an active-site model for the receptor in terms of molecular electrostatic, steric and
hydrophobicity fields. In the CoMFA analysis, a sufficiently large box containing a grid with a
certain grid spacing is positioned around the aligned molecules. Different atomic probes, e.g.,
a carbon atom, a positively or negatively charged atom, a hydrogen bond acceptor or donor,
or a lipophilic probe are used to calculate field values on each grid point for each molecule.
These field values are the energy values, the probe would experience at the corresponding grid
intersections when it would interact with a particular molecule. A PLS analysis is used for
correlating the biological activities with the field values. Normally, cross-validation is used to
check the predictive power of the derived model. [211]
Within CoMSIA, SEAL similarity fields [212, 213] are calculated at the grid points. These
similarities are not a direct measure of similarity between all mutual pairs of molecules, but
they are indirectly evaluated via the similarity of each molecule in the data set with a common
probe atom placed at the grid points. The advantage of CoMSIA is the smooth nature of fields
with a Gaussian type distance dependence. This is in contrast to the CoMFA fields which
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have singularities at the atomic positions since Coulomb or Lennard-Jones potentials are used
[212, 213].
The results of the CoMFA/CoMSIA analysis are usually evaluated in terms of contribution
maps. The contour maps display favourable and unfavourable steric regions, favourable and
unfavourable regions for electropositive or electronegative substituents, or favourable and un-
favourable regions for lipophilic or hydrophilic substituents in certain positions of the molecules.
[210, 211, 212, 213]
It is recommended that the set of molecules is sufficiently large and diverse in structural and
affinity terms. Furthermore, the prediction of the binding affinity of novel compounds requires
that they resemble the molecules in the training set, thus the method can only interpolate, not
extrapolate. Underlying assumptions of the method are: (i) all molecules follow the same mode
of action, (ii) occupy the same receptor binding site and (iii) adopt a comparable binding mode.
3D-QSAR methods are only reliable for relative comparisons of related structures. The ap-
proaches can only interpolate, attempts to extrapolate beyond the information comprised in the
data used for training cannot provide reasonable results. Furthermore, the results of a CoMFA
or CoMSIA analysis are not only depending on the training dataset, but also on the alignment
of the structures and the conformations of the structures of the training set. The alignment
should represent as closely as possible the relative geometry of the compounds when accom-
modated in the binding site of the receptor protein. In order to prove the validity of the derived
CoMFA/CoMSIA-model, the consideration of an independent test set is mandatory [211].
A possible method to generate a reliable alignment of a set of molecules is implemented into the
SEAL program [214, 230]. The alignment condition of SEAL is based on the mutual similarity
indices pairwise calculated between all atoms of the molecules being compared. The program
tries to align two molecules rigidly so that similar properties are located close to each other
in both molecules. A molecule is described in terms of set of spatial distributions of charge,
density (volume), lipophilicity and hydrogen-bond features, whereby every atom is represented
by a Gaussian distribution endowed with a property vector. A molecule corresponds to the
sum of such distributions. The SEAL program has been extended and improved by Klebe et
al. [230]. The program TORSEAL [230] uses the alignment condition of SEAL, however it
applies a geometry optimisation in torsion angle space considering van der Waals interactions
together with empirically derived potentials. The later potentials are based on statistically evalu-
ated torsional fragments retrieved form the Cambridge Structural Database. In the optimisation
step, the initially generated geometries are minimised to remove unfavourable steric contacts
between adjacent atoms in a molecule, simultaneously keeping the torsion angles as close as
possible to the most frequently occurring values in experimental structures. TORSEAL fits
flexibly a set of molecules onto a rigid reference simultaneously considering atomic properties
such as hydrogen-bond acceptor and donor abilities, the charge distribution and lipophilicity for
similarity fields in the alignment procedure [230].
However, an alignment can also be obtained as the result of a docking procedure. Both kind of
alignment procedures were used in this study.
The property fields of the SEAL method can also be applied in the development of a pharma-
cophore. For all aligned molecules, property fields are calculated and these property fields are
geometrically (the AND-method) or arithmetically (the OR-method) averaged. The new fields
are then approximated by new sums of Gaussian distributions and these can be visualised by
contour maps representing the features of a field-based pharmacophore.
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6.2 Method
All calculations, analyses and molecular simulations were carried out on Silicon Graphics O2
workstations and on a Silicon Graphics Origin parallel computer equipped with 20 R12000 pro-
cessors. The interactive model building and graphical analysis were mostly done using the pro-
grams included in the molecular modelling software package INSIGHT II (version 98.0) from
Biosym Technologies (San Diego, CA). Molecular dynamics simulations and energy minimisa-
tions were performed using the consistent valence force field (cvff) without Morse potential or
cross terms as implemented in the DISCOVER simulation package (version 2.98). All the com-
parative molecular field evaluations and some of the interactive modelling for the DRAGHOME
docking procedures were performed using SYBYL version 6.5 and 6.6.
6.2.1 The Protein Model
The receptor protein of interest in this study is the human CCK-B receptor. The construction of a
3D-model for this receptor was described in Chapter 4. The different conformations needed for
the docking procedure with the DRAGHOME program were derived from a molecular dynam-
ics simulation, which was described in Chapter 4. The 750 different conformations of the last
750 ps (301-1050 ps) of the molecular dynamics simulation are considered as representatives
covering the conformational space accessible to the protein. The program NMRCLUST [231]
was used to determine the most representative models out of these 750 conformations. This
program superimposes the different conformations and subsequently clusters the superimposed
conformations with respect to the root mean square deviation (RMSD) of several selected atoms.
In order to be able to cluster the structures and to derive the most representative conformations
of these clusters, reference atoms have to be assigned. The atoms used for superpositioning
were the backbone heavy atoms of the determined transmembrane domain sequences (refer to
Chapter 3: residues I:33-59; II:64-90; III:103-137; IV:145-169; V:197-226; VI:241-270 and
VII:287-310 of the human CCK-B receptor). As clustering atoms, the keys atoms of the amino
acid residues were selected, which were determined in several mutagenesis experiments [147,
232, 233] to be important for antagonist binding (see Table 6.1). The applied pre-set threshold
for the clustering cut-off was set to 1.25 Å in order to obtain a reasonable number of clusters.
To estimate the conformational behaviour of these 14 residues, their χ1 and χ2 sidechain tor-
sions were analysed.
The obtained representative conformations of the receptor were used in the subsequent proce-
dure of building the protein binding site representation (6 Å around each key atom of Table 6.1)
with the DRAGHOME program.
6.2.2 The Ligands
In Chapter 5 an overview of the CCK-B antagonists was given. In Table 6.2, a selection of
these compounds is listed which were investigated in this docking study. These compounds
all possess a rather rigid structure. Furthermore, they exhibit a large structural variation with
respect to their attached substituents and a large spread in biological activity.
A search in the Cambridge Structural Database (CSD) was performed to retrieve compounds
with close structural similarity to our ligands in order to suggest a plausible starting conforma-
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residue no. amino acid key ref.
in human CCK-B atom mut. data
57 Arg NE [147]
100 Asp OD1 [150]
111 Thr OG [147]
131 Ser OG [147]
219 Ser OG [147, 149]
227 Phe CZ [232]
342 Phe CZ [232]
346 Trp NE1 [149, 232]
349 Val CG1 [147, 233, 149]
350 Tyr OH [149]
353 Asn OD1 [149, 234]
356 Arg NE [147]
376 His ND1 [147]
379 Ser OG [149]
Table 6.1: Key atoms of amino acid residues that were identified by mutagenesis as being in-
volved in antagonist binding.
tion. These conformations were then used as basis for the modelling of the remaining ligands.
As an initial test for the general applicability of the docking approach, a first rigid docking trial
was performed for the 41 ligands of Table 6.2, using only one conformation for 34 ligands and
two conformations (pseudo-axial and pseudo-equatorial, see Figure 5.14 Chapter 5 [208]) for
7 ligands. These conformations were obtained by a mutual alignment using TORSEAL [230].
For this purpose, compound 89 was used as the reference molecule, since it is the most rigid
entry in the data set. Since TORSEAL performs only a local optimisation into the next local
minimum of the alignment space a reasonable preorientation of the considered molecules has
to be ássumed. For the benzodiazepine derivatives it is clear that the benzodiazepine moieties
should be aligned. However, the superpositioning of the quinazolinone derivatives and the
diphenylpyrazolidinone derivatives onto the benzodiazepine derivatives is difficult, since they
do not share obvious structural similarity with the benzodiazepine derivatives.
After the initial rigid docking trial the following points were considered:
• One of the strengths of the docking approach of DRAGHOME is the independent docking
of the ligands within the representation of the binding-site. However, by assuming an ini-
tial mutual prealignment, there will be some dependence of the generated conformations
of the docked ligands with respect to the conformation of the reference molecule.
• Although, the alignment obtained by TORSEAL indicates that the ligands have similar
property fields, the initial mutual alignment was not reproduced in the first rigid docking
trial. This might indicate that several ligands as, e.g., the quinazolinone derivatives, might
adopt a slightly different binding mode and/or conformation than was suggested by the
mutual alignment.
• The quinazolinone derivatives and the diphenylpyrazolidinone derivatives have possibly
a slightly different binding mode in respect to compound 89. This could explain the diffi-
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compound nr., CCK-B exp. axial
firm name affinity 4G and/or
[nM] [kJ/mol] equit.
44 LY-247348 26 -44.372
48 585 -36.462
49 137 -40.150
50 14 -45.945
51 108 -40.754
52 29 -44.095
53 1.0 -52.650
54 11 -46.558
55 97 -41.027
56 63 -42.124
57 LY 288512 370 -37.626
58 LY 288513 19 -45.169
60 LY 294920 1900 -33.469
61 LY 294919 550 -36.619
31 L-364,718 270 -38.427 E + A
66 "L-364,718-R" 3700 -31.776 E
71"L-365-260-S" 151 -39.903 E + A
72 L-365,260 2.0 -50.889 E
73 L-740,093 0.1 -58.500 E
73S "L-740,093-S" N.T.1 E
74 L-708,474 0.28 -55.884 E
75 YM-022 0.11 -58.258 E + A
75S "YM-022-S" N.T.1 E + A
76 L-368,935 0.14 -57.645 E
77 L-738,425 0.11 -58.258 E + A
78 0.58 -54.034 E
79 7.5 -47.531 E
80 1.1 -52.408 E
81 L-736,380 0.054 -60.065 E
82 137 -40.150 E
83 1.5 -51.620 E
84 54 -42.515 E
85 18 -45.307 E
87 480 -36.965 E
88 23 -44.684 E
89 8 -47.367 E + A
90 2 -50.889 E
92 84 -41.393 E
97 1 -52.650 E
98 48 -42.815 E
100 26 -44.372 E + A
1 N.T. = not tested.
Table 6.2: The compounds of Chapter 5 used in this docking study. The last coulom describes
for the benzodiazepine derivatives which orientation of the 3-amide sidechain was used, namely
the pseudo-axial (A) and/or the pseudo-equatorial (E) orientation (see also Figure 5.14).
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culties in the alignment of the quinazolinone derivatives and the diphenylpyrazolidinone
derivatives to compound 89 using TORSEAL.
• The initially assumed prealignment for TORSEAL biases the conformations of the lig-
ands used for rigid docking.
• A more realistic approach would be, not only to account for receptor flexibility and re-
ceptor conformational uncertainty by using several receptor conformations (see section
6.2.1), but also to account for ligand flexibility and a possible multiplicity of ligand bind-
ing modes by using multiple conformations of each ligand.
Therefore, it would be preferable to dock in a second docking trial multiple conformations of a
ligand and select after the docking step, the best docked conformation of this ligand based on
the criteria imposed by the binding site representation. Schafferhans et al. [221] also tackled
the problem of accounting for ligand flexibility by using pre-calculated multiple conformations
for each ligand.
In order to examine the conformational freedom of the ligands and to obtain the possible con-
formations of a ligand, Monte Carlo-based conformational analyses (MOCCA) [235] were per-
formed for all the ligands. The parameters were set to the values given in Table 6.3. In this
approach all rotatable bonds are allowed to move. However, by allowing only the torsion angles
to rotate, the so-called “flipped” conformation of the benzodiazepine derivatives (the 3-amide
side chain in the pseudo-axial position instead of the pseudo-equatorial position, see Figure
5.14, Chapter 5 [208]) could not be obtained in a MOCCA analysis [235]. Consequently, for
some benzodiazepine derivatives MOCCA analyses were done with a “flipped” benzodiazepine
ring conformation (see Table 6.2).
parameter value
force field cvff
dielectric constant 80
start temperature of the simulation 10000 K
end temperature of the simulation 300 K
number of Monte Carlo steps 1000
start angle change 180◦
exponent for the torsion angle scaling -0.002303
scaling factor for hydrogen-bonds 0.70
scaling factor for the chirality energy 1.0
standard randomvalue 4711
number of structures 900
Table 6.3: The parameters of the MOCCA program used for the calculations.
6.2.3 Docking of the Ligands
As mentioned before, an initial docking trial was performed in order to test the applicability of
the docking approach. In this initial trial a rigid docking was performed for the 41 structures
of Table 6.2, using only one conformation for 34 ligands and two conformations for 7 ligands.
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These conformations were obtained by mutual alignment using TORSEAL. The docking of
these 48 structures was done interactively and the results were analysed by visual inspection of
the obtained solutions for every ligand.
A flexible docking was performed in the second docking trial by using pre-calculated multiple
conformations for each ligand generated by a MOCCA analysis [235]. The docking procedure
and the selection of the best solutions for each ligand in this docking trial were automated by
computer scripts, since 900 conformations for each structure had to be docked in the binding
site representation.
For each docking solution, DRAGHOME gives a normalised total score, a hydrophobic, a steric,
an electrostatic, a donor, and an acceptor score, respectively. The total score is a weighted sum
of the five different scores (equation [6.3]). This total scores was optimised by reproducing
best the ligand binding modes for a set of crystallographically determined thrombin-inhibitor
complexes. For this test set the electrostatic property contributed very little to the total score
[221]. Possibly, the electrostatic property displays redundant information, since it is located
mainly in the same regions as the acceptor and donor properties [221]. It is therefore likely that
the considered physico-chemical properties are not linearly independent and in the present study
it is assumed that excluding the electrostatic property will not affect the results significantly.
Furthermore, Schafferhans et al. [221] mention that the total score is strongly dominated by the
steric property. The normalised contributions of the five properties is 98.0, 1.9, 2.9, -2.9 and
<0.1 for steric, acceptor, donor, lipophilicity and electrostatic properties, respectively. However,
the total variance of the properties is more important than their contribution, since orientations
are optimised and ranked according to their scoring differences. If the contribution of one
property is almost constant, it cannot render prominent one particular orientation. Although
the steric contribution to the score variance is still larger than the contributions of the other
properties, it is less dominant than the steric contribution to the total score. The contributions to
the variance are for the steric, acceptor, donor, lipophilic and electrostatic properties, 7.4, 0.8,
1.6, 1.0, and 0.1, respectively [221].
In the initial visual inspection of the docking results obtained in the first initial rigid docking
trial with 48 structures, the domination of the steric property was clearly observed. The steric
property dominated the total score rather strongly, thus the ranking of the docking solutions
was mainly based on the steric contribution and the contributions of the other properties are
of very little importance. It can be hypothesised that the weighted sum, optimised by using
thrombin-inhibitor complexes, is not necessarily representative for the application to other pro-
teins. Therefore, other criteria than the total score given by DRAGHOME were applied to select
the best docking solutions out of the different solutions produced by DRAGHOME.
The first method is based on the idea that a solution with high rankings in all four different
properties will be a good solution. The variance within a property, represented by the rankings,
is in this selection method more important then the quantitative score of a property. For each
docking performed by DRAGHOME, the scores of each property were ranked. The rankings
were multiplied with an exponential function in order to favor the high rankings more than
the low rankings. The resulting weighted ranking number of the four different properties were
averaged to a total weighted ranking number following a consensus scoring philosophy. The
best solution is then the solution with the lowest total weighted ranking number. This is the
solution on average ranked the highest in all the four scores.
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In the second flexible docking trial, for every docked conformation of a ligand the best two
solutions were selected with the lowest total weighted ranking number. These selected solu-
tions (1800 for every ligand) were for each ligand again ranked to each other using the above
described ranking procedure. The 10 solutions with the lowest total weighted ranking number
were selected for visual inspection.
Schafferhans et al. [221] evaluated a strategy to identify the best solutions on the basis of the
spatial similarity of various solutions generated for the different ligands for internal similarity
consistency, even if they are not scored on the first rank by DRAGHOME. This strategy is of
course only valid as long as the ligands bind to the same binding site. A similar strategy can
also be applied in this study.
On basis of the spatial similarity strategy of Schafferhans et al. [221] and the visually inspected
results an extra selection rule was defined. The best 10 solutions of compound 76 (L-368,935),
a ligand with a high affinity for the CCK-B receptor, were all in a very similar position. Their
urea-group, an essential group for CCK-B antagonists (see Chapter 5), was positioned in close
proximity to the amino-acid residue Ser379. Also many solutions of the other benzodiazepine
ligands are found in a similar orientation. Therefore, it was hypothesised that an acceptable
solution should have its urea group, or at least a similar group, in an area of 3 Å around the
urea group of compound 76 (L-368,935). This selection rule will be called in the following
the “urea-group”-rule. For the quinazolinone and the diphenylpyrazolidinone ligands both O-
and/or S-atoms were applied subsequently in this “urea-group”-rule.
The number of solutions from the top 100 which follow this rule were counted and could be
an indication for the quality of the docking in analogy to a selection criterion of the docking
approach of Baxter et al. [236]. The solution which followed the “urea-group”-rule and had the
highest rank/the lowest total weighted ranking number was selected as the best solution of the
ligand. In an ideal situation it could be found on the first rank.
However, the selection of the best solutions on basis of the average of the weighted rankings of
the four properties combined with the “urea-group”-rule is not a validated selection criterion,
since this strategy is not tested on ligand-receptor complexes for which the experimental binding
affinity and binding geometry are known. Furthermore, the results are depending on the applied
weighting functions and the “urea-group”-rule is only based on the hypothesis that the amino-
acid residue Ser379 interacts with an O- and/or S-atom of the ligand. Mutagenesis data suggest
that Ser379 plays a role in ligand binding, but its specific role in the binding modus of a ligand
is not yet known. Therefore, a second selection strategy was applied.
This selection strategy is not based on such hypothetical rules. It takes advantage of the large
number of solutions created by DRAGHOME by docking a large number of different con-
formations for a single ligand (900 conformations for each ligand). All solutions created by
DRAGHOME for one ligand were clustered on the basis of the root mean square deviation
(RMSD) of their heavy atoms. This grouping method is not a stringent clustering that can be
performed with the program NMRCLUST [231], since this kind of clustering of all solutions
obtained by DRAGHOME for one ligand would be computationally too intensive. The ap-
plied method calculates the RMSD between the considered solution and the first member of
a group. When this RMSD is smaller than a given RMSD threshold, the solution is added to
this group. However, when the solution could be assigned on basis of the threshold to several
groups, it is merged to the group with the smallest RMSD value. If all calculated RMSD values
are greater than the pre-defined RMSD threshold, the solution underconsideration forms a new
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group. Thus, at the end, all members of a group have a RMSD value to the first member of
the group smaller than the RMSD threshold, but not necessarily to each member of the group.
Furthermore, the RMSD value between a member of one group and a member of another group
could be lower than the RMSD threshold, but the RMSD value between the first member of
a group and the first member of any other group is always greater than the RMSD threshold.
Schafferhans mentioned in her thesis [237] that solutions with a RMSD smaller than 2 Å can be
considered as solutions with similar orientations within the binding site representation. There-
fore, a RMSD threshold of 2 Å was applied in the final grouping in order to obtain groups of
solutions whereby the different groups represent different orientations and the members of one
group have similar orientations. However, since the computing time is highly depending on
the number of groups formed, first a preclustering was performed with a threshold of 7 Å. The
most populated groups (the number of solutions) with the highest number of hits (every solu-
tion can be obtained several times in one docking trial by DRAGHOME and the summation
of these countings over all members of a group is the amont of hits) and a low average of the
total scores of all the members were selected for the final grouping. In cases were these three
criteria do not hold simultaneously, the criterion considering the highest number of members
is dominant, whereby the number of hits has to be at least twice the number of members of
the group and the average of the total scores of the members has to be in the top 10 of lowest
averages of the total scores. This selection of the best groups is done by manual intervention.
Therefore, the selection is not totally unbiased, but the selection was done with the utmost care
and consistency.
The solutions of the selected groups were clustered in a second attempt, but now using a RMSD
threshold of 2 Å. The best group with the best solutions of DRAGHOME was selected by
the same selection strategy as was applied in the preclustering. However, a spatial similarity
criterion based on the strategy of Schafferhans et al. [221] was also taken into account during
the visual inspection of the results.
6.2.4 Energy Minimisation and Molecular Dynamics Simulations
The binding-site representation calculated by DRAGHOME is an average representation. Con-
sequently, complexes modelled by applying the DRAGHOME-derived positions of the docked
ligands with one of the representative models of the receptor are not of refined geometry, since
they still could be affected by unfavourable contacts between receptor and ligand. Therefore,
a scoring function to rank the docking solutions is not yet applicable. The structure of such
a complex has to be relaxed following an energy minimisation and/or a molecular dynamics
simulation. The details of the protocols of these calculations are summarised in Tables 6.4 and
6.5.
For every ligand five complexes were modelled by placing into five different receptor models
the best DRAGHOME solution following the above-described selection strategy including the
weighted rankings of the four properties and the “urea-group”-rule. The five receptors models
were the representative conformations of the top five clusters of the receptor conformations of
the molecular dynamics run of Chapter 4 (see Table 6.6). The computationally more extensive
protocol of Table 6.5 was used only for selected complexes. The best DRAGHOME solution of
the compounds 50, 53, 57, 66, 73, 75, 80, 81, 84, and 89 were placed into the binding site of the
representative conformation of cluster 4, frame 393 of the molecular dynamics run of Chapter
4, since it is the most representative conformation of the 14 clusters of the receptor.
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method number of step force fix/tethering
kcal/Å
1. template force, 1000 100 fix backbone protein
steepest descents tethering urea-group + side chains protein
force on urea-group torsions
2. template force 500 100 fix backbone protein
steepest descents tethering urea-group + side chains protein
force on urea-group torsions
3. minimize 500 - fix backbone protein
steepest descents force on urea-group torsions
4. minimize 1000 - fix backbone protein
conjugate gradients force on urea-group torsions
Table 6.4: Energy minimisation protocol of the protein-ligand complexes.
force
method number [kcal/Å] fix/tethering
of steps or temp. [K]
1. template force 2000 1000 fix backbone TMDs protein
steepest descents tethering side chains TMDs protein
force on urea-group torsions
2. template force 2000 1000 fix backbone TMDs protein
conjugate gradients tethering side chains TMDs protein
force on urea-group torsions
3. template force 2000 100 fix backbone TMDs protein
steepest descents tethering side chains TMDs protein
force on urea-group torsions
4. template force 2000 100 fix backbone TMDs protein
conjugate gradients tethering side chains TMDs protein
force on urea-group torsions
5. template force 2000 10 fix backbone TMDs protein
steepest descents tethering side chains TMDs protein
force on urea-group torsions
6. template force 2000 10 fix backbone TMDs protein
conjugate gradients tethering side chains TMDs protein
force on urea-group torsions
7. minimize 5000 - fix backbone TMDs protein
steepest descents force on urea-group torsions
8. minimize 5000 - fix backbone TMDs protein
conjugate gradients force on urea-group torsions
9. initialize dynamics 2000 10 force on urea-group torsions
10. resume dynamics 48000 10 force on urea-group torsions
11. resume dynamics 100000 150 force on urea-group torsions
12. resume dynamics 75000 300 force on urea-group torsions
13. resume dynamics 25000 150 force on urea-group torsions
14. resume dynamics 25000 10 force on urea-group torsions
Table 6.5: Energy minimisation and molecular dynamics simulation protocol of the protein-
ligand complexes.
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6.2.5 CoMSIA Analyses
For the CoMSIA analysis the standard SYBYL parameters were applied. The grid spacing of
the lattice was 1 Å and by changing the grid box coordinates manually consistent grids were
used in both analyses.
The statistical significance of the models were checked by leave-one-out cross validations with
the SAMPLS method. The optimal number of components was determined by selecting the
smallest sPRESS value which usually corresponds to the highest q2 value. They were computed
as defined in SYBYL. The same number of components was subsequently used to derive the
final QSAR models.
By scrambling the biological data and repeating the model derivation process, the consistency of
the derived models were checked. Negative values for q2 in the PLS analysis are then expected.
These CoMSIA analyses were done for two alignments of the ligands. The first alignment
was obtained by using the best solution of the second flexible docking trial with DRAGHOME
selected with the strategy on the basis of the average of the weighted rankings of the four
properties in combination with the “urea-group”-rule. The second alignment was obtained by
visually selecting for each ligand of the first alignment a representative conformation of the five
minimised conformations of each ligand (see also section 6.2.4).
6.2.6 Docking of CCK-4 and CCK-8
For reasons of qualitative comparison between the binding of antagonists and endogenous lig-
ands, an additional docking procedure was carried out for two peptides, notably CCK-4 and
CCK-8. For this purpose, the same procedure was followed as described for the antagonists.
Only within the MOCCA [235] calculations distance restraints were applied in order to avoid
artificially contracted conformations, since the peptide binds in an extended conformation to
the receptor [120]. Again, 900 conformers were created for each ligand which were all sub-
sequently docked in the binding site representation created by DRAGHOME using the same
procedures as were applied for the antagonists.
6.3 Results and Discussion
6.3.1 Protein Receptor Conformations
The 750 conformations of the 3D-model of the human CCK-B receptor described in Chapter 4
were clustered into 14 clusters by NMRCLUST [231]. The details of the RMS distribution of
the clusters and the number of members are given in Table 6.6. The representatives of these 14
clusters were used in the subsequent docking procedures.
In order to determine the flexibility of the side chains of the 14 amino acid residues identified
by mutagenesis as important for ligand binding (Table 6.1), their χ1 and χ2 torsion angles were
evaluated (except for Val349, which has no χ2 torsion angle). Graphs of the torsion angles
χ1 versus χ2 are depicted in Figure 6.2 for the 13 amino acid residues. It can be seen that
Arg57, Phe227, Phe342, Trp346, Tyr350 and His376 adopt a preferred sidechain conformation,
Thr111, Asn353, Arg356 and Ser 379 display a moderate distribution, while Asp100, Ser131
and Ser219 show almost unrestricted conformational variability around their χ2 torsion. Only
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Figure 6.2: χ1 and χ2 torsion distribution of 14 representative receptor conformations of amino
acid residues identified bu mutagenesis as being crucial for antagonist binding.
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cluster number of spread frame number
members in RMS (Å) of representative
within cluster conformation
1 187 1.116 1040
2 109 1.139 687
3 94 1.074 753
4 73 1.036 393
5 70 1.106 565
6 69 1.059 618
7 38 1.078 663
8 30 0.924 819
9 26 1.112 328
10 17 0.967 321
11 11 1.022 343
12 9 1.051 526
13 8 0.799 811
14 7 0.914 306
outliers 2 -
total: 750
Table 6.6: Size, RMS-spread, and frame number of the reprensative conformation of the clusters
created by NMRCLUST [231].
Arg57, Ser219, and His376 expose their side chains in or in close proximity to the water com-
partment, while the other side chains are all buried within the protein as discussed in Chapter
4.
6.3.2 First Docking Attempts
Before we applied the DRAGHOME docking method in this study, the docking programs FlexX
[238, 239] and FlexiDock (a module in SYBYL) were tested. However, the docking results of
FlexX were not in agreement with any experimental evidence, as, e.g., the mutagenesis data
(Table 6.1). The program was only able to identify binding modes at the outside of the receptor,
i.e. the extracellular loop region. The results of FlexiDock were better, but they were highly
depending on the start conformation of the protein-ligand complex, thus giving no convergent
results. Thus both docking routines were not further applied in this study.
6.3.3 Docking with DRAGHOME
6.3.3.1 Representation of the Binding Site
The DRAGHOME program calculates the representation of the binding site based on five
molecular property functions:
• volume accessible to the ligands
• volume inaccessible for the ligands
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• lipophilic sites inside the accessible volume
• putative H-bond donor partners
• putative H-bond acceptor partners
These five calculated molecular property functions of the binding site can be depicted in terms
of contour maps as shown in Figures 6.3, 6.4 and 6.5, respectively. The extracellular and intra-
cellular membrane planes are approximately at contour-map-levels of +6 Å and -26 Å, respec-
tively. These contour levels correspond to the dimensions of the box around the representation,
it is not a measure of the membrane height.
From the 12 volume contour maps it can clearly be seen that cavities exists within the upper part
of the transmembrane domain of the receptor. From contour map +8 to 0 Å and from -4 to -12
Å cavities between the helices 3, 4, 5, 6 and 7 can be identified. Between the helices 1, 2, 3 and
7 a cavity stretches from contour map 0 to -4 Å. The first two cavities are located approximately
at the position of the binding site of the mono-amine receptors (see Figure 2.3) [240, 118]. The
third cavity is located near the important residue His376.
As can be expected, donor and acceptor sites are found in spatial proximity of the backbone
atoms of the receptor protein. However, in several contour maps the distribution functions of
putative donor and acceptor partners possess high values at sites between the helices. A dense
donor functionality can be found in the contour map at +8 Å in the upper part of the first cavity
in proximity to helix 3 and in proximity to the amino acid residues His207, Arg208, Arg356
and Tyr192. Further, in map +2 Å between the helices 3 and 7 there is a high density of donor
functionality, probably caused by Tyr189 at helix 4, Met134 at helix 3, His376 at helix 7 and
several backbone atoms, respectively. The area between helices 3 and 7 is in numerous contour
maps assigned to a high density of donor and/or acceptor functionality. The contour maps
between 0 and -6 Å of the acceptor functionality and the contour maps between -4 and -8 Å of
the donor functionality show enhanced densities. Most likely, both densities orginate from two
amino-acid residues which possess dual character being either donor and/or acceptor. These
two residues are Ser137 and Ser379 at helix 3 and helix 7, respectively. The later residue has
already been rationalised as important for antagonist binding through mutagenesis studies [147]
and Ser137 is located one helical turn below the position of the key aspartate residue of the
mono-amine receptors [79], supporting the hypothesis of a similar location of binding sites for
the small ligands within different GPCRs [32, 28].
In the upper part of the second cavity, a high density of acceptor functionality is found which
might result from the presence of Asn353 at helix 6. Also this residue has been identified as
being involved in ligand binding. However, not only these enhanced putative donor and ac-
ceptor functionalities at several locations in the receptor are interesting, furthermore the lack
of comparable profiles between helices 3, 4, 5, 6, and 7 in the acceptor distribution maps be-
tween -4 and +14 Å and in the donor distribution maps 0, -6 and -8 Å are remarkable. When
this indication is combined with the observation that in exactly this area of the contour maps a
strong contribution of lipophilic potential is found, it can be hypothesised that the second cavity
which is located in the same area is of rather hydrophobic nature with only a few possibilities
for hydrogen bonding. In contrast, the third cavity has almost no hydrophobic properties as
shown in the contour maps from 0 to -4 Å.
It should be emphasised that the contour maps shown in Figures 6.3 to 6.5 are not computed
for rigid entities, they represent an averaged property distributions across 14 representative
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Figure 6.3: Property distribution maps averaged over the 14 conformations of the human CCK-
B receptor calculated by DRAGHOME for putative acceptor (acc) and donor partners (don),
lipophilic sites of the accessible volume (hydro) and the allowed and disallowed volume (vol).
The positions of the maps are depicted in the square at the bottom left. The map at +8 Å is in
the extracellular part of the receptor, the map at 0 Å approximately in the center of the binding
site and the map at -18 Å is in the intracellular part of the receptor. The colour legends are also
depicted at the bottom.
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Figure 6.4: Property distribution maps averaged over the 14 conformations of the human CCK-
B receptor calculated by DRAGHOME for putative acceptor (acc) and donor partners (don),
lipophilic sites of the accessible volume (hydro) and allowed and disallowed volume (vol). The
positions of the maps and the colour legends are depicted in Figure 6.3.
conformations of the receptor protein. However, these property distributions of the receptor are
used for the subsequent alignment to match with complementary molecular properties of the
ligands.
6.3.3.2 Docking with TORSEAL Alignment
In order to start with a reasonable conformation, the ligands were modelled with a conformation
based on the crystal structures found for some representatives in the CSD (see also Figure 5.14,
Chapter 5). All ligand molecules were then aligned to compound 89. This compound shows
the most rigid skeleton in the data set and it is assumed that all ligands bind with a similar
overall shape to the same binding site. All benzodiazepine derivatives could be well aligned to
compound 89 using TORSEAL after a preorientation of the benzodiazepine part with respect
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Figure 6.5: Property distribution maps averaged over the 14 conformations of the human CCK-
B receptor calculated by DRAGHOME for putative acceptor (acc) and donor partners (don),
lipophilic sites of the accessible volume (hydro) and allowed and disallowed volume (vol). The
positions of the maps and the colour legends are depicted in Figure 6.3.
to the reference has been applied. Only the R-enantiomer of L-364,718 (66), was somewhat
less well aligned (“black” structure in Figure 6.6A). This is due to the lack of an urea group
within the compound. The S-enantiomers of the benzodiazepine derivatives could be aligned to
compound 89 after a ring flip analog to the suggestion of Van der Bent et al. [208] described
in Section 5.6 and Figure 5.13. However, the quinazolinone derivatives, e.g., compound 52,
(Figure 6.6) and the diphenylpyrazolidinone derivatives, e.g., compounds 57 and 58, (Figure
6.6C) are difficult to align with compound 89. It is not obvious which ring has to be aligned to
which position of compound 89 and also TORSEAL suggests several solutions of comparable
significance and similarity.
The best solutions selected by visual inspection of the first initial rigid docking trial with
DRAGHOME are depicted in Figure 6.7. It can be seen that the cavities 2 and 3 (the cavity
between the helices 3, 4, 5, 6, and 7 in maps -4 to -12 Å and the cavity between helices 1, 2,
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A
B C
Figure 6.6: TORSEAL alignments of several benzodiazepine derivatives with compound 66 in
black (A) and of a selected quinazolinone derivative (compound 52) with compound 89 (stick-
mode structure) (B) and two enantiomers of a diphenylpyrazolidinone derivative (compounds
57 and 58) with compound 89 (stick-mode structure) (C).
3 and 7 in maps 0 to -4 Å, respectively, section 6.3.3.1) are almost completely occupied by the
ligands. Only cavity one (the cavity between the helices 3, 4, 5, 6 and 7 in maps +8 to 0 Å)
remained unoccupied. Furthermore, it is obvious that many important residues, e.g., His376,
Phe342, Ser379, Phe227, Val349, Tyr350, Trp346 and Asn353 are located in close proximity to
the two occupied cavities and are therefore in direct contact to the docked ligands.
Figure 6.8 depicts for five ligands the docking mode within the receptor with respect to com-
pound 89, whereby the membrane plane is oriented parallel to the paper plane. The benzo-
diazepine derivatives are fitting rather well on each other although two main positions can be
determined. In the first position, the two substituents on the benzodiazepine ring are oriented
in a plane parallel to the membrane plane as for compound 89 and in the second orientation
those substituents are oriented in a plane orthogonal to the membrane plane as for compound
76 (Figure 6.8A). It is remarkable that compound 73 L-740,093 is the only benzodiazepine
derivative which fails to fit with its urea group onto the corresponding group of compound 89
(Figure 6.8B). The quinazolinone and the diphenylpyrazolidinone derivatives are docked well
in the receptor, but in none of the solutions the three substituents are fitted onto all the three
substituents of compound 89. Either the substituent attached to the urea-group together with
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Figure 6.7: Side-by-side stereo presentation of the ligands docked in the first initial rigid dock-
ing trial with DRAGHOME in the binding site of the human CCK-B receptor model. A contour
grid (at value 4 ∼ 90%) is depicted of the volume property of the protein, together with key
amino acid residues, Tyr380, and the ribbon of the protein.
one of the other rings fits reasonably well, while the other ring does not fit at all (compound 57,
the light structure in Figure 6.8C, and compound 53, Figure 6.8D), or the three aromatic rings
are fitted approximately without matching the urea group (compound 58, the dark structure in
Figure 6.8C). These last results confirm the observations with the TORSEAL alignment, that
the alignment of these classes of derivatives to compound 89 is difficult, since they do not share
exactly the same structural properties with compound 89.
6.3.3.3 Docking with MOCCA Conformations
Up to this stage of the investigation, the flexibility of the ligands were only considered in the
prealignment step, not during the docking procedure. However, in order to assess whether better
results can be obtained using alternative conformations of the ligands, especially when referring
to the quinazolinone and the diphenylpyrazolidinone derivatives (see considerations of section
6.2.2), MOCCA calculations and analyses [235] were performed and subsequently docked with
DRAGHOME. These analyses resulted in 900 conformations for each compound. Reduction
of the number of conformations of each ligand and thereby decreasing the number of docking
experiments could be achieved by some kind of conformational filtering, as, e.g., by selecting
representative conformations with NMRCLUST [231]. However, this was not pursued in this
study, in contrast all 900 conformations were used in the subsequent docking procedure. The
minimum and maximum energy found by the MOCCA analyses for every ligand is listed in
Table 6.7.
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min. max. # best energy # best energy # best energy rank
compound energy energy rule 1 rank best rule 2 rank best rule 3 rank best minim. of
[kcal/mol] [kcal/mol] rule1 rank rule 2 rank rule 3 rank conf.
31 L-364,718-flipped 149.536 154.584 0 1258
66 L-364,718-R 148.805 152.557 61 4 150.249 1 4
66 L-364,718-R-flipped 152.829 157.945 0 1774
71 L-365,260-S-flipped 187.544 193.938 0 1197
71 L-365,260-S 142.269 147.809 57 1 144.214
72 L-365,260 162.814 167.397 8 3 165.404 1 3
73 L-740,093 176.518 181.705 92 1 178.832 1 1
73b L-740,093-S 162.004 167.741 0 329 163.464
74 L-708,474 156.986 163.266 17 15 159.007 1 15
75 YM-022 203.804 212.749 100 1 206.804 1 1
75 YM-022-flipped 208.390 217.613 1 58 209.691
75b YM-022-S -flipped 214.089 223.490 13 8 216.123
75b YM-022-S 184.886 193.826 7 58 187.253
76 L-368,935 173.747 182.857 100 1 175.556 1 1
77 L-738,425 115.418 122.628 98 1 118.492 1 1
77 L-738,425-flipped 115.883 122.597 36 17 117.642
78 129.801 136.099 98 1 131.976 1 1
79 113.472 120.366 88 1 116.962 1 1
80 120.752 127.064 94 3 123.818 1 3
81 L-736,380 112.633 119.147 98 1 113.645 1 1
82 148.591 153.843 18 1 151.028 1 1
83 166.288 174.703 96 1 167.410 1 1
57 LY 288512 120.702 126.898 0 199 44 1 123.708 1 70 121.839
58 LY 288513 118.377 124.448 0 323 1 42 119.660 85 1 120.981
60 124.790 130.614 0 1204 11 12 129.721 11 1 127.964 1 1
61 128.900 136.139 0 699 7 1 132.770 0 277 130.909
44 LY 247348 127.161 136.539 2 54 130.014 5 55 131.210 17 3 130.551 1 3
48 130.117 143.736 2 26 143.737 3 1 134.190 16 8 133.163 1 8
49 131.762 140.559 0 147 1 71 136.979 3 33 138.385
50 128.710 137.009 0 1069 0 188 132.987 18 4 132.127 1 4
51 105.328 114.523 0 210 2 38 109.768 10 23 109.491 1 23
52 193.597 201.666 0 310 5 1 198.759 18 10 194.897 1 10
53 198.685 207.244 0 461 0 216 204.312 73 8 200.699 1 8
54 191.602 199.201 0 320 0 570 196.251 83 1 194.313 1 1
55 128.592 135.736 0 1073 1 97 131.030 77 3 131.569 1 3
56 132.121 138.370 1 98 135.934 2 10 136.336 3 30 136.405 1 30
84 170.568 178.506 27 10 175.075 1 10
85 153.075 161.184 69 4 155.341 1 4
87 145.672 151.310 93 2 147.791 1 2
88 140.719 147.045 93 1 143.911 1 1
89 247.648 254.887 86 1 250.366 1 1
89-flipped 230.373 237.620 0 1377
90 101.983 111.231 99 1 104.375 1 1
92 153.864 162.730 97 1 159.439 1 1
97 153.683 165.712 87 1 158.849 1 1
98 97.129 106.483 100 1 99.042 1 1
100 147.136 153.910 100 1 150.751 1 1
100-flipped 140.083 147.646 11 3 142.402
CCK-4 69.715 83.540
CCK-8 134.333 161.100
Table 6.7: Minimum and maximum energies of the MOCCA analyses and the results of the
docking selection, see text for details.
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A B
C D
Figure 6.8: Several ligands docked by DRAGHOME are depicted with respect to compound 89.
(A) compound 76, L-368,935; (B) compound 73, L-740,093; (C) compounds 57 (dark) and 58,
LY 288512 and LY 288513, respectively; (D) compound 53.
6.3.3.4 Analyses of Docking Results
Selection Method One
The top 10 solutions of several ligands are depicted in Figures 6.9 to 6.11 after docking. These
top 10 solutions were selected by applying the strategy of the average of the weighted rankings
of the four properties.
It can be seen (Figures 6.9) that all ten solutions for compound 76 L-368,935 have similar
positions, whereby the urea group is located between helices 3 and 7 in proximity to Ser379.
This is a similar position as found in the first rigid docking trial with DRAGHOME. It can be
hypothesised that for a stable complex, the urea group, which is essential for CCK-B antagonists
(see Chapter 5), should adopt a position between helices 3 and 7 in close proximity to Ser379.
Therefore, the so-called “urea-group”-rule (rule 1) is applied to select the solutions out of the
top 100, which have their urea oxygen atom within a distance of 3 Å of the position of the urea
oxygen of compound 76 L-368,935. These countings for all the compounds are listed in Table
6.7, together with the rank and the conformational energy of the compound with the highest
rank obeying the selection-rule.
The top 10 of the R-enantiomer of L-364,718, compound 66, has four solutions comparable to
compound 76, but it displays also solutions which are considerably different (Figure 6.9). The
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76 L-368,935 66 "L-364,718-R"
75 YM-022 75 YM-022-flipped
75b “YM-022-S” 75b "YM-022-S"-flipped
Figure 6.9: The top 10 solutions of several ligands docked with DRAGHOME.
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72 L-365,260 89
79 81 L-736,380
80 77 L-738,425
Figure 6.10: The top 10 solutions of several ligands docked with DRAGHOME.
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latter ones occupy only the second cavity (the cavity between the helices 3, 4, 5, 6, and 7 in
maps -4 to -12 Å, section 6.3.3.1). The urea substituents of these structures are located between
helices 5 and 6 (the most left side of the second cavity in Figure 6.9) and they are almost in
contact with the surrounding membrane by penetrating the helix 5-helix 6 interface. Similar
orientations were also solutions in the first rigid docking trial with DRAGHOME, however on
basis of the mutual spatial similarity strategy of Schafferhans [221] they were then discarted as
good solutions.
57 LY 288512 58 LY 288513
54 49
Figure 6.11: The top 10 solutions of several ligands docked with DRAGHOME.
It was found that all the “flipped” conformations of the benzodiazepine derivatives could not be
docked satisfactory in the binding site of the receptor. Not a single of these conformers adopted
a position that showed some similarity with that of compound 76. It is remarkable that the top
10 solutions obtained for these “flipped”-conformations exhibited a significant divergence. In
Figure 6.9, the top 10 solutions for the different conformations and enantiomers of YM-022
are given as an example for the influence of stereoisomerism and the “flipped”-conformation.
Although for the R-enantiomer in the “non-flipped”-conformation, two main orientations are
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found, with mirrored alignments of the urea-group. It can be seen that the solutions occupy the
cavities two and three and that the urea group of these solutions are in close proximity to Ser379.
The S-enantiomer in the “non-flipped”-conformation adopts only one position, similar to that of
compound 66. The “flipped”-conformations of both enantiomers are scrambled through cavity
two, exceeding beyond the border of this cavity.
It is remarkable that only one solution of L-365,260, compound 72, the prototype CCK-B an-
tagonist, has a somewhat similar position to that of compound 76 L-368,935 (Figure 6.10).
Compound 89, the template structure of the first rigid docking trial with DRAGHOME shows
solutions between helices 3 and 7, comparable to the solutions of compound 76 L-368,935.
However, the two ring-substituents are oriented in two different positions (Figure 6.10).
There are several ligands with a tetrazol-5-yl amino group attached to the urea substituent.
Although this tetrazol-5-yl amino group adopts slightly altered positions (Figure 6.10), it can
be seen that it almost always occupies cavity three (77, 79, 80, and 81). This tetrazol-5-yl amino
group is “sandwiched” by the two aromatic residues His376 and Tyr380, and surrounded by the
residues Phe110, Ala106 (oxygen-backbone-atom), Met134 and Ser137.
It can be seen from Table 6.7 that several of the benzodiazepine derivatives have high counts for
the urea-group-selection rule. It is remarkable that these in general are also the structures pos-
sessing good binding affinity. In contrast to this result, their “flipped”-conformations show low
counts and also the S-enantiomers of YM-022 (75), L-740,093 (73) and L-364,718 (31) have
low counts. L-364,718 (31) was experimentally determined to exhibit a low binding affinity for
the CCK-B receptor. For the other compounds only data for the R-enantiomers were reported.
Only the prototype CCK-B antagonist, compound 72 L-365,260, has better countings for its
S-enantiomer which has been reported to bind with lower affinity than the R-enantiomer to the
CCK-B receptor.
The quinazolinone derivatives (e.g., compounds 57 LY 288512 and 58 LY 288513, Figure 6.11)
and the diphenylpyrazolidinone derivatives (e.g., compounds 54 and 49, in Figure 6.11) have
only few solutions in which their structure occupies both cavities two and three. It is remarkable
that for compound 58 LY 288513, the enantiomer with the better binding affinity, only one
position is found and that in contrast for compound 57 LY 288512, the enantiomer with the
lower binding affinity, several different positions were identified. When all the top 10 solutions
of all the quinazolinone and diphenylpyrazolidinone derivatives were analysed, it was observed
that many solutions have an oxygen atom in proximity to Ser379, however not in an overlapping
mode to the urea group of compound 76 L-368,935. Therefore the above-mentioned “urea-
group”-selection rule was slightly extended to yield two further selection criteria, rule 2 and 3,
respectively. In the second selection rule, the distance between the position close to Ser379 and
the urea oxygen (or sulfur atom) of the compound was measured and the number of solutions
out of the top 100 with a distance smaller then 3 Å were counted. In the third selection rule
the oxygen atom of the ring system (quinazolinone or pyrazolidinone) was selected. These
countings are also listed in Table 6.7. It is obvious from Table 6.7, that only a few solutions
obey the first selection rule, but that the countings for the two extra rules are higher.
In Figure 6.12, several solutions of compound 48 and compound 56 obeying the first selection
rule are shown. Their urea groups are located between helices 3 and 7, similar to the urea group
position of compound 76 L-368,935.
When the solutions of the different quinazolinone compounds, obeying the third selection rule,
are analysed, it can be seen that many solutions are located in similar positions (Figure 6.12,
48, 54 and 56). The solutions obeying the second selection-rule are not only lower in countings,
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56 (ball and stick) and 48, 3rd-selection rule
48, 1st-selection rule
54 , 3rd-selection rule 56 , 3rd-selection rule
57 LY 288512 , 2nd-selection rule 58 LY 288513, 3rd-selection rule
Figure 6.12: The solutions of several quinazolinone and diphenylpyrazolidinone derivatives
obeying the different selection rules.
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they also do not have always very similar positions. Even when the solutions were very different
they almost never occupied the first or third cavity.
The diphenylpyrazolidinone derivatives, compounds 57 LY 288512 and 58 LY 288513, also
have more countings with respect to the second and third selection rules. However, it is remark-
able that compound 57 LY 288512, the weaker binding enantiomer, obeys the second selection
rule and has its urea-oxygen atom in close proximity to Ser379. In contrast, compound 58 LY
288513, the strong binding enantiomer has its ring-oxygen atom in close proximity to Ser379
and thus follows the third selection rule.
60, 2nd (dark) & 3rd-selection rule 61, 2nd-selection rule
Figure 6.13: Solutions of the diphenylpyrazolidinone derivative compounds 60 and 61 obeying
the different selection rules.
Compound 60 is a diphenylpyrazolidinone derivative with RS-enantiomery (see Figure 5.11).
This weak binding compound has solutions obeying both rules, but none is really well docked,
since atoms exceed beyond cavity 2 (Figure 6.13). Compound 61, the stronger binding SR-
enantiomer, obeys only the second rule, however the solutions are better docked in comparison
to compound 60. Therefore, a better binding of the SR-enantiomer can be hypothesised.
The results described here suggest that the binding mode for the quinazolinone and the diphenyl-
pyrazolidinone derivatives is different to that compared with the benzodiazepine derivatives.
However, their binding sites are greatly overlapping in the second cavity of the receptor.
Selection Method Two
The second selection of the best solutions created by DRAGHOME is done using the method
of grouping the solutions based on the RMSD of the non-hydrogen atoms of the ligand.
In the first grouping of the solutions of compound 76 L-368,935 a threshold RMSD value of 7
Å was used and 40 groups were obtained. The first two groups have both the highest number of
members in the group, the highest number of hits (DRAGHOME can find a solution more than
once in a docking trial and this amount for the total group is the number of hits) and the lowest
average of the total scores of the members. The first member of these two groups are depicted
in Figure 6.14A. The first member of the second group is in an orientation that is similar to
the orientations also found for compound 76 L-368,935 in the initial rigid docking trial and in
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the first selection method. In this orientation the ligand occupies cavities 2 and 3 (the cavity
between the helices 3, 4, 5, 6, and 7 in maps -4 to -12 Å, and the cavity between helices 1, 2, 3
and 7 in maps 0 to -4 Å, respectively, section 6.3.3.1). In contrast, the first member of the first
group occupies only cavity 2 and one of its substituents is positioned between the helices 5 and
6, an orientation also found in the first selection method for other compounds.
In Figure 6.15A it can be seen that the spread in total score of the different members of a group
can be large. Thus, solutions which are positioned in the same area within the binding site of
the receptor have rather different total scores. In contrast, the different groups can have similar
distributions in the total scores of their members. However, the first member of all groups have
clearly different orientations, since the RMSD values in the distance matrix of the first member
of all groups are in general larger than 7 Å (Figure 6.15B). The few RMSD values below 7 Å
are obtained through rounding off and are close to 7 Å.
The spread in the total score of the different members of a group is in the second grouping
smaller than in the first grouping, but is still significant (Figure 6.15C). That the 55 groups of
the second grouping have different orientations can be seen in the distance matrix of Figure
6.15D. The distance matrix shows that the RMSD value of the first member of each group to
the first member of each other group is larger than 2 Å (only a few yellow boxes caused by
rounding up).
The distance matrix of group 2 in Figure 6.15E shows that the RMSD values within one group
are in general not larger than 2 Å. Only a few RMSD values are larger than 2 Å (0.1% of all
RMSD values and the largest RMSD value is 2.36 Å). However, the members of group 2 do not
have identical total scores. The total score of the members of group 2 varies between -23363.0
and -28103.1. Thus, small deviations within the orientation of the ligand are responsible for
considerable differences in the total score.
The best three groups of the second grouping (groups 2, 3 and 5) have the highest number of
members, are in the top 4 of the highest number of hits, and are in the top 10 of the lowest
averages of the total scores. The first member of these three groups are depicted in Figure
6.14B. These three stuctures have orientations occupying cavities 2 and 3, and have their urea-
group positioned in close proximity to Ser379. These orientations are similar to the orientations
of the best solutions of compound 76 L-368,935 selected by the first selection method and also
similar to the orientation of compound 76 L-368,935 found in the first rigid docking trial with
DRAGHOME. In contrast, the three groups with the lowest averages of the total scores (groups
1, 31 and 50) are only occupying cavity 2 and have their urea-group not in close proximity
to Ser379 (Figure 6.14C). Furthermore, the urea-group substituent of these three structures is
positioned between helices 5 and 6, disrupting the interhelical interactions between these two
helices. Groups 31 and 50 have only a few members and they have also only a small number
of hits. Therefore, these orientations are probably not favourable orientations for compound 76
L-368,935. However, group 1 is the fourth group in the number of members and the second in
the number of hits. This group can be seen as the fourth best group. However, it has a significant
smaller number of members in comparison to the best three groups.
The three groups with their first member depicted in Figure 6.14B, have rather similar number of
members. However, their number of hits and their averages of the total scores of their members
are different. Group 5 with as first member the magenta coloured structure, has a significant
larger number of hits than groups 2 and 3, with as first member the purple and the green coloured
structures, respectively. However, the average of the total scores of group 5 is significant higher
(-23529.8) than the averages of the total scores of groups 2 and 3 (-26494.1 and -24410.3,
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350 TYR
346 TRP
106 ALA
110 PHE
356 ARG
353 ASN
compound: L368935 logfile: output_cluster clusters: 0001 0002 0002   
379 SER
100 ASP
376 HIS
380 TYR
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349 VAL
382 SER
111 THR
57 ARG
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compound: L368935 logfile: outputsecond_cluster clusters: 0003 0005 0002   
379 SER
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C
219 SER
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137 SER
142 THR
134 MET
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compound: L368935 logfile: outputsecond_cluster clusters: 0031 0050 0001   
379 SER
100 ASP
376 HIS
380 TYR
342 PHE
349 VAL
382 SER
111 THR
57 ARG
Figure 6.14: (A) The first member of the best two groups of the first grouping of compound 76
L-368,935 with a RMSD threshold value of 7 Å (first member of group one = green compound,
first member of group two = purple compound). (B) The first member of the best three groups of
the second grouping of compound 76 L-368,935 with a RMSD threshold value of 2 Å. (C) The
first member of the three groups of the second grouping of compound 76 L-368,935 with the
lowest averages of the total scores of their members. (The pictures are made with the program
MolScript [241].)
164
CHAPTER 6. ANTAGONIST BINDING SITE
A
0 5 10 15 20 25 30 35 40
Groups
−35000
−30000
−25000
−20000
−15000
−10000
−5000
0
To
ta
l S
co
re
 
B
5010 20 30 40
Groups
50
10
20
30
40
G
ro
up
s
 
14.00 12.00 10.00 8.00 6.00 4.00 2.00
C
0 10 20 30 40 50 60
Groups
−35000
−30000
−25000
−20000
−15000
−10000
−5000
0
To
ta
l S
co
re
 
D
10 20 30 40
Groups
10
20
30
40
G
ro
up
s
 
49.00 42.00 35.00 28.00 21.00 14.00 7.00
E
50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850
Groups
50
100
150
200
250
300
350
400
450
500
550
600
650
700
750
800
850
G
ro
up
s
outputsecond_cluster02.rms
2.45 2.10 1.75 1.40 1.05 0.70 0.35
Figure 6.15: Results of the two groupings of the solutions of compound 76 L-368,935. (A)
The total scores of each solution versus the group number of which they are member after the
first grouping with a threshold RMSD value of 7 Å. (B) The RMSD distance matrix of the first
member of all groups after the first grouping. (C) The total scores of selected solutions from
the first grouping versus the group number of which they are member after the second grouping
with a threshold RMSD value of 2 Å. (D) The RMSD distance matrix of the first member of all
groups after the second grouping. (E) The RMSD distance matrix of the 856 members of the
second group after the second grouping.
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respectively). Group 2 was chosen as the best group of the three groups, since it has significantly
the lowest average of the total score, and has, although not the highest number of hits, still a
large number of hits (more than 9 times the number of members).
Similar thorough analyses can also be done for the other compounds.
For compound 75 YM-022 the two different enantiomers were both docked with conforma-
tions with their 3-amide side chain in the pseudo-axial position and in the pseudo-equatorial
position (Figure 5.14, Chapter 5 [208]). It is remarkable that the grouping of the pseudo-axial
conformations, the so-called “flipped”-conformations, of both enantiomers and the grouping of
the pseudo-equatorial conformation of the S-enantiomer gave very large number of groups. It
can be suggested that these three structures do not have a high preferred specific orientation
within the binding site of the receptor and finding an orientation for them within the binding
site of the receptor is difficult. The best groups of these three structures do not occupy cavity
3 and do not have orientations similar to the best group of compound 76 L-368,935. In con-
trast, the grouping of the conformations of the R-enantiomer with its 3-amide side chain in the
pseudo-equatorial position gives a significant smaller number of groups and the best group is in
a similar orientation as the best group of compound 76 L-368,935.
The compounds 57 LY 288512 and 58 LY 288513 have also a different number of groups. A
larger number of groups was created for the enantiomer with the lower receptor affinity; com-
pound 57 LY 288512. This same correlation between number of created groups and receptor
affinity was also observed for the compounds 60 LY 294920 and 61 LY 294919, for the com-
pounds 31 and 66 L-364,718 and for the compounds 71 and 72 L-365,260. This would suggest
that structures with a smaller affinity have not a specific orientation within the binding site of
the receptor or that it is difficult to find an orientation within the binding site for structures with
a smaller binding affinity. Furthermore, compound 72 L-365,260 has its best group in an orien-
tation similar to the best group of compound 76 L-368,935 and it has also a higher affinity than
compound 71, which has no group in an orientation similar to the best group of compound 76
L-368,935. However, for compound 66, the enantiomer with the lower affinity, an orientation
similar to the orientation of the best group of compound 76 L-368,935 was found for its third
best group, whereas for compound 66 L-364,718, the enantiomer with the higher affinity, no
group was found orientated in that way. This was also observed for compounds 57 LY 288512
and 58 LY 288513. Therefore, it remains difficult to draw correlations between the differences
in binding affinity of the different enantiomers of the compounds and the observed binding
modes.
The first member of the best group of the compounds also mentioned in the discussion of the
first selection method, are depicted in Figure 6.16A. These are the compounds: 48, 49, 50, 54,
56, 57 LY 288512, 58 LY 288513, 60 LY 294920, 61 LY 294919, 31 L-364,718, 66, 71, 71-
“flipped”, 72 L-365,260, 75 YM-022 (both enantiomers and both enantiomers also “flipped”),
76 L-368,935, 77 L-738,425, 77-“flipped” L-738,425-“flipped”, 79, 80, 81 L-736,380, 89, 90,
97, 100, 100-“flipped”. In Figure 6.16B the first member of the best group are depicted for
the same compounds, but now the best group is selected also on basis of the spatial similarity
of various solutions generated for the different ligands for internal similarity consistency. This
extra selection criterion was applied in analogy to the procedure applied by Schafferhans et
al. [221]. Adding this selection criterion to the selection strategy means, that a group is selected
as the best group, which has not only a high number of members, a high number of hits and a
low average of the total scores of its members, but which also has an orientation similar to the
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Figure 6.16: (A) The first member of the best group of the compounds: 48-50, 54, 56, 57 LY
288512, 58 LY 288513, 60 LY 294920, 61 LY 294919, 31 L-364,718, 66, 71 (also “flipped”),
72 L-365,260, 75 YM-022 (two enantiomers and both also “flipped”), 76 L-368,935, 77 L-
738,425 (also “flipped”), 79, 80, 81 L-736,380, 89, 90, 97, 100 (also “flipped”). (B) The
extra criterion of spatial similarity [221] was taken into account. However, compounds 71-
“flipped”, 75 YM-022 (the two S-enantiomer conformations and the R-enantiomer with its side
chain in the pseudo-axial position), 77-“flipped” L-738,425, and 100-“flipped” were left out.
The compounds 48, 49, 57 LY 288512, 60 LY 294920, 61 LY 294919, 31 L-364,718, 66 and
71 have a binding affinity >100nM and are coloured magenta. (C) The magenta coloured
structures are left out. (D) The compounds of (C) are positioned between the transmembrane
helices in the upper part of the receptor. (The pictures are made with the program MolScript
[241].)
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orientation of the best group of compound 76 L-368,935 with its urea-group in close proximity
to Ser379 and occupying both cavities 2 and 3.
The so-called “flipped”-conformations (the 3-amide side chain in the pseudo-axial position) of
the different compounds were left out in Figures 6.16B-C. These “flipped”-conformations gave
orientations that were not following the spatial similarity criterion, or when they followed it,
were less similar to the orientation of the best group of compound 76 L-368,935 than the orien-
tations of the stretched conformations (the 3-amide side chain in the pseudo-axial position).
In Figure 6.16B it can be seen that by applying this spatial similarity criterion, the lefthand side
of cavity 2, the area between helices 5 and 6, is occupied in a lesser extent by the structures.
Figure 6.16C shows that this area is almost not occupied at all, when the structures of the
compounds with a binding affinity higher than 100 nM (compounds 48, 49, 57 LY 288512, 60
LY 294920, 61 LY 294919, 31 L-364,718, 66 and 71, the magenta coloured structures in Figure
6.16B) are left out. The remaining structures occupy similar positions as the best solutions
found in the initial rigid docking trial with DRAGHOME and as the best solutions selected with
the method based on the average of the weighted rankings of the four properties scores.
The second selection method, based on grouping the solutions on the basis of RMSDs of the
non-hydrogen atoms of the ligand, requires the large number of solutions created by DRAG-
HOME using multiple conformations of a ligand. Therefore, this approach needs the results of
a previous broad conformational search for each ligand. However, not only the conformational
search and the docking of all obtained conformations with DRAGHOME, but also the selection
method itself is computationally rather extensive for each ligand. Therefore the application of
this procedure would not be useful for fast docking of a large number of different compounds.
However, the method showed that a selection only on the total score of DRAGHOME could
sometimes give not very plausible solutions, since sometimes solutions were found with a very
low total score and with a very low number of hits, an indication that these solutions are not
very favorable and rather extreme. Furthermore, the method showed that solutions with very
similar orientations can have significant different total scores.
The first selection method on basis of the average of the weighted rankings of the four properties
scores is computational less extensive, but it requires some hypothetical rules which can only be
validated by experimental evidence such as mutagenesis data. The selection method based on
grouping the many solutions of a ligand on the RMSD of the non-hydrogen atoms of the ligand,
is computationally rather extensive, but probably produces less biased coverage of docking
space. However, it loses most of its better coverage by somewhat arbitrary manual intervention
in the selection of solutions.
Since the orientations of the best-ranked solutions selected by method one and method two are
so close to each other and the second selection method which was applied to guarantee a better
coverage of docking space, does not provide any advantage. Accordingly in the following only
the orientations of the first approach are further considered.
6.3.4 Relaxation of Protein-Ligand Complexes
As described above, complexes of the solutions of the ligands with one of the conformations
of the receptor are not ideal 3D-models due to frequent unfavourable contacts produced by the
docking onto averaged representations of the receptor structure. Only complexes with a relaxed
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structure without unfavourably close contacts can be analysed with a scoring function. There-
fore, energy minimisations and/or molecular dynamic simulations were conducted for several
complexes. Only favourable docking solutions were subjected to this simulation protocol (only
33 out of 48, see Table 6.7). The best solution, selected by applying the strategy of the average
of the weighted rankings of the four properties and the three “urea-group”-rules, were trans-
ferred in their orientation into the representative conformations of the first five clusters of the
clustering of the receptor conformations (Table 6.6). All these complexes (33 x 5) were relaxed
with the basic minimisation protocol given in Table 6.4.
The root mean square deviations (RMS) of the non-hydrogen atoms of the ligand for all five
relaxed complexes compared to the initial conformation of the ligand at the start, were calcu-
lated. The average and the standard deviation of these RMS values are depicted in Figure 6.17
as empty boxes. In the same Figure, also the average and the standard deviation of the RMS of
the key atoms of the 14 important residue sidechains are depicted (Table 6.1).
Figure 6.17: The average and standard deviation of the RMS of the heavy atoms of the ligands
(empty box) and of the 14 atoms of the important residue sidechains of the receptor protein
as listed in Table 6.1 (black box) in the 5 different minimised complexes for every computed
compound.
Visual inspection reveals that the overall orientation of the ligands do not change significantly,
which is also indicated by the small RMS values for the non-hydrogen atoms of the ligands.
However, the side chains of the receptor display increased movements as indicated by the RMS
values of the 14 atoms of the important residue sidechains of the receptor. The side chains are
shifted to remove repulsive contacts between the ligand and the receptor.
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An assessment of the degree of relaxation of the complexes can be obtained with the program
PROBE of Word et al. [242]. PROBE allows to monitor the close contacts between the ligand
and the receptor before and after the minimisation. It generates dots in space on the van der
Waals surface of atoms which are in close proximity to atoms of the binding parties. In Figure
6.18, the close contacts for compound 76 L-368,935 are depicted. The number of unfavourable
contacts (red dots) are reduced after minimisation.
A B
Figure 6.18: Close contacts calculated by PROBE for compound 76 L-368,935, before min-
imisation (A) and after minimisation (B). The dots are colour-coded according to the contact
distance from dark blue (far apart) over gray to red (overlap).
Some quinazolinone derivatives are positioned after the docking procedure with part of their
structures between the helices 5 and 6. As mentioned before, this is an unfavourable orientation,
since the structures in this orientation would disrupt interhelical contacts between helices 5 and
6, and furthermore a structure gets into close contact to the lipid compartment. Minimisation
of these quinazolinone derivatives does not remove these unfavourable contacts instead some
ligands moved further towards the exterior of the receptor. This indicates poor docking results.
Supposedly the docking and binding results of the quinazolinone derivatives are thus rather
speculative.
Because the applied energy minimisations were rudimentary, not all the complexes were fully
relaxed and some unfavourable close contacts could still remain between ligand and receptor. In
order to determine whether more elaborate protocols including molecular dynamic simulations
are required, more strigent minimisations with subsequent molecular dynamic simulations were
applied for a few selected complexes. For this purpose, frame 393 of the molecular dynamics
run of Chapter 4 was used as receptor model, since it is the most representative conformation
of the 14 clusters of the receptor (see Table 6.6). For compounds 50, 53, 57, 66, 73, 75, 80, 81,
84, and 89 the extended relaxation script given in Table 6.5 was applied.
In the distance matrices of Figure 6.19, the RMS-values of the non-hydrogen atoms of the ligand
(A), the key atoms of 14 amino acid residues of the protein (B), and the backbone atoms of the
protein (C) for the complex of compound 89 recorded over the complete simulation time are
depicted. The RMS-values are calculated with respect to the start conformation of the complex.
It can be seen that the non-hydrogen atoms of the ligand do not change significantly (RMS <
1.0 Å). This picture is seen for all the complexes and indicates clearly that the initial position
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of the ligand is not dramatically changed during the calculation. The RMS-values for all the
backbone atoms of the protein and the key atoms of the 14 active site residues were significantly
larger. However, also these values are still reasonably small and indicate that the structures of
the complexes do not change dramatically. It was determined that the change of the backbone
atoms is mainly determined by the changes of the residues in the loop regions.
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Figure 6.19: RMS distance matrices of the complex of compound 89, (A) the heavy atoms of the
ligand, (B) the key atoms of the 14 for antagonist binding important residues of the receptor,
and (C) all the heavy backbone atoms of the protein receptor.
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6.3.5 Putative Ligand Binding Site
Interacting residues within the different minimised complexes of the different ligands were
analysed with the program PROBE and by visual inspection. From these analyses a schematic
active site with the interacting amino acids can be developed (Figure 6.20). It is remarkable
Figure 6.20: Schematic view of the active site of the human CCK-B receptor with two benzo-
diazepine derivatives, notably compounds 76 (L-368,935) (red) and 75 (YM-022) (green). The
interacting amino acids identified by several mutagenesis studies as important for antagonists
binding are boxed, amino acids involved in >90% of the different complexes in hydrogen bond-
ing are underlined, and amino acids occassionally involved in hydrogen bonding are underlined
with a dotted line, other residues form hydrophobic interactions.
that all amino acids discovered by several mutagenesis studies [147, 148, 149, 150, 151, 152,
153, 154] as being involved in non-peptide antagonist binding are identified in these analyses
as interacting amino acids. However, also several other amino acids are interacting with the
ligands. These amino acids are considered as interesting candidates for further mutagenesis.
However, since some of these amino acids are interacting via their backbone atoms, mutagenesis
of these residues studies will probably not always reveal conclusive results. So have Kopin
et al. [147] already mutated Ala106 to Phe, but this mutation had no affect on non-peptide
antagonist binding.
Furthermore, not all ligands interact via the same pattern. Already some benzodiazepine deriva-
tives with similar sidechains are indicated to have different interaction patterns and/or partners.
This holds especially for hydrophobic interactions. Since hydrophobic interactions are very dif-
ficult to quantify, it is difficult to indicate in an unambiguous way the interactions between the
amino acid residues and different ligands.
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6.3.6 CoMSIA Analyses
A CoMSIA analysis was performed considering two ligand alignments. The first alignment
was obtained by using the best solution of the second flexible docking trial with DRAGHOME
selected by the strategy on basis of the average of the weighted rankings of the four proper-
ties including the “urea-group”-rule. The second alignment was obtained by selecting visually
for each ligand of the first alignment the best conformation of the five minimised conforma-
tions of each ligand (see also section 6.2.4) on basis of the mutual spatial similarity strategy of
Schafferhans [221].
CoMSIA reveals statistical significant models for both alignments, however these models should
be approached with some caution, since the number of outliers is rather high. The statistical
data is shown in Table 6.8.
CoMSIA CoMSIA
start-conf. end-conf.
Statistics
q2 0.512 0.500
sPRESS 0.855 0.745
r2 0.943 0.951
S 0.292 0.233
# comp. 4 3
Box
Stepsize (Å) 1.0 1.0
x -12 to +18 -12 to +18
y -13 to +8 -13 to +8
z -13 to +11 -13 to +11
# points 17050 17050
Fraction
steric 0.132 0.111
electrostatic 0.245 0.228
hydrophobic 0.250 0.249
H-donor 0.195 0.222
H-acceptor 0.110 0.190
# ligands 29 24
# outliers 4 9
Table 6.8: Statistics of CoMSIA models of the ligand alignments before and after minimisation
calculations.
In Figures 6.21 and 6.22, the different contribution maps of the CoMSIA analysis are depicted
for compounds 51, 75, 76 (L-368,935), and 77 (L-738,425) as top-view and as side-view, re-
spectively. Very similar results were obtained for the CoMSIA analyses of both alignments,
accordingly only contribution maps of the second alignment are given. The contribution maps
are contoured at 90% and 10% level and correspond to the following colour scheme:
173
CHAPTER 6. ANTAGONIST BINDING SITE
property field colour 90% colour 10%
favored level disfavored level
steric green orange
hydrophobic orange blue
electrostatic green red
donor red magenta
acceptor blue purple
As expected, contribution maps of donors and acceptors are found next to the urea-group in
both models. A clearly disfavoured volume is found between helices 5 and 6 (orange and blue
contour maps, disfavored steric and hydrophobic maps, repectively, in Figures 6.21A, B and
6.22A, B). It was already mentioned before that this area is not a favourable area for the ligand
binding due to too close proximity of the lipid compartment. Favourable steric interactions
are predicted near the phenyl of the urea-substituent and at the core of the benzodiazepine.
Furthermore, one ring-substituent is positioned in a favourable hydrophobic area (orange area in
Figures 6.21B and 6.22B). The ring-substituents do not indicate any favourable or disfavourable
contribution of donor, acceptor or electrostatic properties in close proximity (Figures 6.21C, D,
E and 6.22C, D, E).
The binding affinities for the ligands predicted with both CoMSIA models are listed in Table
6.9, together with the delta to the experimental bindings energies and the delta between the
predicted binding energies of the two models.
174
CHAPTER 6. ANTAGONIST BINDING SITE
A
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C
D
E
Figure 6.21: Stereo topview of the property fields of the CoMSIA-analysis of the ligand align-
ment after the minimisation calculation of the complexes, notably (A) steric, (B) hydrophobic,
(C) electrostatic, (D) donor, and (E) acceptor. In (A) are the positions of the helices schematic
depicted by gray ovals. See text for more details.
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D
E
Figure 6.22: Stereo sideview of the property fields of the CoMSIA-analysis of the ligand align-
ment before the minimisation calculation of the complexes, notably (A) steric, (B) hydrophobic,
(C) electrostatic, (D) donor, and (E) acceptor. In (A) are the positions of the helices schematic
depicted by rectangulars. See text for more details.
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compound IC50 log IC50 predicted delta prediction delta delta
name log IC50 log IC50 logIC50 logIC50 logIC50
start conf. start - exp. end conf. end - exp. start conf.- end conf.
66 L-364,718 R 3700.00 5.43 9.06 3.63 9.58 4.15 0.52
72 L-365,260 2.00 8.70 8.60 -0.10 8.72 0.02 0.13
76 L-368,935 0.14 9.85 9.54 -0.32 9.29 -0.56 -0.25
74 L-708,474 0.28 9.55 9.63 0.08 9.72 0.16 0.09
82 137.00 6.86 7.19 0.33 8.77 1.91 1.58
81 L-736,380 0.05 10.27 9.95 -0.32 8.77 -1.5 -1.18
77 L-738,425 0.11 9.96 9.58 -0.38 10.07 0.11 0.49
73 L-740,093 0.10 10.00 8.29 -1.71 8.51 -1.49 0.23
44 LY 247348 26.00 7.59 7.81 0.22 8.99 1.41 1.18
83 1.50 8.82 9.02 0.20 8.59 -0.23 -0.43
84 54.00 7.27 7.61 0.35 7.43 0.17 -0.18
87 480.00 6.32 6.97 0.65 8.09 1.77 1.12
88 23.00 7.64 7.19 -0.45 8.00 0.36 0.82
89 8.00 8.10 8.14 0.04 8.03 -0.06 -0.11
92 84.00 7.08 7.13 0.06 7.36 0.29 0.23
97 1.00 9.00 7.53 -1.47 7.84 -1.16 0.31
100 26.00 7.59 7.19 -0.39 7.79 0.21 0.60
48 585.00 6.23 6.35 0.11 8.71 2.47 2.36
50 14.00 7.85 7.57 -0.28 7.69 -0.16 0.12
55 97.00 7.01 6.94 -0.08 7.04 0.03 0.10
56 63.00 7.20 7.11 -0.09 6.92 -0.28 -0.20
52 29.00 7.54 7.64 0.10 7.52 -0.02 -0.12
53 1.00 9.00 9.25 0.25 9.09 0.09 -0.16
79 7.50 8.12 8.18 0.05 8.07 -0.05 -0.11
78 0.58 9.24 9.11 -0.12 9.15 -0.09 0.03
80 1.10 8.96 9.26 0.30 8.91 -0.05 -0.35
51 108.00 6.97 6.92 -0.04 6.95 -0.02 0.02
54 11.00 7.96 7.75 -0.21 7.96 0.01 0.21
85 18.00 7.74 7.44 -0.31 8.03 0.29 0.60
98 48.00 7.32 7.20 -0.12 7.29 -0.03 0.09
90 2.00 8.70 8.80 0.10 8.33 -0.37 -0.47
60 1900.00 5.72 8.37 2.65 8.58 2.86 0.21
75 YM022 0.11 9.96 10.32 0.36 10.165 0.21 -0.16
Table 6.9: Analysis of the two CoMSIA models. The two predicted binding energies, the deltas
between experimental and predicted binding energies, and in the last column the delta between
the two predicted binding energies are given for 33 compounds.
6.3.7 Docking of CCK-4 and CCK-8
The docking procedure applied to the 48 antagonists was also used to generate complex struc-
tures with CCK-4 and CCK-8 as native ligands. In Figures 6.23 and 6.24, the top 10 solutions
for CCK-8 and CCK-4 docking do not achieve corresponding binding modes. They are posi-
tioned in anti-parallel fashion in the receptor. However, they occupy the same compartment in
the receptor, namely the cavities one and two. These are the cavities located between helices 3,
4, 5, 6 and 7 at two different levels within the transmembrane domain of the receptor. CCK-4
and CCK-8 do not make contacts to cavity three in the proximity to His376.
When these results are compared to experimental findings of the binding of lipo-tetragastrin
derivatives [243, 244, 120] and peptide/benzodiazepine hybrids [245], carried out by the group
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Figure 6.23: Side-by-side stereo presentation of the first 10 solutions of CCK-4 in the receptor.
The N-atom of the NH2-group of Phe (the head) is a CPK with dark blue colour and the N-atom
of the backbone of Trp (the tail) is a CPK coloured light blue.
of L. Moroder, the simulations in this study are in accordance with their results. The agonists
bind to the same binding area, but with different binding patterns. Also the kink, mentioned
by Lutz [120] between Ala and Tyr in the sequence of Gastrin (H-Pyr-Gly-Pro-Trp-Leu-(Glu)5-
Ala-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2) was also observed for Asp and Tyr in the sequence of
CCK-8 (H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2). Furthermore, CCK-4 and CCK-
8 are involved in interactions with amino acids indicated by mutagenesis studies to be important
for agonist binding, as, e.g., His207, Arg 208, Trp209, Asn353, and Trp346. However, interac-
tions with, e.g., Thr111, Asn115, Leu116, Phe120 and Phe122 were not observed. These last
group of residues are positioned in the extracellular loop 2 and this loop is bend away from the
top of the receptor. Therefore, these amino acids are in our model too far apart, but could pos-
sible be much closer in space when the loop is bend towards the top of the receptor. This might
be attributed to the large flexibility of the loop regions of the receptor and of the ligand, no-
tably CCK-8. The approximative character of this study does not allow to conclude on detailed
interaction schemes, only a general idea can be derived in a highly qualitative manner.
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A
B
Figure 6.24: Side-by-side stereo presentation of the first 10 docking solutions of CCK-8 (A) and
a representative orientation of CCK-8 in the receptor. The N-atom of the NH2-group of Phe (the
head) is a CPK with dark blue colour and the N-atom of the backbone of Asp (the tail) is a CPK
coloured light blue.
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Figure 6.25: Side-by-side stereo presentation of CCK-8 (green) with L-368,935 (magenta)
docked within the receptor. The orange coloured amino acids are important for binding of
agonists, while the gray coloured amino acids are only important for antagonist binding.
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6.4 Conclusion
It can be concluded that the benzodiazepine derivatives could be docked into the CCK-B recep-
tor model with DRAGHOME in an orientation in close proximity to amino-acid residues pre-
viously identified as being involved in antagonist binding. In Figure 6.20, the binding site for
these benzodiazepine derivatives is depicted schematically. The urea group is located between
helices 3 and 7. It is capable to form hydrogen bonds to Ser379 and has a further hydrogen
bonding partner in either Ile374 or Met134. Ser379 at helix 7 was indicated by mutagenesis to
play an important role in the binding of non-peptide CCK-B antagonists. Furthermore, it should
be noted that helices 3 and 7 also comprise amino-acid residues which play a key role in ligand
binding with other GPCRs. The important lysine residue of the rhodopsin receptors is located
in helix 7 and the aspartate of the mono-amine receptors is located in helix 3, in close proximity
to Met134 and Ser137 of the CCK-B receptor.
The two ring substituents of the benzodiazepine derivatives are positioned into a large hy-
drophobic pocket. This hydrophobic pocket was clearly detected by the DRAGHOME ap-
proach. Several aromatic residues border this pocket and make contacts to the ligand. It could
not be determined whether there is a specific preference for the placement of the two ring sub-
stituents of the asymmetric benzodiazepine derivatives within this pocket. It might well differ
from ligand to ligand, since Asn353 in the upper part and Ser382 and Thr142 in the lower part
of this pocket are likely polar groups to possibly anchor these ring substituents. However, these
three residues are not the only possible contacting groups, also the backbone atoms and several
other residues are putative candidates. In addition, the hydrophobic residues can take influence
on the adopted orientation of the individual ligands.
In summary, the advantages of the applied docking procedure should be highlighted:
• DRAGHOME accounts for protein flexibility and limited accuracy of the receptor protein
model
• MOCCA analysis of the ligand accounts for the flexibility of the ligand
• combining protein flexibility with ligand flexibility accounts for an exhausive sampling
of the docking space of a ligand, however scoring of the produced solutions becomes an
increasing problem
• orientation of ligands within the protein model is achieved without predescribed binding
contrains and/or interactions
• no overestimation of hydrogen bonds, the contribution of steric parameters is important
• even small cavities deep within the protein receptor are identified
• new amino acids possibly involved in non-peptide antagonists binding are identified
• a general idea was developed for the binding of CCK-8
In general can be concluded that the DRAGHOME docking procedure obtains results which can
be used to plan and suggest subsequent experimental studies. The obtained binding geometries
are clearly not precise enough to allow for a meaningful calculation of binding affinities.
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Chapter 7
Summary, Zusammenfassung
"When I am judging a theory, I ask myself whether, if I were God, I would have
arranged the world in such a way."
• Albert Einstein
(1879-1955), scientist and Nobel Prize
in Physics laureate
CHAPTER 7. SUMMARY, ZUSAMMENFASSUNG
7.1 Summary
Even though pharmaceutical research has entered the frequently quoted post-genome era, it is
still undisputed that G protein-coupled receptors constitute the most densely populated protein
family encompassing numerous disease-relevant drug targets. Consequently, medicinal chem-
istry is expected to pursue targets from that protein family in that hits need to be generated
and subsequently optimized towards viable clinical candidates for a variety of therapeutic ar-
eas. For the purpose of rationalizing structure-activity relationships within such optimization
programs, structural information derived from the ligand’s as well as the macromolecule’s per-
spective is essential. While it is relatively straightforward to define pharmacophore hypotheses
based on comparative modelling of structurally and biologically characterized low-molecular
weight ligands, a deeper understanding of the molecular recognition event underlying, e.g.,
an antagonist-GPCR interaction remains challenging, since the principally available amount of
experimentally derived structural data on GPCRs is extremely scarse when compared to, e.g.,
soluble enzymes.
In this context, the protein modelling methodologies introduced, developed, optimized, and ap-
plied in this thesis provide structural models that are capable of assisting in the development
of structural hypotheses on ligand-receptor complexes. As such they provide a valuable struc-
tural framework not only for a more detailed insight into ligand-GPCR interaction, but also for
guiding the design process towards next-generation compounds which should display enhanced
affinity.
The model building procedure developed in this thesis systematically follows a hierarchical
approach, sequentially generating a 1D topology, followed by a 2D topology that is finally
converted into a 3D topology.
The determination of a 1D topology is based on a compartmentalization of the linear amino acid
sequence of a GPCR of interest into the extracellular, intracellular, and transmembrane sequence
stretches. The entire chapter 3 of this study elaborates on the strengths and weaknesses of
applying automated prediction tools based on the calculation of property profiles, distribution
profiles, and property moments for the purpose of identifying the transmembrane sequence
domains. Based on an once derived 1D topology, a type of in-plane projection structure for
the seven transmembrane helices can be derived with the aide of calculated vectorial property
moments, yielding in the 2D topology. Thorough bioinformatics studies revealed that only
a consensus approach based on a conceptual combination of different methods employing a
carefully made selection of parameter sets gave reliable results, thus emphasizing the danger of
any attempt to fully automate a GPCR modelling procedure.
Chapter 4 of this thesis describes a tailored procedure to further expand the 2D topological find-
ings into 3D space, exemplified on the human CCK-B receptor protein. This particular GPCR
was chosen as the receptor of interest, since an enormous experimentally derived and struc-
turally relevant data-set was available, ranging from detailed structure-activity relationships of
low-molecular weight agonists and antagonists (outlined in detail in chapter 5), to mutagenesis
data that identified receptor protein residues putatively involved in ligand binding. Within the
computational refinement procedure of constructed GPCR models, major emphasis was laid
on the explicit treatment of a non-isotropic solvent environment during molecular mechanics
(i.e. energy minimization and molecular dynamics simulations) calculations. The majority of
simulations was therefore carried out in a tri-phasic solvent box accounting for a central lipid
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environment, flanked by two aqueous compartments, mimicking the extracellular and cytoplas-
mic space.
Chapter 5 introduces the reference compound set, comprising low-molecular weight compounds
modulating CCK receptors, that was used for validation purposes of the generated models of
the receptor protein.
Chapter 6 describes how the generated model of the CCK-B receptor was subjected to intensive
docking studies employing compound series introduced in chapter 5. It turned out that by ap-
plying the DRAGHOME methodology viable structural hypotheses on putative receptor-ligand
complexes could be generated. Based on the methodology pursued in this thesis a detailed
model of the receptor binding site could be devised that accounts for known structure-activity
relationships as well as for results obtained by site-directed mutagenesis studies in a qualitative
manner.
The overall study presented in this thesis is primarily aimed to deliver a feasibility study on gen-
erating model structures of GPCRs by a conceptual combination of tailor-made bioinformatics
techniques with the toolbox of protein modelling, exemplified on the human CCK-B receptor.
In summary, it is again emphasized that the generated structures should be envisioned as models
only, not necessarily providing a detailed image of reality. However, consistent models, when
verified and refined against experimental data, deliver an extremely useful structural contex-
tual platform on which different scientific disciplines such as medicinal chemistry, molecular
biology, and biophysics can effectively communicate.
7.2 Zusammenfassung
Obgleich die pharmazeutisch-chemische Forschung das postgenome Zeitalter erreicht hat, re-
präsentiert die Familie der G Protein-gekoppelten Rezeptoren zweifellos eine der höchst-popu-
lierten Proteinfamilien, die zahllose Krankheits-relevante Zielproteine enthält. Folglich wird die
Medizinische Chemie Repräsentanten dieser Rezeptorfamilie bearbeiten, d. h. Hit-Strukturen
generieren und diese zu vielversprechenden Kandidaten für die klinische Entwicklung weiter
optimieren, wobei sich ein breites Spektrum therapeutischer Indikationen adressieren lässt.
Zum tiefergehenden Verständnis von Struktur-Wirkungsbeziehungen im Kontext solcher Opti-
mierungsprogramme liefern Strukturinformation über Liganden und über die Rezeptorproteine
wertvolle Beiträge. Während Pharmakophorhypothesen relativ einfach aus vergleichenden Stu-
dien von strukturell wie biologisch charakterisierten niedermolekularen Substanzen aufzustellen
sind, stellt die Generierung eines detaillierten Verständnisses über das zugrundeliegende moleku-
laren Erkennungsgeschehen von z. B. Antagonist-GPCR Wechselwirkung nach wie vor eine
grosse Herausforderung dar. Dies liegt unter anderem daran, dass die prinzipiell zur Verfü-
gung stehende, experimentell abgeleitete Strukturinformation im Vergleich zu z. B. löslichen
Enzymen extrem limitiert ist.
Vor diesem Hintergrund erlauben die in dieser Arbeit eingeführten, entwickelten und opti-
mierten Methoden der Proteinmodellierung die Erstellung von Strukturmodellen, die wertvolle
Hilfestellung zum Aufstellen von Strukturhypothesen zu Ligand-Rezeptorkomplexen liefern.
Dadurch wird es nicht nur möglich, Ligand-Rezeptor Interaktion auf einem detaillierteren Ni-
veau zu verstehen, es wird vielmehr auch der Designprozess zu Verbindungen der nächsten
Generation beeinflusst, der letztlich zu Substanzen mit verbesserter Affinität führen soll.
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Das in dieser Arbeit entwickelte Verfahren zum Modellbau von Rezeptorproteinen folgt sys-
tematisch einem hierarchischen Vorgehen, das sequentiell eine 1D Topologie erzeugt, gefolgt
von einer 2D Topologie die letztendlich in eine 3D Topologie transformiert wird.
Die Erstellung der 1D Topologie beruht auf einer Kompartmentierung der linearen Primärstruk-
tur, sprich der Aminosäuresequenz des GPCRs in extrazelluläre, intrazelluläre und transmem-
brane Sequenzabschnitte. Kapitel 3 dieser Arbeit setzt sich intensiv mit den Vor- und Nachteilen
der Anwendung automatisierter Vorhersage Programme auseinander, die im wesentlichen auf
der Berechnung von Eigenschaftsprofilen, Verteilungsprofilen und vektoriellen Eigenschaftsmo-
menten beruhen, anhand derer die potentiell transmembranen Sequenzbereiche identifizierbar
sein sollten.
Ausgehend von einer einmal erstellten 1D Topologie wird eine Art Projektionsstruktur für die
sieben transmembranen Helices erstellt, wobei die Projektionsebene parallel zur Membranober-
fläche liegt. Diese Projektionsstruktur (2D Topologie) wird mit Hilfe der vektoriellen Eigen-
schaftsmomente der einzelnen Helices erhalten. Intensive Studien mit den Werkzeugen der
Bioinformatik führten zu dem Resultat, dass nur ein Konsensus-Vorgehen, also eine konzep-
tionelle Kombination unterschiedlicher Methoden, basierend auf sorgfältig ausgewählten Pa-
rametersätzen valide 2D Topologien lieferte, was auf die Gefahr hinweist, die sich in der An-
wendung voll-automatisierter GPCR Modellingverfahren zur Modellgenerierung verbirgt.
Kapitel 4 der vorliegenden Arbeit beschreibt ein maßgeschneidertes Procedere zur Transfor-
mation der bis dahin abgeleiteten 2D Topologie in ein 3D Strukturmodell, was exemplarisch
am humanen CCK-B Rezeptorprotein demonstriert wird. Dieser spezielle Rezeptor wurde
ausgewählt, da eine Grosszahl experimentell abgeleiteter strukturrelevanter Daten vorhanden
sind, die von detaillierten Struktur-Wirkungsbeziehungen niedermolekularer Agonisten und
Antagonisten (siehe Kapitel 5) bis zu Mutagenese-Studien zur Identifikation Ligand-bindender
Rezeptorprotein-Aminosäuren reichen.
Zur Computer-gestützten energetischen Verfeinerung konstruierter GPCR-Modelle wurde die
Hauptaufmerksamkeit auf die explizite Berücksichtigung der anisotropen Umgebung im Rah-
men von molekulardynamischen-Simulationen (Energieminimierung und Molekulardynamik
Rechnungen) gelegt. Annähernd alle Simulationen wurden demzufolge in einem speziell en-
twickelten Drei-Phasen-System durchgeführt, das aus einer zentralen Lipidphase besteht, die
von zwei wässrigen Phasen flankiert wird, welche das extrazelluläre und das cytoplasmatische
Kompartiment imitieren sollen.
Im Kapitel 5 wird der Ligandsatz vorgestellt, der als Referenz zur Validierung der Rezeptor-
modelle im Zuge der in Kapitel 6 beschriebenen Docking-Studien darstellt. Im Kontext dieser
Docking-Studien stellte sich heraus, dass durch Verwendung der DRAGHOME Methodik vali-
dierbare Strukturmodelle zur Rezeptor-Ligand Interaktion erhalten werden konnten.
Mithilfe des in dieser Studie verwendeten und entwickelten Methodenarsenals gelang es schließ-
lich, ein detailliertes Modell der Rezeptor-Bindungstasche zu formulieren, das sowohl bekannte
Struktur-Wirkungsbeziehungen, als auch Ergebnisse aus Mutagenese-Studien zufriedenstellend
zu erklären vermag. Ein wesentliches Ziel der Arbeit bestand auch darin, eine Art Mach-
barkeitsstudie zur Modellierung von GPCRs durchzuführen, indem konzeptionell maßgeschnei-
derte Bioinformatik-Techniken mit Methoden der Proteinmodellierung kombiniert wurden, was
am Beispiel des humanen CCK-B Rezeptors demonstriert worden ist.
Zusammenfassend sei an dieser Stelle erneut hervorgehoben, dass die erzeugten Strukturmod-
elle auch wirklich als Modelle einzustufen sind, die nicht notwendigerweise mit den realen
Gegebenheiten am Rezeptor übereinstimmen. Trotzdem stellt ein in sich konsistentes Mod-
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ell, sofern es ausreichend verifiziert und gegen experimentelle Daten verfeinert ist, eine extrem
hilfreiche Plattform dar, auf der unterschiedlichste wissenschaftliche Disziplinen miteinander
effektiv kommunizieren können, was die Medizinische Chemie, die Molekularbiologie und die
Biophysik betrifft.
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